Methods for treatment of cancer comprising tigit-binding agents

ABSTRACT

Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present invention is a continuation of U.S. patent application Ser.No. 16/464,820, filed May 29, 2019, which is the U.S. National Phase ofInternational Patent Application No. PCT/US2017/063918, filed Nov. 30,2017, which claims the benefit of priority to U.S. ProvisionalApplication No. 62/479,609, filed Mar. 31, 2017, and to U.S. ProvisionalApplication No. 62/427,903, filed Nov. 30, 2016, each of which isincorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Dec. 9, 2021, isnamed OMP-164US-CON2_SeqListing.txt and is 48 kilobytes in size.

FIELD OF THE INVENTION

The present invention generally relates to methods for treating cancerusing agents that bind human TIGIT, particularly antibodies thatspecifically bind the extracellular domain of TIGIT.

BACKGROUND OF THE INVENTION

The basis for immunotherapy is the manipulation and/or modulation of theimmune system, including both innate immune responses and adaptiveimmune responses. The general aim of immunotherapy is to treat diseasesby controlling the immune response to a “foreign agent”, for example apathogen or a tumor cell. However, in some instances immunotherapy isused to treat autoimmune diseases which may arise from an abnormalimmune response against proteins, molecules, and/or tissues normallypresent in the body Immunotherapy may include agents and methods toinduce or enhance specific immune responses or to inhibit or reducespecific immune responses.

The immune system is a highly complex system made up of a great numberof cell types, including but not limited to, T-cells, B-cells, naturalkiller cells, antigen-presenting cells, dendritic cells, monocytes, andmacrophages. These cells possess complex and subtle systems forcontrolling their interactions and responses. The cells utilize bothactivating and inhibitory mechanisms and feedback loops to keepresponses in check and not allow negative consequences of anuncontrolled immune response (e.g., autoimmune diseases).

The concept of cancer immunosurveillance is based on the theory that theimmune system can recognize tumor cells, mount an immune response, andsuppress the development and/or progression of a tumor. However, it isclear that many cancer/tumor cells have developed mechanisms to evadethe immune system which can allow for uninhibited growth of those cells.Cancer/tumor immunotherapy focuses on the development of new and novelagents that can activate and/or boost the immune system to achieve amore effective attack against tumor cells resulting in increased killingof tumor cells and/or inhibition of tumor growth.

BRIEF SUMMARY OF THE INVENTION

The present invention provides methods for treatment of cancer (i.e.,inhibiting tumor growth) using agents that bind T-cell immunoreceptorwith Ig and ITIM domains (TIGIT), including, but not limited to,antibodies that specifically bind the extracellular domain of TIGIT. Incertain embodiments, the agent is a TIGIT antagonist. In someembodiments, a method comprises using a TIGIT-binding agent to induce,activate, promote, increase, enhance, or prolong an immune response tocancer and/or a tumor. In some embodiments, a method comprises using aTIGIT-binding agent to inhibit tumor growth. In some embodiments, amethod comprises using a TIGIT-binding agent for the treatment ofcancer. In some embodiments, a method comprises using a TIGIT-bindingagent in combination with at least one additional therapeutic agent.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor is a colorectal cancer (CRC) such as a microsatelliteinstability-high colorectal cancer (MSI CRC) or a microsatellite stablecolorectal cancer (MSS CRC), a triple negative breast cancer (TNBC), aMerkel cell carcinoma, an endometrial cancer, or an esophageal cancer.In some embodiments, a method of inhibiting tumor growth in a subjectcomprises administering to the subject a therapeutically effectiveamount of an antibody that specifically binds the extracellular domainof human TIGIT, wherein the tumor is a microsatellite instability-highcolorectal cancer, a microsatellite stable colorectal cancer, a triplenegative breast cancer, a Merkel cell carcinoma, an endometrial cancer,or an esophageal cancer, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor is a solid tumor with high microsatellite instability (MSI). Insome embodiments, a method of inhibiting tumor growth in a subjectcomprises administering to the subject a therapeutically effectiveamount of an antibody that specifically binds the extracellular domainof human TIGIT, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments the solid tumor with high MSI is selected from the groupconsisting of a MSI CRC, a MSI gastric cancer, a MSI endometrium cancer,a MSI ovarian cancer, a MSI hepatobiliary tract cancer, a MSI urinarytract cancer, a MSI brain cancer, or a MSI skin cancer.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumor is amicrosatellite instability-high colorectal cancer, a microsatellitestable colorectal cancer, a triple negative breast cancer, a Merkel cellcarcinoma, an endometrial cancer, or an esophageal cancer. In someembodiments, a method of inhibiting tumor growth in a subject comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of human TIGITin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor is a colorectal cancer (CRC) such as a microsatelliteinstability-high colorectal cancer or a microsatellite stable colorectalcancer, a triple negative breast cancer, a Merkel cell carcinoma, anendometrial cancer, or an esophageal cancer, and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the combination therapycomprises an anti-PD-1 antibody. In some embodiments, the combinationtherapy comprises an anti-PD-L1 antibody.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumor is asolid tumor with high MSI. In some embodiments, a method of inhibitingtumor growth in a subject comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-1antagonist or a PD-L1 antagonist, wherein the tumor is a solid tumorwith a high microsatellite instability, and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the combination therapy comprises ananti-PD-1 antibody. In some embodiments, the combination therapycomprises an anti-PD-L1 antibody. In some embodiments the solid tumorwith high MSI is selected from the group consisting of a MSI CRC, a MSIgastric cancer, a MSI endometrium cancer, a MSI ovarian cancer, a MSIhepatobiliary tract cancer, a MSI urinary tract cancer, a MSI braincancer or a MSI skin cancer.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor is resistant or refractory to treatment with a PD-1 antagonist ora PD-L1 antagonist. In some embodiments, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT, wherein the tumor is resistantor refractory to treatment with a PD-1 antagonist or a PD-L1 antagonist;and wherein the antibody that binds human TIGIT comprises a heavy chainCDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor was resistant or refractory to treatment with aPD-1 antagonist or a PD-L1 antagonist. As used herein, a tumor isresistant or refractory to treatment with an agent wherein there istumor growth progression during or after treatment with the agent. Insome embodiments, a tumor is resistant or refractory to treatment withan agent that is administered as a single agent. In some embodiments, atumor is resistant or refractory to treatment with an agent that isadministered as a first-line treatment or a second-line treatment. Insome embodiments, the tumor is resistant or refractory to treatment withan anti-PD-1 antibody (e.g., as a single agent). In some embodiments,the tumor is resistant or refractory to treatment with an anti-PD-L1antibody (e.g., as a single agent). In some embodiments, the tumorresistant or refractory to treatment with a PD-1 antagonist or a PD-L1antagonists is selected from the group consisting of melanoma, non-smallcell lung cancer (NSCLC), renal cell carcinoma, squamous cell carcinomaof the head and neck, urothelial carcinoma, colorectal cancer (e.g. MSIor DNA mismatch repair defective (dMMR) metastatic CRC) andhepatocellular carcinoma.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumor isresistant or refractory to treatment with a PD-1 antagonist or a PD-L1antagonist as a single agent. In some embodiments, a method ofinhibiting tumor growth in a subject comprises administering to thesubject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT incombination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor is resistant or refractory to treatment with a PD-1 antagonist ora PD-L1 antagonist as a single agent; and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, a tumor is resistant or refractory totreatment with an agent that is administered as a first-line treatmentor a second-line treatment. In some embodiments, a tumor is resistant orrefractory to treatment with a PD-1 antagonist as a single agent, but isresponsive to treatment with this agent in combination with aTIGIT-binding agent. In some embodiments, a tumor is resistant orrefractory to treatment with a PD-L1 antagonist as a single agent, butis responsive to treatment with this agent in combination with aTIGIT-binding agent. In some embodiments, the tumor is resistant orrefractory to treatment with an anti-PD-1 antibody (e.g., as a singleagent). In some embodiments, the tumor is resistant or refractory totreatment with an anti-PD-L1 antibody (e.g., as a single agent). In someembodiments, the combination therapy comprises an anti-PD-1 antibody. Insome embodiments, the combination therapy comprises an anti-PD-L1antibody. In some embodiments, the tumor resistant or refractory totreatment with a PD-1 antagonist or a PD-L1 antagonists is selected fromthe group consisting of melanoma, NSCLC, renal cell carcinoma, squamouscell carcinoma of the head and neck, urothelial carcinoma, colorectalcancer (e.g. MSI or dMMR metastatic CRC) and hepatocellular carcinoma.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thesubject has previously been treated with a PD-1 antagonist or a PD-L1antagonist as a single agent. In some embodiments, a method ofinhibiting tumor growth in a subject comprises administering to thesubject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT, wherein thesubject has previously been treated with a PD-1 antagonist or a PD-L1antagonist as a single agent; and wherein the antibody that binds humanTIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), aheavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavychain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the subject has previously been treated witha PD-1 antagonist or a PD-L1 antagonist, wherein there was diseaseprogression on or after treatment. In some embodiments, there is tumorgrowth recurrence after treatment with a PD-1 antagonist or a PD-L1antagonist. As used herein, tumor growth recurrence is defined as thereturn of cancer after treatment and after a period of time during whichthe cancer was not detected. The cancer may come back where it was firstfound or it may be found somewhere else in the body. In someembodiments, the recurrence is local recurrence, regional recurrence, ordistant recurrence. In some embodiments, the subject has previously beentreated with an anti-PD-1 antibody. In some embodiments, the subject haspreviously been treated with an anti-PD-L1 antibody. In someembodiments, the tumor is selected from the group consisting ofmelanoma, NSCLC, renal cell carcinoma, squamous cell carcinoma of thehead and neck, urothelial carcinoma, colorectal cancer (e.g. MS1 or dMMRmetastatic CRC) and hepatocellular carcinoma,

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the subject haspreviously been treated with a PD-1 antagonist or a PD-L1 antagonist asa single agent. In some embodiments, a method of inhibiting tumor growthin a subject comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT in combination with a PD-1antagonist or a PD-L1 antagonist, wherein the subject has previouslybeen treated with a PD-1 antagonist or a PD-L1 antagonist as a singleagent; and wherein the antibody that binds human TIGIT comprises a heavychain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the subject has previously been treated with a PD-1antagonist or a PD-L1 antagonist, wherein there was disease progressionon or after treatment. In some embodiments, there is tumor growthrecurrence after treatment with a PD-1 antagonist or a PD-L1 antagonist.In some embodiments, the recurrence is local recurrence, regionalrecurrence, or distant recurrence. In some embodiments, the combinationtherapy “resensitizes” the tumor to treatment with a PD-1 antagonist ora PD-L1 antagonist. In some embodiments, the subject has previously beentreated with an anti-PD-1 antibody. In some embodiments, the subject haspreviously been treated with an anti-PD-L1 antibody. In someembodiments, the combination therapy comprises an anti-PD-1 antibody. Insome embodiments, the combination therapy comprises an anti-PD-L1antibody. In some embodiments, the tumor is selected from the groupconsisting of melanoma, NSCLC, renal cell carcinoma, squamous cellcarcinoma of the head and neck, urothelial carcinoma, colorectal cancer(e.g. MSI or dMMR metastatic CRC) and hepatocellular carcinoma.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor expresses poliovirus receptor (PVR) and/or poliovirusreceptor-related 2 (PVRL2). In some embodiments, a method of inhibitingtumor growth in a subject comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT, wherein the tumor expresses PVRand/or PVRL2; and wherein the antibody that binds human TIGIT comprisesa heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumorexpresses PVR and/or PVRL2. In some embodiments, a method of inhibitingtumor growth in a subject comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-1antagonist or a PD-L1 antagonist, wherein the tumor expresses PVR and/orPVRL2; and wherein the antibody that binds human TIGIT comprises a heavychain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor is selected from the group consisting ofmelanoma. NSCLC, renal cell carcinoma, squamous cell carcinoma of thehead and neck, urothelial carcinoma, colorectal cancer (e.g. MSI ordMMR) metastatic CRC and hepatocellular carcinoma.

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor comprises tumor-infiltrating lymphocytes (TILs). In someembodiments, a method of inhibiting tumor growth in a subject comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of humanTIGIT, wherein the tumor comprises tumor-infiltrating lymphocytes; andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject, comprising administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumorcomprises tumor-infiltrating lymphocytes. In some embodiments, a methodof inhibiting tumor growth in a subject, comprising administering to thesubject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT incombination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor comprises tumor-infiltrating lymphocytes; and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9).

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent, wherein thetumor comprises regulatory T-cells (Tregs). In some embodiments, amethod of inhibiting tumor growth in a subject comprises administeringto the subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT, wherein thetumor comprises Tregs; and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the invention, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of a TIGIT-binding agent in combinationwith a PD-1 antagonist or a PD-L1 antagonist, wherein the tumorcomprises Tregs. In some embodiments, a method of inhibiting tumorgrowth in a subject comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-1antagonist or a PD-L1 antagonist, wherein the tumor comprises Tregs; andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the methods described herein, the tumor isselected from the group consisting of: lung tumor, liver tumor, breasttumor, renal cell carcinoma/kidney tumor, prostate tumor,gastrointestinal/gastric tumor, melanoma, cervical tumor, bladder tumor,glioblastoma, head and neck tumor, pancreatic tumor, ovarian tumor,colorectal tumor, endometrial tumor, anal tumor and esophageal tumor.

In some embodiments, the lung tumor comprises NSCLC, such as NSCLCsquamous cell or NSCLC adenocarcinoma.

In some embodiments, the breast tumor comprises triple-negative breastcancer (TNBC).

In some embodiments, the tumor is a solid tumor with high MSI. In someembodiments, the solid tumor with high microsatellite instability is aMSI colorectal cancer (MSI CRC), a MSI gastric cancer, a MSI endometriumcancer, a MSI ovarian cancer, a MSI hepatobiliary tract cancer, a MSIurinary tract cancer, a MSI brain cancer or a MSI skin cancer. In someembodiments, the solid tumor with high MSI is a MSI CRC.

In some embodiments, the tumor is a microsatellite stable (MSS) tumor.In some embodiments, the tumor is a microsatellite stable colorectalcancer (MSS CRC).

In some embodiments, the tumor is selected from the group consisting ofa melanoma, a NSCLC, a renal cell carcinoma, a squamous cell carcinomaof the head and neck, a urothelial carcinoma, a colorectal cancer (e.g.MSI or dMMR metastatic CRC) and hepatocellular carcinoma.

In some embodiments of the methods described herein, the agent is anantibody that specifically binds the extracellular domain of humanTIGIT, which comprises a heavy chain CDR1 comprising TSDYAWN (SEQ IDNO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), anda heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), and/or a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9).

In some embodiments of the methods described herein, the agent is anantibody that specifically binds the extracellular domain of TIGIT,wherein the antibody comprises a heavy chain variable region having atleast 90% sequence identity to SEQ ID NO:10 and/or a light chainvariable region having at least 90% sequence identity to SEQ ID NO:11.In some embodiments, an antibody comprises a heavy chain variable regionhaving at least 95% sequence identity to SEQ ID NO:10 and/or a lightchain variable region having at least 95% sequence identity to SEQ IDNO:11. In some embodiments, an antibody comprises a heavy chain variableregion comprising SEQ ID NO:10 and a light chain variable regioncomprising SEQ ID NO:11.

In some embodiments of the methods described herein, the TIGIT-bindingagent is an antibody which is a monoclonal antibody, a humanizedantibody, a human antibody, a recombinant antibody, a chimeric antibody,a bispecific antibody, an antibody fragment comprising anantigen-binding site, an IgG antibody, an IgG1 antibody, an IgG2antibody, or an IgG4 antibody. In some embodiments, the antibody ismonovalent. In some embodiments, the antibody is bivalent. In someembodiments, the antibody is monospecific. In some embodiments, theantibody is bispecific.

In some embodiments of the methods described herein, an antibody thatspecifically binds human TIGIT comprises a heavy chain amino acidsequence of SEQ ID NO:13 and a light chain amino acid sequence of SEQ IDNO:15. In some embodiments, an antibody that specifically binds humanTIGIT comprises a heavy chain amino acid sequence of SEQ ID NO:17 and alight chain amino acid sequence of SEQ ID NO:15.

In some embodiments of the methods described herein, an antibody thatspecifically binds human TIGIT, does not bind mouse TIGIT. In someembodiments an antibody that specifically binds human TIGIT, does notbind rat TIGIT. In some embodiments an antibody that specifically bindshuman TIGIT, does not bind rabbit TIGIT. In some embodiments an antibodythat specifically binds human TIGIT, does not bind marmoset TIGIT. Insome embodiments an antibody that specifically binds human TIGIT, doesnot bind dog TIGIT. In some embodiments an antibody that specificallybinds human TIGIT, does not bind pig TIGIT. In some embodiments anantibody that specifically binds human TIGIT, does not bind cynomolgusmonkey TIGIT. In some embodiments an antibody that specifically bindshuman TIGIT, does not bind rhesus monkey TIGIT.

In some embodiments of the methods described herein, an antibody thatspecifically binds human TIGIT comprises the heavy chain variable regionand the light chain variable region from antibody OMP-313M32. In someembodiments, the antibody comprises the heavy chain variable regionencoded by the plasmid deposited with ATCC as Designation No.PTA-122346. In some embodiments, the antibody comprises a polypeptidecomprising the heavy chain variable region encoded by the plasmiddeposited with ATCC as Designation No. PTA-122346. In some embodiments,the antibody comprises the light chain variable region encoded by theplasmid deposited with ATCC as Designation No. PTA-122347. In someembodiments, the antibody comprises the light chain encoded by theplasmid deposited with ATCC as Designation No. PTA-122347. In someembodiments, the antibody comprises the heavy chain variable regionencoded by the plasmid deposited with ATCC as Designation No. PTA-122346and the light chain variable region encoded by the plasmid depositedwith ATCC as Designation No. PTA-122347. In some embodiments, theantibody comprises a polypeptide encoded by the plasmid deposited withATCC as PTA-122346 and a polypeptide encoded by the plasmid depositedwith ATCC as Designation No. PTA-122347.

In some embodiments of the methods described herein, the TIGIT-bindingagent is monovalent. In some embodiments, the TIGIT-binding agent isbivalent. In some embodiments, the TIGIT-binding agent is monospecific.In some embodiments, the TIGIT-binding agent is bispecific. In someembodiments, the bispecific agent is a heterodimeric agent orheterodimeric molecule. In some embodiments, a heterodimeric agentcomprises an antibody that specifically binds TIGIT. In someembodiments, the bispecific agent is a homodimeric agent or homodimericmolecule. In some embodiments, a homodimeric agent comprises an antibodythat specifically binds TIGIT.

In some embodiments of the methods described herein, the TIGIT-bindingagent is an antibody that competes for specific binding to human TIGITwith an antibody described herein. In some embodiments, a TIGIT-bindingagent binds the same epitope on human TIGIT as an antibody describedherein. In some embodiments, a TIGIT-binding agent binds an epitope onhuman TIGIT that overlaps with the epitope on TIGIT bound by an antibodydescribed herein. In some embodiments, a TIGIT-binding agent binds anepitope comprising amino acids within SEQ ID NO:27. In some embodiments,a TIGIT-binding agent binds an epitope comprising amino acids within SEQID NO:28. In some embodiments, a TIGIT-binding agent binds an epitopecomprising amino acids within SEQ ID NO:27 and SEQ ID NO:28. In someembodiments, a TIGIT-binding agent binds an epitope comprising aminoacids Q62 and I109 of SEQ ID NO:1. In some embodiments, a TIGIT-bindingagent binds an epitope comprising amino acids Q62 and T119 of SEQ IDNO:1. In some embodiments, a TIGIT-binding agent binds an epitopecomprising amino acids Q64 and I109 of SEQ ID NO:1. In some embodiments,a TIGIT-binding agent binds an epitope comprising amino acids Q64 andT119 of SEQ ID NO:1. In some embodiments, a TIGIT-binding agent binds anepitope comprising amino acids Q62, Q64, and I109 of SEQ ID NO:1. Insome embodiments, a TIGIT-binding agent binds an epitope comprisingamino acids Q62, Q64, and T119 of SEQ ID NO:1. In some embodiments, aTIGIT-binding agent binds an epitope comprising amino acids Q62, I109,and T119 of SEQ ID NO:1. In some embodiments, a TIGIT-binding agentbinds an epitope comprising amino acids Q64, I109, and T119 of SEQ IDNO:1. In some embodiments, a TIGIT-binding agent binds an epitopecomprising amino acids Q62, Q64, I109, and T119 of SEQ ID NO:1. In someembodiments, a TIGIT-binding agent binds an epitope comprising at leastone amino acid selected from the group consisting of: N58, E60, Q62,Q64, L65, F107, I109, H111, T117, T119, G120, and R121 of SEQ ID NO:1.In some embodiments, the epitope is a conformational epitope. In someembodiments, a TIGIT-binding agent binds an epitope that does notcomprise amino acid V100 of SEQ ID NO:1.

In some embodiments of the methods described herein, the agent thatspecifically binds TIGIT is an antibody, wherein the antibody is part ofa bispecific agent. In some embodiments, a bispecific agent comprises afirst arm which binds TIGIT and a second arm which binds a secondtarget. In some embodiments, a bispecific agent comprises a first armthat specifically binds TIGIT and a second arm, wherein the first armcomprises an anti-TIGIT antibody. In some embodiments, a bispecificagent comprises a first arm that binds TIGIT and a second arm whichcomprises an antigen-binding site from an antibody. In some embodiments,a bispecific agent comprises a first arm that binds TIGIT and a secondarm that specifically binds PD-1, PD-L1, CTLA4, TIM-3, LAG-3, OX-40, orGITR. In some embodiments, a bispecific agent comprises a first arm thatbinds TIGIT and a second arm that specifically binds a tumor antigen. Insome embodiments, a bispecific agent comprises a first arm that bindsTIGIT and a second arm that comprises an immune response stimulatingagent. In some embodiments, the immune response stimulating agent isselected from the group consisting of: granulocyte-macrophage colonystimulating factor (GM-CSF), macrophage colony stimulating factor(M-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 2(IL-2), interleukin 3 (IL-3), interleukin 12 (IL-12), interleukin 15(IL-15), B7-1 (CD80), B7-2 (CD86), 4-1BB ligand, GITRL, OX-40L, anti-CD3antibody, anti-CTLA4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody,anti-GITR antibody, anti-OX-40 antibody, anti-LAG-3 antibody, andanti-TIM-3 antibody.

In some embodiments, the bispecific agent is a heterodimeric agent orheterodimeric molecule. In some embodiments, the bispecific agent is ahomodimeric agent or homodimeric molecule. In some embodiments, aheterodimeric molecule comprises a first arm which binds human TIGIT anda second arm which binds a second target. In some embodiments, aheterodimeric molecule comprises a first arm that specifically bindshuman TIGIT and a second arm, wherein the first arm comprises ananti-TIGIT antibody. In some embodiments, a heterodimeric moleculecomprises a first arm that binds human TIGIT and a second arm whichcomprises an antigen-binding site from an antibody that specificallybinds a second target. In some embodiments, a heterodimeric molecule isa bispecific antibody. In some embodiments, a heterodimeric moleculecomprises a first arm that binds human TIGIT and a second arm thatspecifically binds a tumor antigen. In some embodiments, a heterodimericmolecule comprises a first arm that binds human TIGIT and a second armthat specifically binds PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, OX-40, 4-1BB,or GITR. In some embodiments, a heterodimeric molecule comprises a firstarm that binds TIGIT and a second arm that comprises animmunotherapeutic agent. In some embodiments, the immunotherapeuticagent is selected from the group consisting of: granulocyte-macrophagecolony stimulating factor (GM-CSF), macrophage colony stimulating factor(M-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 2(IL-2), interleukin 3 (IL-3), interleukin 12 (IL-12), interleukin 15(IL-15), B7-1 (CD80), B7-2 (CD86), 4-1BB ligand, GITRL, OX-40L, anti-CD3antibody, anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody,anti-4-1BB antibody, anti-GITR antibody, anti-OX-40 antibody, anti-LAG-3antibody, and anti-TIM-3 antibody.

In some embodiments of the methods described herein, an agentspecifically binds TIGIT and inhibits binding of TIGIT to PVR. In someembodiments, an agent specifically binds TIGIT and inhibits or blocksthe interaction between TIGIT and PVR. In some embodiments, an agentspecifically binds TIGIT and inhibits binding of TIGIT to PVRL2. In someembodiments, an agent specifically binds TIGIT and inhibits or blocksthe interaction between TIGIT and PVRL2. In some embodiments, an agentspecifically binds TIGIT and inhibits binding of TIGIT to PVRL3. In someembodiments, an agent specifically binds TIGIT and inhibits or blocksthe interaction between TIGIT and PVRL3. In some embodiments, the agentis an antagonist of TIGIT. In some embodiments, an agent specificallybinds TIGIT and inhibits TIGIT signaling. In some embodiments, an agentspecifically binds TIGIT and is an antagonist of TIGIT-mediatedsignaling. In some embodiments, an agent specifically binds TIGIT andinhibits TIGIT activation. In some embodiments, an agent specificallybinds TIGIT and inhibits phosphorylation of TIGIT. In some embodiments,an agent specifically binds TIGIT and decreases cell surface expressionof TIGIT.

In some embodiments of the methods described herein, an agentspecifically binds TIGIT and induces, activates, promotes, increases,enhances, and/or prolongs an immune response. In some embodiments, theimmune response is directed to (e.g., kills) a tumor or tumor cell. Insome embodiments, the agent increases cell-mediated immunity. In someembodiments, the agent increases T-cell activity. In some embodiments,the agent increases cytolytic T-cell (CTL) activity. In someembodiments, the agent increases natural killer (NK) cell activity. Insome embodiments, the agent increases IL-2 production and/or the numberof IL-2-producing cells. In some embodiments, the agent increasesIFN-gamma production and/or the number of IFN-gamma-producing cells. Insome embodiments, the agent increases a Th1-type immune response. Insome embodiments, the agent decreases IL-4 production and/or the numberof IL-4-producing cells. In some embodiments, the agent decreases IL-10and/or the number of IL-10-producing cells. In some embodiments, theagent decreases IL-6 production and/or the number of IL-6-producingcells. In some embodiments, the agent decreases IL-5 production and/orthe number of IL-5-producing cells. In some embodiments, the agentdecreases a Th2-type immune response. In some embodiments, the agentdecreases the number of Treg cells. In some embodiments, the agentdecreases Treg activity. In some embodiments, the agent inhibits and/ordecreases the suppressive activity of Tregs. In some embodiments, theagent decreases the number of myeloid-derived suppressor cells (MDSCs).In some embodiments, the agent inhibits and/or decreases the suppressiveactivity of MDSCs.

In some embodiments of the methods described herein, an agentspecifically binds TIGIT and inhibits tumor growth. In some embodiments,the agent reduces tumor growth. In some embodiments, the agent reducestumor growth to an undetectable size. In some embodiments, the agentinduces long-term anti-tumor immunity.

In another aspect, the invention provides compositions comprising aTIGIT-binding agent for use in the methods described herein. In someembodiments, the invention provides pharmaceutical compositionscomprising a TIGIT-binding agent for use in the methods described hereinand a pharmaceutically acceptable carrier.

In certain embodiments of the methods described herein, theTIGIT-binding agent is isolated. In certain embodiments, theTIGIT-binding agent is substantially pure.

The invention also provides polynucleotides comprising a polynucleotidethat encodes a TIGIT-binding agent. In some embodiments, thepolynucleotide is isolated. In some embodiments, the invention providesvectors that comprise the polynucleotides, as well as cells thatcomprise the vectors and/or the polynucleotides. In some embodiments,the invention also provides cells comprising or producing aTIGIT-binding agent. In some embodiments, the cell is a monoclonal cellline.

In some embodiments of the methods described herein, a method furthercomprises administering at least one additional therapeutic agent. Insome embodiments, the additional therapeutic agent is a chemotherapeuticagent. In some embodiments, the additional therapeutic agent is anantibody. In some embodiments, the additional therapeutic agent is ananti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, ananti-LAG-3 antibody, or an anti-TIM-3 antibody. In some embodiments, theadditional therapeutic agent is an inhibitor of the Notch pathway, theWnt pathway, or the RSPO/LGR pathway. In some embodiments, theadditional therapeutic agent is an immunotherapeutic agent. As usedherein, the phrase “immunotherapeutic agent” is used in the broadestsense and refers to a substance that directly or indirectly affects ormodulates the immune system. In some embodiments, an immunotherapeuticagent is an agent that directly or indirectly stimulates the immunesystem by inducing activation or increasing activity of any of theimmune system's components. As the TIGIT-binding agents are consideredimmunotherapeutic agents, this additional immunotherapeutic agent may beconsidered a “second” immunotherapeutic agent. In some embodiments, thesecond immunotherapeutic agent is selected from the group consisting of:GM-CSF, M-CSF, G-CSF, IL-2, IL-3, IL-12, IL-15, B7-1 (CD80), B7-2(CD86), 4-1BB ligand, GITRL, OX-40 ligand, anti-CD3 antibody,anti-CTLA-4 antibody, anti-CD28 antibody, anti-PD-1 antibody, anti-PD-L1antibody, anti-4-1BB antibody, anti-GITR antibody, anti-OX-40 antibody,anti-LAG-3 antibody, and anti-TIM-3 antibody. In some embodiments, thesecond immunotherapeutic agent is a fusion protein comprising: GM-CSF,M-CSF, G-CSF, IL-2, IL-3, IL-12, IL-15, B7-1 (CD80), B7-2 (CD86), 4-1BBligand, GITRL, OX-40 ligand, or a fragment thereof. In some embodiments,the second immunotherapeutic agent is a fusion protein comprising atleast one copy of the extracellular domain of GITRL, OX40 ligand, or4-1BB ligand.

In some embodiments of the methods described herein, the subject ishuman In some embodiments, the subject has had a tumor or a cancer, atleast partially, removed.

In some embodiments of the methods described herein, the tumor or thecancer expresses PD-L1. In some embodiments, a method further comprisesa step of determining the level of PD-L1 expression in the tumor orcancer. In some embodiments, determining the level of PD-L1 expressionis done prior to treatment or contact with a TIGIT-binding agent. Insome embodiments, if the tumor or cancer has an elevated expressionlevel of PD-L1, a TIGIT-binding agent is administered to the subject.

In some embodiments, the invention comprises a method of inhibitingtumor growth in a subject, comprising administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT, wherein the tumor is a head andneck cancer, esophageal/gastroesophageal cancer, gastric cancer,colorectal cancer, anal cancer, hepatocellular cancer/liver cancer,cervical cancer, lung cancer (e.g., NSCLC), melanoma, Merkel cellcarcinoma, renal cell carcinoma/kidney cancer, bladder cancer, ovariancancer, pancreatic cancer, endometrial cancer, and triple negativebreast cancer, a known MSI high solid tumor (including MSI CRC) or a MSScolorectal cancer; wherein the tumor is resistant or refractory totreatment with an anti-PD-1 antibody or an anti-PD-L1 antibody; andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments of the methods described herein, the subject haspreviously been treated with an anti-PD-1 antibody or an anti-PD-L1antibody. In some embodiments, the antibody that specifically binds theextracellular domain of human TIGIT is administered to the subject at adose of about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 1.5mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg,about 7.5 kg/kg, or about 10 mg/kg. In some embodiments, the antibodythat specifically binds the extracellular domain of human TIGIT isadministered once about every week, once about every two weeks, onceabout every three weeks, or once about every four weeks. In someembodiments, the subject has a histologically confirmed advancedrelapsed or refractory solid tumor.

Where aspects or embodiments of the invention are described in terms ofa Markush group or other grouping of alternatives, the present inventionencompasses not only the entire group listed as a whole, but also eachmember of the group individually and all possible subgroups of the maingroup, and also the main group absent one or more of the group members.The present invention also envisages the explicit exclusion of one ormore of any of the group members in the claimed invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Inhibition of tumor growth by anti-TIGIT antibody OMP-313M32 ina humanized mouse model. Humanized mice were injected subcutaneouslywith patient-derived melanoma tumor cells (OMP-M9, 75,000 cells/mouse).Tumors were allowed to grow 19 days until they had reached an averagevolume of approximately 50 mm³. Tumor-bearing mice were randomized intogroups (n=8 mice per group). Tumor-bearing mice were treated with eithera control antibody or anti-TIGIT antibody OMP-313M32. Mice were dosedevery 5 days at 1 mg/kg or 5 mg/kg. Tumor growth was monitored and tumorvolumes were measured with electronic calipers at the indicated timepoints.

FIG. 2. A schematic diagram showing dose escalation and expansion forthe initial phase of a clinical trial using anti-TIGIT antibody 313M32.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods of using novel agents, whereinthe agents include, but not limited to, polypeptides, antibodies,heterodimeric molecules, and homodimeric molecules that specificallybind human TIGIT. Methods of using the novel agents for inhibiting tumorgrowth and/or for treating cancer are provided. Methods of using thenovel agents, such as methods of activating an immune response, methodsof stimulating an immune response, methods of promoting an immuneresponse, methods of increasing an immune response, methods ofactivating natural killer (NK) cells and/or T-cells, methods ofincreasing the activity of NK cells and/or T-cells, methods of promotingthe activity of NK cells and/or T-cells, methods of decreasing and/orinhibiting suppressor T-cells (i.e., regulatory T-cells), and/or methodsof decreasing and/or inhibiting myeloid-derived suppressor cells arefurther provided.

I. Definitions

To facilitate an understanding of the present invention, a number ofterms and phrases are defined below.

The terms “agonist” and “agonistic” as used herein refer to or describean agent that is capable of, directly or indirectly, substantiallyinducing, activating, promoting, increasing, or enhancing the biologicalactivity of a target and/or a pathway. The term “agonist” is used hereinto include any agent that partially or fully induces, activates,promotes, increases, or enhances the activity of a protein.

The terms “antagonist” and “antagonistic” as used herein refer to ordescribe an agent that is capable of, directly or indirectly, partiallyor fully blocking, inhibiting, reducing, or neutralizing a biologicalactivity of a target and/or pathway. The term “antagonist” is usedherein to include any agent that partially or fully blocks, inhibits,reduces, or neutralizes the activity of a protein.

The terms “modulation” and “modulate” as used herein refer to a changeor an alteration in a biological activity. Modulation includes, but isnot limited to, stimulating an activity or inhibiting an activity.Modulation may be an increase or a decrease in activity, a change inbinding characteristics, or any other change in the biological,functional, or immunological properties associated with the activity ofa protein, a pathway, a system, or other biological targets of interest.

The term “antibody” as used herein refers to an immunoglobulin moleculethat recognizes and specifically binds a target through at least oneantigen-binding site. The target may be a protein, polypeptide, peptide,carbohydrate, polynucleotide, lipid, or a combination of any of theforegoing. As used herein, the term encompasses intact polyclonalantibodies, intact monoclonal antibodies, antibody fragments (such asFab, Fab′, F(ab′)2, and Fv fragments), single chain Fv (scFv)antibodies, multispecific antibodies, bispecific antibodies,monospecific antibodies, monovalent antibodies, chimeric antibodies,humanized antibodies, human antibodies, fusion proteins comprising anantigen-binding site of an antibody, and any other modifiedimmunoglobulin molecule comprising an antigen-binding site as long asthe antibodies exhibit the desired biological activity. An antibody canbe any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG,and IgM, or subclasses (isotypes) thereof (e.g., IgG1, IgG2, IgG3, IgG4,IgA1 and IgA2), based on the identity of their heavy-chain constantdomains referred to as alpha, delta, epsilon, gamma, and mu,respectively. The different classes of immunoglobulins have differentand well-known subunit structures and three-dimensional configurations.Antibodies can be naked or conjugated to other molecules, including butnot limited to, toxins and radioisotopes.

The term “antibody fragment” refers to a portion of an intact antibodyand generally refers to the antigenic determining variable regions of anintact antibody. Examples of antibody fragments include, but are notlimited to, Fab, Fab′, F(ab′)2, and Fv fragments, linear antibodies,single chain antibodies, and multispecific antibodies formed fromantibody fragments. “Antibody fragment” as used herein comprises anantigen-binding site or epitope-binding site.

The term “variable region” of an antibody refers to the variable regionof an antibody light chain or the variable region of an antibody heavychain, either alone or in combination. Generally, the variable region ofa heavy chain or a light chain consists of four framework regionsconnected by three complementarity determining regions (CDRs), alsoknown as “hypervariable regions”. The CDRs in each chain are heldtogether in close proximity by the framework regions and, with the CDRsfrom the other chain, contribute to the formation of the antigen-bindingsite(s) of the antibody. There are at least two techniques fordetermining CDRs: (1) an approach based on cross-species sequencevariability (i.e., Kabat et al., 1991, Sequences of Proteins ofImmunological Interest, 5th Edition, National Institutes of Health,Bethesda Md.), and (2) an approach based on crystallographic studies ofantigen-antibody complexes (Al Lazikani et al., 1997, J. Mol. Biol.,273:927-948). In addition, combinations of these two approaches aresometimes used in the art to determine CDRs.

The term “monoclonal antibody” as used herein refers to a homogenousantibody population involved in the highly specific recognition andbinding of a single antigenic determinant or epitope. This is incontrast to polyclonal antibodies that typically include a mixture ofdifferent antibodies that recognize different antigenic determinants.The term “monoclonal antibody” encompasses both intact and full-lengthmonoclonal antibodies as well as antibody fragments (e.g., Fab, Fab′,F(ab′)2, Fv), single chain (scFv) antibodies, fusion proteins comprisingan antibody fragment, and any other modified immunoglobulin moleculecomprising an antigen-binding site. Furthermore, “monoclonal antibody”refers to such antibodies made by any number of techniques, includingbut not limited to, hybridoma production, phage selection, recombinantexpression, and transgenic animals.

The term “humanized antibody” as used herein refers to antibodies thatare specific immunoglobulin chains, chimeric immunoglobulins, orfragments thereof that contain minimal non-human sequences. Typically,humanized antibodies are human immunoglobulins in which amino acidresidues of the CDRs are replaced by amino acid residues from the CDRsof a non-human species (e.g., mouse, rat, rabbit, or hamster) that havethe desired specificity, affinity, and/or binding capability. In someinstances, the framework variable region amino acid residues of a humanimmunoglobulin may be replaced with the corresponding amino acidresidues in an antibody from a non-human species. The humanized antibodycan be further modified by the substitution of additional amino acidresidues either in the framework variable region and/or within thereplaced non-human amino acid residues to further refine and optimizeantibody specificity, affinity, and/or binding capability. The humanizedantibody may comprise variable domains containing all or substantiallyall of the CDRs that correspond to the non-human immunoglobulin, whereasall or substantially all of the framework variable regions are those ofa human immunoglobulin sequence. In some embodiments, the variabledomains comprise the framework regions of a human immunoglobulinsequence. In some embodiments, the variable domains comprise theframework regions of a human immunoglobulin consensus sequence. Thehumanized antibody can also comprise at least a portion of animmunoglobulin constant region or domain (Fc), typically that of a humanimmunoglobulin.

The term “human antibody” as used herein refers to an antibody producedby a human or an antibody having an amino acid sequence corresponding toan antibody produced by a human made using any of the techniques knownin the art.

The term “chimeric antibody” as used herein refers to an antibodywherein the amino acid sequence of the immunoglobulin molecule isderived from two or more species. Typically, the variable regions of thelight and heavy chains correspond to the variable regions of an antibodyderived from one species of mammal (e.g., mouse, rat, rabbit, etc.) withthe desired specificity, affinity, and/or binding capability, while theconstant regions are homologous to the sequence in an antibody derivedfrom another species.

The terms “epitope” and “antigenic determinant” are used interchangeablyherein and refer to that portion of an antigen or target capable ofbeing recognized and specifically bound by a particular antibody. Whenthe antigen or target is a polypeptide, epitopes can be formed both fromcontiguous amino acids and noncontiguous amino acids juxtaposed bytertiary folding of the protein. Epitopes formed from contiguous aminoacids (also referred to as linear epitopes) are typically retained uponprotein denaturing, whereas epitopes formed by tertiary folding (alsoreferred to as conformational epitopes) are typically lost upon proteindenaturing. An epitope typically includes at least 3, and more usually,at least 5, 6, 7, or 8-10 amino acids in a unique spatial conformation.

The terms “selectively binds” or “specifically binds” mean that an agentinteracts more frequently, more rapidly, with greater duration, withgreater affinity, or with some combination of the above to the epitope,protein, or target molecule than with alternative substances, includingrelated and unrelated proteins. In certain embodiments “specificallybinds” means, for instance, that an agent binds a protein or target witha K_(D) of about 0.1 mM or less, but more usually less than about 1 μM.In certain embodiments, “specifically binds” means that an agent binds atarget with a K_(D) of at least about 0.1 μM or less, at least about0.01 μM or less, or at least about 1 nM or less. Because of the sequenceidentity between homologous proteins in different species, specificbinding can include an agent that recognizes a protein or target in morethan one species (e.g., mouse TIGIT and human TIGIT). Likewise, becauseof homology within certain regions of polypeptide sequences of differentproteins, specific binding can include an agent that recognizes morethan one protein or target. It is understood that, in certainembodiments, an agent that specifically binds a first target may or maynot specifically bind a second target. As such, “specific binding” doesnot necessarily require (although it can include) exclusive binding,i.e. binding to a single target. Thus, an agent may, in certainembodiments, specifically bind more than one target. In certainembodiments, multiple targets may be bound by the same antigen-bindingsite on the agent. For example, an antibody may, in certain instances,comprise two identical antigen-binding sites, each of which specificallybinds the same epitope on two or more proteins. In certain alternativeembodiments, an antibody may be bispecific and comprise at least twoantigen-binding sites with differing specificities. Generally, but notnecessarily, reference to binding means specific binding.

As used herein. “selecting” and “selected” in reference to a patient isused to mean that a particular patient is specifically chosen from alarger group of patients on the basis of (due to) the particular patienthaving a predetermined criteria, e.g., the patient has a tumor with anelevated expression level of PVR and/or PVRL2. Similarly, “selectivelytreating a patient having a tumor” refers to providing treatment to acancer patient that is specifically chosen from a larger group ofpatients on the basis of (due to) the particular patient having apredetermined criteria, e.g., the patient has a tumor with an elevatedexpression level of PVR and/or PVRL2. Similarly, “selectivelyadministering” refers to administering a drug to a cancer patient thatis specifically chosen from a larger group of patients on the basis of(due to) the particular patient having a predetermined criteria, e.g.,the patient the patient has a tumor with an elevated expression level ofPVR and/or PVRL2. By selecting, selectively treating and selectivelyadministering, it is meant that a patient is delivered a personalizedtherapy for cancer based on the patient's cancer biology, rather thanbeing delivered a standard treatment regimen based solely on the patienthaving a cancer, such as CRC or NSCLC.

The terms “polypeptide” and “peptide” and “protein” are usedinterchangeably herein and refer to polymers of amino acids of anylength. The polymer may be linear or branched, it may comprise modifiedamino acids, and it may be interrupted by non-amino acids. The termsalso encompass an amino acid polymer that has been modified naturally orby intervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids), as well as other modifications known in the art. It isunderstood that, because the polypeptides of this invention may be basedupon antibodies or other members of the immunoglobulin superfamily, incertain embodiments, a “polypeptide” can occur as a single chain or astwo or more associated chains.

The terms “polynucleotide” and “nucleic acid” and “nucleic acidmolecule” are used interchangeably herein and refer to polymers ofnucleotides of any length, and include DNA and RNA. The nucleotides canbe deoxyribonucleotides, ribonucleotides, modified nucleotides or bases,and/or their analogs, or any substrate that can be incorporated into apolymer by DNA or RNA polymerase.

The terms “identical” or percent “identity” in the context of two ormore nucleic acids or polypeptides, refer to two or more sequences orsubsequences that are the same or have a specified percentage ofnucleotides or amino acid residues that are the same, when compared andaligned (introducing gaps, if necessary) for maximum correspondence, notconsidering any conservative amino acid substitutions as part of thesequence identity. The percent identity may be measured using sequencecomparison software or algorithms or by visual inspection. Variousalgorithms and software that may be used to obtain alignments of aminoacid or nucleotide sequences are well-known in the art. These include,but are not limited to, BLAST, ALIGN, Megalign BestFi, GCG WisconsinPackage, and variants thereof. In some embodiments, two nucleic acids orpolypeptides of the invention are substantially identical, meaning theyhave at least 70%, at least 75%, at least 80%, at least 85%, at least90%, and in some embodiments at least 95%, 96%, 97%, 98%, 99% nucleotideor amino acid residue identity, when compared and aligned for maximumcorrespondence, as measured using a sequence comparison algorithm or byvisual inspection. In some embodiments, identity exists over a region ofthe sequences that is at least about 10, at least about 20, at leastabout 40-60 nucleotides or amino acid residues, at least about 60-80nucleotides or amino acid residues in length or any integral value therebetween. In some embodiments, identity exists over a longer region than60-80 nucleotides or amino acid residues, such as at least about 80-100nucleotides or amino acid residues, and in some embodiments thesequences are substantially identical over the full length of thesequences being compared, for example, the coding region of a nucleotidesequence.

A “conservative amino acid substitution” is one in which one amino acidresidue is replaced with another amino acid residue having a similarside chain. Families of amino acid residues having similar side chainshave been generally defined in the art, including basic side chains(e.g., lysine, arginine, histidine), acidic side chains (e.g., asparticacid, glutamic acid), uncharged polar side chains (e.g., glycine,asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolarside chains (e.g., alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, tryptophan), beta-branched side chains (e.g.,threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine). For example, substitution of aphenylalanine for a tyrosine is considered to be a conservativesubstitution. Generally, conservative substitutions in the sequences ofpolypeptides and/or antibodies of the invention do not abrogate thebinding of the polypeptide or antibody containing the amino acidsequence, to the target binding site. Methods of identifying nucleotideand amino acid conservative substitutions which do not eliminate bindingare well-known in the art.

The term “vector” as used herein means a construct, which is capable ofdelivering, and usually expressing, one or more gene(s) or sequence(s)of interest in a host cell. Examples of vectors include, but are notlimited to, viral vectors, naked DNA or RNA expression vectors, plasmid,cosmid, or phage vectors, DNA or RNA expression vectors associated withcationic condensing agents, and DNA or RNA expression vectorsencapsulated in liposomes.

A polypeptide, soluble protein, antibody, polynucleotide, vector, cell,or composition which is “isolated” is a polypeptide, soluble protein,antibody, polynucleotide, vector, cell, or composition which is in aform not found in nature. Isolated polypeptides, soluble proteins,antibodies, polynucleotides, vectors, cells, or compositions includethose which have been purified to a degree that they are no longer in aform in which they are found in nature. In some embodiments, apolypeptide, soluble protein, antibody, polynucleotide, vector, cell, orcomposition which is isolated is substantially pure.

The term “substantially pure” as used herein refers to material which isat least 50% pure (i.e., free from contaminants), at least 90% pure, atleast 95% pure, at least 98% pure, or at least 99% pure.

The term “immune response” as used herein includes responses from boththe innate immune system and the adaptive immune system. It includesboth cell-mediated and/or humoral immune responses. It includes, but isnot limited to, both T-cell and B-cell responses, as well as responsesfrom other cells of the immune system such as natural killer (NK) cells,monocytes, macrophages, etc.

The terms “cancer” and “cancerous” as used herein refer to or describethe physiological condition in mammals in which a population of cellsare characterized by unregulated cell growth. Examples of cancerinclude, but are not limited to, carcinoma, blastoma, sarcoma, andhematologic cancers such as lymphoma and leukemia.

The terms “tumor” and “neoplasm” as used herein refer to any mass oftissue that results from excessive cell growth or proliferation, eitherbenign (non-cancerous) or malignant (cancerous) including pre-cancerouslesions.

The term “metastasis” as used herein refers to the process by which acancer spreads or transfers from the site of origin to other regions ofthe body with the development of a similar cancerous lesion at a newlocation. Generally, a “metastatic” or “metastasizing” cell is one thatloses adhesive contacts with neighboring cells and migrates via thebloodstream or lymph from the primary site of disease to secondary sitesthroughout the body.

The terms “cancer cell” and “tumor cell” refer to the total populationof cells derived from a cancer or tumor or pre-cancerous lesion,including both non-tumorigenic cells, which comprise the bulk of thecancer cell population, and tumorigenic stem cells (cancer stem cells).As used herein, the terms “cancer cell” or “tumor cell” will be modifiedby the term “non-tumorigenic” when referring solely to those cellslacking the capacity to renew and differentiate to distinguish thosetumor cells from cancer stem cells.

The term “subject” refers to any animal (e.g., a mammal), including, butnot limited to, humans, non-human primates, canines, felines, rabbits,rodents, and the like, which is to be the recipient of a particulartreatment. Typically, the terms “subject” and “patient” are usedinterchangeably herein in reference to a human subject.

The term “pharmaceutically acceptable” refers to a substance approved orapprovable by a regulatory agency of the Federal government or a stategovernment or listed in the U.S. Pharmacopeia or other generallyrecognized pharmacopeia for use in animals, including humans.

The terms “pharmaceutically acceptable excipient, carrier, or adjuvant”or “acceptable pharmaceutical carrier” refer to an excipient, carrier,or adjuvant that can be administered to a subject, together with atleast one agent of the present disclosure, and which does not destroythe pharmacological activity thereof and is non-toxic when administeredin doses sufficient to deliver a therapeutic effect. In general, thoseof skill in the art and the U.S. FDA consider a pharmaceuticallyacceptable excipient, carrier, or adjuvant to be an inactive ingredientof any formulation.

The terms “effective amount” or “therapeutically effective amount” or“therapeutic effect” refer to an amount of an agent, an antibody, apolypeptide, a polynucleotide, a small organic molecule, or other drugeffective to “treat” a disease or disorder in a subject such as, amammal In the case of cancer or a tumor, the therapeutically effectiveamount of an agent (e.g., polypeptide or antibody) has a therapeuticeffect and as such can enhance or boost the immune response, enhance orboost the anti-tumor response, increase cytolytic activity of immunecells, increase killing of tumor cells, increase killing of tumor cellsby immune cells, reduce the number of tumor cells; decreasetumorigenicity, tumorigenic frequency, or tumorigenic capacity; reducethe number or frequency of cancer stem cells; reduce the tumor size;reduce the cancer cell population; inhibit or stop cancer cellinfiltration into peripheral organs including, for example, the spreadof cancer into soft tissue and bone; inhibit and stop tumor or cancercell metastasis; inhibit and stop tumor or cancer cell growth; relieveto some extent one or more of the symptoms associated with the cancer;reduce morbidity and mortality; improve quality of life; or acombination of such effects.

The terms “treating” or “treatment” or “to treat” or “alleviating” or“to alleviate” refer to both (1) therapeutic measures that cure, slowdown, lessen symptoms of, and/or halt progression of a diagnosedpathologic condition or disorder and (2) prophylactic or preventativemeasures that prevent or slow the development of a targeted pathologiccondition or disorder. Thus those in need of treatment include thosealready with the disorder; those prone to have the disorder; and thosein whom the disorder is to be prevented. In the case of cancer or atumor, a subject is successfully “treated” according to the methods ofthe present invention if the patient shows one or more of the following:an increased immune response, an increased anti-tumor response,increased cytolytic activity of immune cells, increased killing of tumorcells, increased killing of tumor cells by immune cells, a reduction inthe number of or complete absence of cancer cells; a reduction in thetumor size; inhibition of or an absence of cancer cell infiltration intoperipheral organs including the spread of cancer cells into soft tissueand bone; inhibition of or an absence of tumor or cancer cellmetastasis; inhibition or an absence of cancer growth; relief of one ormore symptoms associated with the specific cancer; reduced morbidity andmortality; improvement in quality of life; reduction in tumorigenicity;reduction in the number or frequency of cancer stem cells; or somecombination of effects.

As used in the present disclosure and claims, the singular forms “a”,“an” and “the” include plural forms unless the context clearly dictatesotherwise.

It is understood that wherever embodiments are described herein with thelanguage “comprising” otherwise analogous embodiments described in termsof “consisting of” and/or “consisting essentially of” are also provided.It is also understood that wherever embodiments are described hereinwith the language “consisting essentially of” otherwise analogousembodiments described in terms of “consisting of” are also provided.

As used herein, reference to “about” or “approximately” a value orparameter includes (and describes) embodiments that are directed to thatvalue or parameter. For example, description referring to “about X”includes description of “X”.

The term “and/or” as used in a phrase such as “A and/or B” herein isintended to include both A and B; A or B; A (alone); and B (alone).Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C”is intended to encompass each of the following embodiments: A, B, and C;A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A(alone); B (alone); and C (alone).

II. Methods of Use and Pharmaceutical Compositions

The TIGIT-binding agents of the invention are useful in a variety ofapplications including, but not limited to, therapeutic treatmentmethods, such as treatment of cancer. In some embodiments, thetherapeutic treatment methods comprise immunotherapy for cancer. Incertain embodiments, a TIGIT-binding agent is useful for activating,promoting, increasing, and/or enhancing an immune response, inhibitingtumor growth, reducing tumor volume, increasing tumor cell apoptosis,and/or reducing the tumorigenicity of a tumor.

The present invention provides methods for inhibiting tumor growth usinga TIGIT-binding agent. In certain embodiments, the method of inhibitingtumor growth comprises administering to a subject a therapeuticallyeffective amount of a TIGIT-binding agent. In some embodiments, theTIGIT-binding agent is an antibody that specifically binds theextracellular domain of human TIGIT. In certain embodiments, the subjectis a human In certain embodiments, the subject has a tumor or thesubject had a tumor which was at least partially removed.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the tumor is a microsatellite instability-high colorectal cancer(MSI CRC), a microsatellite stable colorectal cancer (MSS CRC), a triplenegative breast cancer (TNBC), a Merkel cell carcinoma, an endometrialcancer, or an esophageal cancer. In some embodiments, a method ofinhibiting tumor growth (e.g., treating cancer) in a subject, comprisingadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of humanTIGIT, wherein the tumor is a microsatellite instability-high colorectalcancer (MSI CRC), a microsatellite stable colorectal cancer (MSS CRC), atriple negative breast cancer (TNBC), a Merkel cell carcinoma, anendometrial cancer, or an esophageal cancer; and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the tumor is an esophagealcancer. In some embodiments, the tumor is an esophageal cancer that hasprogressed on at least one prior systemic therapy or line of treatmentfor unresectable and/or metastatic disease. In some embodiments, thetumor is a triple-negative breast cancer. In some embodiments, the tumoris a triple negative breast cancer that has been histologicallyconfirmed as an incurable, advanced estrogen receptor-neg, progesteronereceptor-neg, and human epidermal growth factor receptor 2-negadenocarcinoma of the breast.

In some embodiments, histological confirmation is conducted by a skilledartisan, such as a trained clinical physician, using any method known inthe art, such as immunohistochemistry.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the tumor is a solid tumor with high MSI. In some embodiments, amethod of inhibiting tumor growth (e.g., treating cancer) in a subject,comprising administering to the subject a therapeutically effectiveamount of an antibody that specifically binds the extracellular domainof human TIGIT, wherein the tumor is a solid tumor with high MSI; andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In some embodimentsthe solid tumor with high MSI can include a MSI CRC, a MSI gastriccancer, a MSI endometrium cancer, a MSI ovarian cancer, a MSIhepatobiliary tract cancer, a MSI urinary tract cancer, a MSI braincancer, or a MSI skin cancer.

Generally, tumors can be classified according to their microsatellitestability (MSI). For example, solid tumors can be classified asMSI-high, MSI-low or MSI-stable tumors. MSI-high tumors can include,without limitation, colon cancer, gastric cancer, endometrium cancer,ovarian cancer, hepatobiliary tract cancer, urinary tract cancer, braincancer and skin cancer. MSI can be determined using any method known inthe art, such as polymerase chain reaction (PCR) or immunohistochemistry(IHC). In some embodiments, MSI is determined in a sample obtained froma cancer patient. In some embodiments the sample is a biopsy sample(e.g., needle biopsy). In some embodiments, MSI is determined in apolymerase chain reaction (PCR) based method, such as but not limitedto, reverse transcription PCR (RT-PCR), quantitative RT-PCR (qPCR),TaqMan™, or TaqMan™ low density array (TLDA). In some embodiments, theMSI is determined using a microarray. In some embodiments, MSI isdetermined by DNA sequencing, such as next-generation sequencing. Insome embodiments, MSI is determined in an immunohistochemistry (IHC)assay. In some embodiments, a tumor MSI is compared to a pre-determinedMSI. In some embodiments, a tumor is classified as a MSI-high tumor ifthe MSI in the tumor is higher than the predetermined MSI. In someembodiments, the predetermined MSI is the MSI in a reference tumorsample, a reference normal tissue sample, a series of reference tumorsamples, or a series of reference normal tissue samples.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor is a microsatellite instability-high colorectal cancer, amicrosatellite stable colorectal cancer, a triple negative breastcancer, a Merkel cell carcinoma, an endometrial cancer, or an esophagealcancer. In some embodiments, a method of inhibiting tumor growth (e.g.,treating cancer) in a subject, comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-1antagonist, wherein the tumor is a microsatellite instability-highcolorectal cancer, a microsatellite stable colorectal cancer, a triplenegative breast cancer, a Merkel cell carcinoma, an endometrial cancer,or an esophageal cancer, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT in combination with a PD-L1antagonist, wherein the tumor is a microsatellite instability-highcolorectal cancer, a microsatellite stable colorectal cancer, a triplenegative breast cancer, a Merkel cell carcinoma, an endometrial cancer,or an esophageal cancer, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor is an esophageal cancer. In some embodiments, thetumor is an esophageal cancer that has progressed on at least one priorsystemic therapy or line of treatment for unresectable and/or metastaticdisease. In some embodiments, the tumor is a triple-negative breastcancer. In some embodiments, the tumor is a triple negative breastcancer that has been histologically confirmed as an incurable, advancedestrogen receptor-neg, progesterone receptor-neg, and human epidermalgrowth factor receptor 2-neg adenocarcinoma of the breast.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor is a solid tumor with high MSI. In some embodiments, a method ofinhibiting tumor growth (e.g., treating cancer) in a subject, comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of human TIGITin combination with a PD-1 antagonist, wherein the tumor is a solidtumor with high MSI, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT in combination with a PD-L1antagonist, wherein the tumor is a solid tumor with high MSI, andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In some embodimentsthe solid tumor with high microsatellite instability can include a MSICRC, a MSI gastric cancer, a MSI endometrium cancer, a MSI ovariancancer, a MSI hepatobiliary tract cancer, a MSI urinary tract cancer, aMSI brain cancer, or a MSI skin cancer.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the tumor is resistant or refractory to treatment with a PD-1antagonist or a PD-L1 antagonist. In some embodiments, a method ofinhibiting tumor growth (e.g., treating cancer) in a subject, comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of humanTIGIT, wherein the tumor is resistant or refractory to treatment with aPD-1 antagonist, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor is resistant or refractory to treatment with ananti-PD-1 antibody. In some embodiments, a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprises administering tothe subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT, wherein thetumor is resistant or refractory to treatment with a PD-L1 antagonist,and wherein the antibody that binds human TIGIT comprises a heavy chainCDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor is resistant or refractory to treatment with ananti-PD-L1 antibody.

In some embodiments, the tumor that is resistant or refractory totreatment with a PD-1 antagonist or a PD-L1 antagonist is selected fromthe group consisting of melanoma, NSCLC, renal cell carcinoma, squamouscell carcinoma of the head and neck, urothelial carcinoma, colorectalcancer (e.g. MSI or dMMR metastatic CRC) and hepatocellular carcinoma.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor is resistant or refractory to treatment with a PD-1 antagonist asa single agent or a PD-L1 antagonist as a single agent. In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT in combination with a PD-1antagonist, wherein the tumor is resistant or refractory to treatmentwith a PD-1 antagonist as a single agent; and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the PD-1 antagonist is an anti-PD-1antibody. In some embodiments, the anti-PD-1 antibody is pembrolizumab(KEYTRUDA®). In some embodiments, the anti-PD-1 antibody is nivolumab(OPDIVO®). In some embodiments, a method of inhibiting tumor growth(treating cancer) in a subject, comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-L1antagonist, wherein the tumor is resistant or refractory to treatmentwith a PD-L1 antagonist as a single agent; and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the PD-L1 antagonist is an anti-PD-L1antibody. In some embodiments, the anti-PD-L1 antibody is atezolizumab(TECENTRIQ). In some embodiments, the anti-PD-L1 antibody is avelumab(MSB0010718C).

In some embodiments, the tumor is resistant or refractory to treatmentwith a PD-1 antagonist as a single agent or a PD-L1 antagonist as asingle agent can include a melanoma, a NSCLC, a renal cell carcinoma, asquamous cell carcinoma of the head and neck, a urothelial carcinoma, acolorectal cancer (e.g. MSI or dMMR metastatic CRC) and a hepatocellularcarcinoma.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the subject has previously been treated with a PD-1 antagonistor a PD-L1 antagonist. In some embodiments, a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprises administering tothe subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT, wherein thesubject has previously been treated with a PD-1 antagonist, and whereinthe antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT, wherein the subject has previouslybeen treated with a PD-L1 antagonist, and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the subject has previously been treated witha PD-1 antagonist or a PD-L1 antagonist as a single agent. In someembodiments, the subject has previously been treated with a PD-1antagonist or a PD-L1 antagonist, wherein there was disease progressionon or after treatment. Subjects that have disease progression on orafter a specific treatment may be referred to herein as “progressors”.In some embodiments, the subject has previously been treated with ananti-PD-1 antibody as a first-line treatment. In some embodiments, thesubject has previously been treated with an anti-PD-1 antibody as asecond-line or third-line treatment. In some embodiments, the subjecthas previously been treated with pembrolizumab (KEYTRUDA®). In someembodiments, the subject has previously been treated with nivolumab(OPDIVO®). In some embodiments, the subject has previously been treatedwith an anti-PD-L1 antibody as a first-line treatment. In someembodiments, the subject has previously been treated with an anti-PD-L1antibody as a second-line or third-line treatment. In some embodiments,the subject has previously been treated with atezolizumab (TECENTRIQ®).In some embodiments, the subject has previously been treated withavelumab (MSB0010718C). In some embodiments, the subject has previouslybeen treated with a PD-1 antagonist or a PD-L1 antagonist as part of acombination therapy. In some embodiments, the subject has previouslybeen treated with an anti-PD-1 antibody and a second checkpointinhibitor. In some embodiments, the subject has previously been treatedwith an anti-PD-1 antibody and an anti-CTLA-4 antibody. In someembodiments, the subject has previously been treated with nivolumab(OPDIVO®) and ipilimumab (YERVOY®). In some embodiments, the subject haspreviously been treated with an anti-PD-1 antibody and achemotherapeutic agent. In some embodiments, the subject has previouslybeen treated with an anti-PD-L1 antibody and a second checkpointinhibitor. In some embodiments, the subject has previously been treatedwith an anti-PD-L1 antibody and an anti-CTLA-4 antibody. In someembodiments, the subject has previously been treated with an anti-PD-L1antibody and ipilimumab (YERVOY®). In some embodiments, the subject haspreviously been treated with an anti-PD-L1 antibody and achemotherapeutic agent.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist, wherein the subject haspreviously been treated with a PD-1 antagonist or a PD-L1 antagonist. Insome embodiments, a method of inhibiting tumor growth (e.g., treatingcancer) in a subject, comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT in combination with a PD-1antagonist, wherein the subject has previously been treated with a PD-1antagonist; and wherein the antibody that binds human TIGIT comprises aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the subject has previously been treated with an anti-PD-1antibody. In some embodiments, the subject has previously been treatedwith pembrolizumab (KEYTRUDA®). In some embodiments, the subject haspreviously been treated with nivolumab (OPDIVO®). In some embodiments,tumor growth progressed during treatment with an anti-PD-1 antibody. Insome embodiments, tumor growth recurred after treatment with ananti-PD-1 antibody. In some embodiments, the tumor is responsive to acombination therapy of the anti-TIGIT antibody and an anti-PD-1antibody. In some embodiments, the tumor is responsive to a combinationtherapy of the anti-TIGIT antibody and an anti-PD-1 antibody, whereinthe response is better than the response obtained with administration ofthe anti-TIGIT antibody alone. In some embodiments, a method ofinhibiting tumor growth (treating cancer) in a subject, comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of human TIGITin combination with a PD-L1 antagonist, wherein the subject haspreviously been treated with a PD-L1 antagonist as a single agent; andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the subject has previously been treated with an anti-PD-L1antibody. In some embodiments, the subject has previously been treatedwith atezolizumab (TECENTRIQ®). In some embodiments, the subject haspreviously been treated with avelumab (MSB0010718C). In someembodiments, tumor growth progressed during treatment with an anti-PD-L1antibody. In some embodiments, tumor growth recurred after treatmentwith an anti-PD-L1 antibody. In some embodiments, the tumor isresponsive to a combination therapy of the anti-TIGIT antibody and ananti-PD-L1 antibody. In some embodiments, the tumor is responsive to acombination therapy of the anti-TIGIT antibody and an anti-PD-L1antibody, wherein the response is better than the response obtained withadministration of the anti-TIGIT antibody alone.

In some embodiments, the tumor in the subject previously treated with aPD-1 antagonist or a PD-L1 antagonist can have a tumor such as amelanoma, a NSCLC, a renal cell carcinoma, a squamous cell carcinoma ofthe head and neck, a urothelial carcinoma, a colorectal cancer (e.g. MSIor dMMR metastatic CRC) or a hepatocellular carcinoma.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the tumor/cancer expresses PVR and/or PVRL2. In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT, wherein the tumor/cancer expressesPVR and/or PVRL2; and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, a tumor sample is obtained from the subject and theexpression level of PVR and/or PVRL2 is determined. In some embodiments,the expression level of PVR is used to select a subject for treatment.In some embodiments, the expression level of PVRL2 is used to select asubject for treatment.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising selectivelyadministering to the subject a therapeutically effective amount of aTIGIT-binding agent, on the basis that the tumor/cancer expresses PVRand/or PVRL2. In some embodiments, a method of inhibiting tumor growth(e.g., treating cancer) in a subject, comprises selectivelyadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of humanTIGIT, on the basis that the tumor/cancer expresses PVR and/or PVRL2;and wherein the antibody that binds human TIGIT comprises a heavy chainCDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the tumor/cancer expressing PVR and/or PVRL2includes a NSCLC, a. renal cell carcinoma, a squamous cell carcinoma ofthe head and neck, a urothelial carcinoma, a colorectal cancer (e.g. MSIor dMMR metastatic CRC) or a hepatocellular carcinoma.

In some embodiments, the tumor/cancer expressing PVR and/or PVRL2includes a CRC, a gastric cancer, a endometrium cancer, a ovariancancer, a hepatobiliary tract cancer, a urinary tract cancer, a braincancer, or a skin cancer.

In some embodiments, the tumor/cancer expressing PVR and/or PVRL2includes a MSI CRC, a MSI gastric cancer, a MSI endometrium cancer, aMSI ovarian cancer, a MSI hepatobiliary tract cancer, a MSI urinarytract cancer, a MSI brain cancer, or a MSI skin cancer.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor expresses PVR and/or PVRL2. In some embodiments, a method ofinhibiting tumor growth (e.g., treating cancer) in a subject, comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of human TIGITin combination with a PD-1 antagonist, wherein the tumor expresses PVRand/or PVRL2; and wherein the antibody that binds human TIGIT comprisesa heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT in combination with a PD-L1antagonist, wherein the tumor expresses PVR and/or PVRL2; and whereinthe antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the anti-TIGIT antibody is administered in combination withan anti-PD-1 antibody. In some embodiments, the anti-TIGIT antibody isadministered in combination with pembrolizumab (KEYTRUDA®). In someembodiments, the anti-TIGIT antibody is administered in combination withnivolumab (OPDIVO®). In some embodiments, the anti-TIGIT antibody isadministered in combination with an anti-PD-L1 antibody. In someembodiments, the anti-TIGIT antibody is administered in combination withatezolizumab (TECENTRIQ®).

In some embodiments, the expression level of PVR and/or PVRL2 in a tumorsample is determined to be at a high level. In some embodiments, theexpression level of PVR in the sample is compared to a pre-determinedexpression level of PVR. In some embodiments, the expression level ofPVRL2 in the sample is compared to a pre-determined expression level ofPVRL2. In some embodiments, the pre-determined expression level of PVRexpression is an expression level of PVR in a reference tumor sample, areference normal tissue sample, a series of reference tumor samples, ora series of reference normal tissue samples. In some embodiments, thepre-determined expression level of PVRL2 expression is an expressionlevel of PVRL2 in a reference tumor sample, a reference normal tissuesample, a series of reference tumor samples, or a series of referencenormal tissue samples. In some embodiments, the expression level of PVRor PVRL2 is determined using an immunohistochemistry (IHC) assay. Insome embodiments, the expression level of PVR and/or PVRL2 is determinedusing an assay which comprises an H-score evaluation. In someembodiments, the expression level of PVR is determined using an antibodythat specifically binds PVR. In some embodiments, the expression levelof PVRL2 is determined using an antibody that specifically binds PVRL2.In some embodiments, PVR is detected on tumor cells. In someembodiments, the PVRL2 is detected on tumor cells. In some embodiments,PVR is detected on tumor-infiltrating immune cells and/or in the tumormicroenvironment. In some embodiments, PVRL2 is detected ontumor-infiltrating immune cells and/or in the tumor microenvironment.

In certain embodiments, the expression level of PVR and/or PVRL2 isdetermined using PCR-based methods, such as but not limited to, reversetranscription PCR (RT-PCR), quantitative RT-PCR (qPCR), TaqMan™, orTaqMan™ low density array (TLDA). In some embodiments, the expressionlevel of a biomarker is determined using a microarray.

In certain embodiments, the expression level PVR and/or PVRL2 isdetermined using protein-based methods. In some embodiments, theexpression level of a biomarker is measured or determined bymulti-analyte profile testing, radioimmunoassay (RIA), Western blotassay, immunofluorescent assay, enzyme immunoassay, enzyme linkedimmunosorbent assay (ELISA), immunoprecipitation assay, chemiluminescentassay, immunohistochemical (IHC) assay, dot blot assay, or slot blotassay. In some embodiments, the expression level of PVR and/or PVRL2 isdetermined using an IHC assay. In some embodiments, the assay uses anantibody (e.g., as anti-PVR or PVRL2 antibody). In some embodimentswherein the assay uses an antibody, the antibody is detectably labeled.In some embodiments, the label is selected from the group consisting ofan immunofluorescent label, a chemiluminescent label, a phosphorescentlabel, an enzyme label, a radiolabel, an avidin/biotin label, colloidalgold particles, colored particles, and magnetic particles.

In some embodiments, the determining of the level of PVR and/or PVRL2expression is done prior to treatment with a TIGIT-binding agent. Insome embodiments, if a tumor or cancer has an elevated expression levelof PVR and/or PVRL2, a TIGIT-binding agent is administered to thesubject. In some embodiments, a method comprises (i) obtaining a tumorsample from the subject; (ii) measuring the expression level of PVRand/or PVRL2 in the sample; and (iii) administering an effective amountof a TIGIT-binding agent to the subject if the tumor or cancer has anelevated or high expression level of PVR and/or PVRL2.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising selectivelyadministering to the subject a therapeutically effective amount of aTIGIT-binding agent in combination with a PD-1 antagonist or a PD-L1antagonist, on the basis that the tumor has an elevated expression levelof PVR and/or PVRL2. In some embodiments, a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprises administering tothe subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT incombination with a PD-1 antagonist, wherein the tumor has an elevatedexpression level of PVR and/or PVRL2; and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, a method of inhibiting tumor growth (e.g.,treating cancer) in a subject, comprises selectively administering tothe subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT incombination with a PD-L1 antagonist, on the basis that the tumor has anelevated expression level of PVR and/or PVRL2; and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the anti-TIGIT antibody isadministered in combination with an anti-PD-1 antibody. In someembodiments, the anti-TIGIT antibody is administered in combination withpembrolizumab (KEYTRUDA®). In some embodiments, the anti-TIGIT antibodyis administered in combination with nivolumab (OPDIVO®). In someembodiments, the anti-TIGIT antibody is administered in combination withan anti-PD-L1 antibody. In some embodiments, the anti-TIGIT antibody isadministered in combination with atezolizumab (TECENTRIQ®).

In some embodiments, the sample is a biopsy sample. In some embodiments,the sample comprises tumor cells, tumor-infiltrating immune cells,stromal cells, and any combination thereof. In some embodiments, thesample is a formalin-fixed paraffin embedded (FFPE) sample. In someembodiments, the sample is archival, fresh, or frozen tissue.

Some patients have tumors with an active immune microenvironment. Thesetumors are referred to as “inflamed” or “hot” tumors and arecharacterized by the presence of, for example, tumor-infiltratinglymphocytes (TILs), IFN-gamma producing CD8+ T-cells, and expression ofPD-L1. In some studies, inflamed or hot tumors have been associated withclinical response to immunotherapies.

Thus in some embodiments, the invention provides a method of inhibitingtumor growth (e.g., treating cancer) in a subject, comprisingadministering to the subject a therapeutically effective amount of aTIGIT-binding agent, wherein the tumor comprises TILs. In someembodiments, a method of inhibiting tumor growth (e.g., treating cancer)in a subject, comprises administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of human TIGIT, wherein the tumor comprises TILs;and wherein the antibody that binds human TIGIT comprises a heavy chainCDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor comprises a high level of TILs as compared to apredetermined level. In some embodiments, the level of TILs is anabsolute number of TILs. In some embodiments, the level of TILs is apercentage of a total cell number.

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor comprises TILs. In some embodiments, a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprises administering tothe subject a therapeutically effective amount of an antibody thatspecifically binds the extracellular domain of human TIGIT incombination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor comprises TILs; and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor comprises a high level of TILs as compared to apredetermined level. In some embodiments, the level of TILs is anabsolute number of TILs. In some embodiments, the level of TILs is apercentage of a total cell number. In some embodiments, the anti-TIGITantibody is administered in combination with an anti-PD-1 antibody. Insome embodiments, the anti-TIGIT antibody is administered in combinationwith pembrolizumab (KEYTRUDA®). In some embodiments, the anti-TIGITantibody is administered in combination with nivolumab (OPDIVO®). Insome embodiments, the anti-TIGIT antibody is administered in combinationwith an anti-PD-L1 antibody. In some embodiments, the anti-TIGITantibody is administered in combination with atezolizumab (TECENTRIQ®).

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agent,wherein the tumor comprises a high level of regulatory T-cells (Tregs).In some embodiments, a method of inhibiting tumor growth (e.g., treatingcancer) in a subject, comprises administering to the subject atherapeutically effective amount of an antibody that specifically bindsthe extracellular domain of human TIGIT, wherein the tumor comprises ahigh level of Tregs; and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:7), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:8).

In some embodiments, the invention provides a method of inhibiting tumorgrowth (e.g., treating cancer) in a subject, comprising administering tothe subject a therapeutically effective amount of a TIGIT-binding agentin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor comprises a high level of Tregs. In some embodiments, a method ofinhibiting tumor growth (e.g., treating cancer) in a subject, comprisesadministering to the subject a therapeutically effective amount of anantibody that specifically binds the extracellular domain of human TIGITin combination with a PD-1 antagonist or a PD-L1 antagonist, wherein thetumor comprises a high level of Tregs; and wherein the antibody thatbinds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN (SEQID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5),a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the anti-TIGIT antibody is administered incombination with an anti-PD-1 antibody. In some embodiments, theanti-TIGIT antibody is administered in combination with pembrolizumab(KEYTRUDA®). In some embodiments, the anti-TIGIT antibody isadministered in combination with nivolumab (OPDIVO®). In someembodiments, the anti-TIGIT antibody is administered in combination withan anti-PD-L1 antibody. In some embodiments, the anti-TIGIT antibody isadministered in combination with atezolizumab (TECENTRIQ®).

In some embodiments, the presence of immune cells (e.g., TILs, Tregs,Teffs) in a tumor or within the tumor microenvironment is analyzed byassessing expression of specific proteins on or in the cells. Commonlyused methods for the analysis of protein expression, include but are notlimited to, immunohistochemistry (IHC)-based, antibody-based, and massspectrometry-based methods. In some embodiments, protein expression onor in an immune cell is determined by an assay known to those of skillin the art, including but not limited to, multi-analyte profile test,enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, Westernblot assay, immunofluorescent assay, enzyme immunoassay,immunoprecipitation assay, chemiluminescent assay, immunohistochemical(IHC) assay, dot blot assay, or slot blot assay. Antibodies, generallymonoclonal antibodies, may be used to detect expression of a geneproduct (e.g., protein). In some embodiments, the antibodies can bedetected by direct labeling of the antibodies themselves. In otherembodiments, an unlabeled primary antibody is used in conjunction with alabeled secondary antibody.

In some embodiments, the expression of a specific protein is determinedusing an agent that specifically binds that protein. Any molecularentity that displays specific binding to the protein can be employed toassess the expression of the protein in a sample. Specific bindingagents include, but are not limited to, antibodies, antibody mimetics,and polynucleotides (e.g., aptamers). One of skill understands that thedegree of specificity required is determined by the particular assayused to detect the protein.

CD45 (leukocyte common antigen, LCA; including all proteins in the CD45family) is used as a marker for immune cells, including lymphocytes, NKcells, macrophages, monocytes, etc. T-cell can be separated intodifferent subsets, including but not limited to, CD4+ T-cells or CD8+T-cells. In some embodiments, CD45 is used as a marker for TILs in atumor sample. In some embodiments, TILs are detected and/or assessedusing an anti-CD45 antibody. In some embodiments, a cocktail ofmonoclonal anti-CD45 antibodies are used, each of which recognizes adifferent CD45 isotype and/or different epitopes. In some embodiments,TILs are detected and/or assessed using an anti-CD4 antibody. In someembodiments, TILs are detected and/or assessed using an anti-CD8antibody.

It is known by those of skill in the art that FOXP3 is a regulatoryT-cell (Treg) marker and can be used to detect and/or identify Tregs ina tumor sample. Studies have shown that Treg cells are comprised of manysubpopulations with different functions and one subpopulation has beenidentified to be FOXP3+ and TIGIT+. In some embodiments, Tregs aredetected and/or assessed by FOXP3 expression. In some embodiments, FOXP3expression is detected and/or assessed using an anti-FOXP3 antibody. Insome embodiments, a cocktail of monoclonal anti-FOXP3 antibodies areused, each of which recognizes a different isotype and/or differentepitopes. In some embodiments, Tregs are detected and/or assessed byFOXP3 and TIGIT expression. In some embodiments, the TIGIT expression isdetected and/or assessed using an anti-TIGIT antibody.

In some embodiments, wherein an antibody is used in the assay theantibody is detectably labeled. Examples of detectable substancesinclude various enzymes, prosthetic groups, fluorescent materials,phosphorescent materials, luminescent materials, bioluminescentmaterials, chemiluminescent materials, radioactive materials,avidin/biotin, colloidal gold particles, colored particles and magneticparticles. Examples of suitable enzymes include horseradish peroxidase,alkaline phosphatase, ?-galactosidase, or acetylcholinesterase; examplesof suitable prosthetic group complexes include streptavidin/biotin andavidin/biotin; examples of suitable fluorescent materials includeumbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; anexample of a luminescent material includes luminol; examples ofbioluminescent materials include luciferase, luciferin, and aequorin;and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S,or ³H.

In some embodiments, the expression of CD45, CD4, CD8, FOXP3, and/orTIGIT is determined using an IHC assay. For example, FFPE sections arecut from a tumor sample and mounted on coated glass slides. Tissues aredeparaffinized and rehydrated by successively incubating them in xylene,100% ethanol, 95% ethanol, 70% ethanol, and distilled water for antigenretrieval. Slides are placed into retrieval solution and placed in adecloaker for antigen retrieval. To block endogenous peroxidase activityslides are incubated in hydrogen peroxide and washed in PBS. To blocknon-specific background staining slides are incubated in blocker. Slidesare incubated with an anti-PD-L1 antibody. Specific binding is detectedusing a kit including diaminobenzidine (DAB). The sections arecounterstained with hematoxylin. In some embodiments, the FFPE sectionsare mounted on coated glass slides and stained using an automatedsystem, e.g., on a Ventana® BenchMark® ULTRA instrument using Ventanareagents.

In some embodiments, the antibody is a polyclonal antibody. In someembodiments, the antibody is a monoclonal antibody. In some embodiments,the antibody is a mouse antibody that binds a human biomarker (e.g.,CD45, CD4, CD8, FOXP3, TIGIT). In some embodiments, the antibody is arabbit antibody that binds a human biomarker (e.g., CD45, CD4, CD8,FOXP3, TIGIT). In some embodiments, the antibody is a goat antibody thatbinds a human biomarker (e.g., CD45, CD4, CD8, FOXP3, TIGIT).

IHC slides may be analyzed using an automated instrument or evaluatedmanually by microscope. The staining intensity of each cell (0: noexpression, 1: weak expression, 2: moderate expression, 3: strongexpression) is measured and cells of each staining level are counted anda percentage for each type is calculated. The data is combined into aweighted H-score for each tissue section: H-score=[3×(% 3+cells)]+[2×(%2+cells)]+[1×(% 1+cells)]. Using these parameters, the highest scoreavailable is H-score=300. In some embodiments, an H-score of 1 or lessis considered negative. In some embodiments, the IHC assay has a cut-offvalue. In some embodiments, the IHC assay has a cut-off value forspecificity. In some embodiments, the IHC assay has a cut-off value forefficacy. In some embodiments, the IHC assay has a cut-off valuedetermined by screening of positive and negative tumor tissues. In someembodiments, the IHC assay has a cut-off value of about 25. In someembodiments, the IHC assay has a cut-off value of about 30, about 40,about 50, about 60, about 70, about 80, about 90, about 100, or about110, or about 120.

Other suitable methods for analyzing the expression level of a biomarkerinclude proteomics-based methods. Proteomics includes, among otherthings, study of the global changes of protein expression in a sample.In some embodiments, a proteomic method comprises the following steps:(1) separation of individual proteins in a sample by 2-D electrophoresis(2-D PAGE), (2) identification of individual proteins recovered from thegel (e.g., by mass spectrometry or N-terminal sequencing), and (3)analysis of the data using bioinformatics. In some embodiments, aproteomic method comprises using a tissue microarray (TMA). Tissuearrays may be constructed according to a variety of techniques known toone of skill in the art. In certain embodiments, a manual tissue arrayeris used to remove a “core” from a paraffin block prepared from a tissuesample. The core is then inserted into a separate paraffin block in adesignated location on a grid. Cores from as many as about 400 samplescan be inserted into a single recipient block. The resulting tissuearray may be processed into thin sections for analysis. In someembodiments, a proteomic method comprises an antibody microarray. Insome embodiments, a proteomic method comprises using mass spectrometry,including but not limited to, SELDI, MALDI, electro spray, and surfaceplasmon resonance methods. In some embodiments, a proteomic methodcomprises bead-based technology, including but not limited to,antibodies on beads in an array format. In some embodiments, theproteomic method comprises a reverse phase protein microarray (RPPM). Insome embodiments, the proteomic method comprises multiplexed proteinprofiling, including but not limited to, the Global Proteome Survey(GPS) method.

Other suitable methods for analyzing the expression level of a biomarkerinclude, but are not limited to, methods based on analyses ofpolynucleotide expression, sequencing of polynucleotides, and/oranalyses of protein expression. For example, determination of biomarkerexpression levels may be performed by detecting the expression of mRNAexpressed from the genes of interest, and/or by detecting the expressionof a polypeptide encoded by the genes.

Commonly used methods for the analysis of polynucleotides, includeSouthern blot analysis, Northern blot analysis, and in situhybridization, RNAse protection assays, and polymerase chain reaction(PCR)-based methods, such as reverse transcription polymerase chainreaction (RT-PCR), quantitative PCR (qPCR) as known as real-time PCR,TaqMan™, TaqMan™ low density array (TLDA), anchored PCR, competitivePCR, rapid amplification of cDNA ends (RACE), and microarray analyses.RT-PCR is a quantitative method that can be used to compare mRNA levelsin different samples to examine gene expression profiles. A variation ofRT-PCR is real time quantitative PCR, which measures PCR productaccumulation through a dual-labeled fluorigenic probe (e.g., TaqMan™probe). There are many other PCR-based techniques known to one of skillin the art, including but not limited to, differential display,amplified fragment length polymorphism, BeadArray™ technology, highcoverage expression profiling (HiCEP) and digital PCR. Representativemethods for sequencing-based gene expression analyses include SerialAnalysis of Gene Expression (SAGE), Massively Parallel SignatureSequencing (MPSS), and NexGen sequencing analysis, including mRNAsequencing.

In certain embodiments, biomarker expression is determined using a qPCRassay. For example, total RNA is extracted from a fresh frozen (FF)tissue sample or total RNA is extracted from a macro-dissectedformalin-fixed paraffin embedded (FFPE) tissue sample. The quantity andquality of the total RNA is assessed by standard spectrophotometryand/or any other appropriate method (e.g., an Agilent Bioanalyzer).Following RNA extraction, the RNA sample is reverse transcribed usingstandard methods and/or a commercially available cDNA synthesis kit(e.g., Roche Transcriptor First Strand cDNA synthesis kit). Theresultant cDNA is pre-amplified using, for example, an ABIpre-amplification kit. Expression of the biomarker(s) (e.g., CD45, CD4,CD8, Foxp3, TIGIT, other immune response genes) is assessed on, forexample, a Roche LightCycler® 480 system (Roche Diagnostics) using anABI TaqMan™ Gene Expression Mastermix. qPCR reactions are performed intriplicate. For each assay a subset of the samples is run withoutreverse transcription (the RT-neg control), as well as, control samplesrun without template. A universal human reference RNA sample is includedon each plate to act as a positive control. Suitable reference genes areidentified from a standard panel of reference genes. Candidate referencegenes are selected with different cellular functions to eliminate riskof co-regulation. The most suitable reference genes are evaluated andselected using specific software and algorithms (e.g., Genex® software;GeNorm and Normfinder algorithms). The expression level of eachbiomarker is normalized using the selected optimum reference genes. Insome embodiments, these normalized (or standardized) expression valuesfor each biomarker are used to calculate the decision value of thesample. In some embodiments, these normalized (or standardized)expression values for each biomarker are used to calculate an expressionlevel.

In some embodiments, biomarker expression is determined using aPCR-based assay comprising specific primers and/or probes for a humanbiomarker (e.g., CD45, CD4, CD8, Foxp3, TIGIT). As used herein, the term“probe” refers to any molecule that is capable of selectively binding aspecifically intended target biomolecule. Probes can be synthesized byone of skill in the art using known techniques, or derived frombiological preparations. Probes may include but are not limited to, RNA,DNA, proteins, peptides, aptamers, antibodies, and organic molecules.The term “primer” or “probe” encompasses oligonucleotides that have asequence of a specific SEQ ID NO or oligonucleotides that have asequence complementary to a specific SEQ ID NO. In some embodiments, theprobe is modified. In some embodiments, the probe is modified with aquencher. In some embodiments, the probe is labeled. Labels can include,but are not limited to, colorimetric, fluorescent, chemiluminescent, orbioluminescent labels.

Alternatively, biomarker expression levels may be determined byamplifying complementary DNA (cDNA) or complementary RNA (cRNA) producedfrom mRNA and analyzing it using a microarray. Microarray technologyallows for simultaneous analysis of the expression of thousands ofgenes. A number of different array configurations and methods for theirproduction are known to those skilled in the art. In addition,microarrays are commercially available (e.g., Affymetrix GeneChip®s) orcan be custom-produced. Microarrays currently in wide use include cDNAarrays and oligonucleotide arrays. In general, polynucleotides ofinterest (e.g., probes or probe sets) are plated, or arrayed, on amicrochip substrate. In some embodiments, probes to at least 10, 25, 50,100, 500, 1000, 5000, 10,000, 20,000, or 25,000 or more genes areimmobilized on an array substrate. The substrate may be a porous ornonporous support, such as a glass, plastic or gel surface. The probescan include DNA, RNA, copolymer sequences of DNA and RNA, DNA and/or RNAanalogues, or combinations thereof. In some embodiments, a microarrayincludes a support with an ordered array of binding sites for eachindividual gene. The microarrays can be addressable arrays orpositionally addressable arrays, e.g., each probe of the array islocated at a known, predetermined position on the solid support suchthat the identity of each probe can be determined from its position ofthe array.

Each probe on the microarray can be between 10-50,000 nucleotides inlength. In some embodiments, the probes of the microarray can consist ofnucleotide sequences with lengths of less than about 1,000 nucleotides,less than about 750 nucleotides, less than about 500 nucleotides, lessthan about 250 nucleotides, less than about 100 nucleotides, or lessthan about 50 nucleotides in length. Generally, an array includespositive control probes and negative control probes.

In certain embodiments, biomarker expression is determined using amicroarray. For example, total RNA is extracted from a fresh frozen (FF)tissue sample or total RNA is extracted from a macro-dissectedformalin-fixed paraffin embedded (FFPE) tissue sample. The quantity andquality of the total RNA is assessed by standard spectrophotometryand/or any other appropriate technology (e.g., an Agilent Bioanalyzer).Following RNA extraction, the RNA sample is amplified using standardmethods and/or a commercially available amplification system (e.g.,NuGEN Ovation® RNA Amplification System V2). The amplified cDNA isfragmented, labeled, and hybridized to a microarray (e.g., using NuGENEncore® Biotin Module and Affymetrix GeneChip® array) following standardprocedures. The array is washed, stained, and scanned in accordance withthe instructions for the microarray. The microarray data ispre-processed, the probe-level intensity measurements are backgroundcorrected, normalized, and summarized as expression measurements usingthe Robust Multichip algorithm (RMA). The probe level data is summarizedto get the expression level of each biomarker (e.g., CD45, CD4, CD8,Foxp3, TIGIT). A combination of quality parameter threshold and datareduction techniques (e.g., principal component analysis) is applied tothe data set to establish profile quality and identify potentialoutlying samples. These normalized (or standardized) expression valuesfor each biomarker are used to calculate the decision value of thesample.

In some embodiments of any of the methods described herein, thetumor/cancer is selected from the group consisting of: lung, liver,breast, renal cell carcinoma/kidney, prostate, gastrointestinal/gastric,melanoma, cervical, bladder, glioblastoma, head and neck, pancreatic,ovarian, colorectal, endometrial, and esophageal. In some embodiments, acolorectal cancer is a microsatellite instability-high colorectalcancer. In some embodiments, a colorectal cancer is a microsatellitestable colorectal cancer. In some embodiments, an esophageal tumor is ahistologically confirmed unresectable, advanced or recurrent esophagealor gastroesophageal junction cancer. In some embodiments, an esophagealtumor is a tumor that progressed on at least one prior systemic therapyor line of treatment for unresectable or metastatic disease. In someembodiments, a colorectal tumor is a histologically confirmed incurable,advanced adenocarcinoma of the colon or rectum. In some embodiments, acolorectal tumor is a tumor that has been treated with at least oneprior line of standard chemotherapies for colorectal cancer ormetastatic colorectal cancer and is refractory to or is progressing onthose therapies. In some embodiments, a colorectal tumor is a tumor thathas been treated with at least two prior lines of standardchemotherapies for colorectal cancer or metastatic colorectal cancer andis refractory to or is progressing on those therapies. In someembodiments, a liver tumor or hepatocellular tumor is a histologicallyconfirmed advanced hepatocellular carcinoma, not eligible for surgicaland/or locoregional therapies. In some embodiments, a liver tumor orhepatocellular tumor is progressing or has progressed after surgicaland/or locoregional therapies. In some embodiments, a cervical tumor isa histologically confirmed recurrent or metastatic cervical cancer. Insome embodiments, a cervical tumor is a tumor that progressed on atleast one prior line of chemotherapy for cervical cancer. In someembodiments, a breast tumor is a triple-negative breast cancer. In someembodiments, a breast tumor has been histologically confirmed as anincurable, advanced estrogen receptor-neg, progesterone receptor-neg,and human epidermal growth factor receptor 2-neg adenocarcinoma of thebreast. In some embodiments, a head and neck tumor is a histologicallyconfirmed recurrent or metastatic squamous cell carcinoma of the headand neck (SCCHN), not amenable to standard curative or palliativetherapies. In some embodiments, a head and neck tumor includes, but isnot limited to, squamous cell carcinoma of the oral cavity, nasalcavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx orlarynx. In some embodiments, a head and neck tumor includes primary orrecurrent cancer for which no curative or established palliativetreatments are amenable.

In some embodiments of the methods described here, the inventionprovides use of a TIGIT-binding agent in the manufacture or preparationof a medicament for inhibiting growth of a tumor or tumor cell. In someembodiments of the methods described here, the invention provides use ofa TIGIT-binding agent in the manufacture or preparation of a medicamentfor the treatment of cancer. In some embodiments, a TIGIT-binding agentbinds human TIGIT and inhibits or reduces growth of the cancer. Incertain embodiments, the tumor/cancer comprises cancer stem cells. Incertain embodiments, the frequency of cancer stem cells in thetumor/cancer is reduced. In certain embodiments, the subject is a humanIn certain embodiments, the subject has had a tumor at least partiallyremoved.

Combination therapy with two or more therapeutic agents often usesagents that work by different mechanisms of action, although this is notrequired. Combination therapy using agents with different mechanisms ofaction may result in additive or synergetic effects. Combination therapymay allow for a lower dose of each agent than is used in monotherapy,thereby reducing toxic side effects and/or increasing the therapeuticindex of the agent(s). Combination therapy may decrease the likelihoodthat resistant cancer cells will develop. In some embodiments,combination therapy comprises a therapeutic agent that affects theimmune response (e.g., enhances or activates the response) and atherapeutic agent that affects (e.g., inhibits or kills) thetumor/cancer cells.

In some embodiments of the methods described herein, the combination ofa TIGIT-binding agent and at least one additional therapeutic agentresults in additive or synergistic results. In some embodiments, thecombination therapy results in an increase in the therapeutic index ofthe TIGIT-binding agent. In some embodiments, the combination therapyresults in an increase in the therapeutic index of the additionaltherapeutic agent(s). In some embodiments, the combination therapyresults in a decrease in the toxicity and/or side effects of theTIGIT-binding agent. In some embodiments, the combination therapyresults in a decrease in the toxicity and/or side effects of theadditional therapeutic agent(s).

In certain embodiments of the methods described herein, in addition toadministering a TIGIT-binding agent, the method or treatment furthercomprises administering at least one additional therapeutic agent. Anadditional therapeutic agent can be administered prior to, concurrentlywith, and/or subsequently to, administration of the agent. In someembodiments, the at least one additional therapeutic agent comprises 1,2, 3, or more additional therapeutic agents.

Therapeutic agents that may be administered in combination with theTIGIT-binding agents include chemotherapeutic agents. Thus, in someembodiments, the method or treatment involves the administration of aTIGIT-binding agent in combination with a chemotherapeutic agent or incombination with a cocktail of chemotherapeutic agents. Treatment with aTIGIT-binding agent can occur prior to, concurrently with, or subsequentto administration of chemotherapies. Combined administration can includeco-administration, either in a single pharmaceutical formulation orusing separate formulations, or consecutive administration in eitherorder but generally within a time period such that all active agents canexert their biological activities simultaneously. Preparation and dosingschedules for such chemotherapeutic agents can be used according tomanufacturers' instructions or as determined empirically by the skilledpractitioner. Preparation and dosing schedules for such chemotherapy arealso described in The Chemotherapy Source Book, 4^(th) Edition, 2008, M.C. Perry, Editor, Lippincott, Williams & Wilkins, Philadelphia, Pa.

Useful classes of therapeutic agents include, for example, anti-tubulinagents, auristatins, DNA minor groove binders, DNA replicationinhibitors, alkylating agents (e.g., platinum complexes such ascisplatin, mono(platinum), bis(platinum) and tri-nuclear platinumcomplexes and carboplatin), anthracyclines, antibiotics, anti-folates,antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides,fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas,platinols, purine antimetabolites, puromycins, radiation sensitizers,steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, or thelike. In certain embodiments, the second therapeutic agent is analkylating agent, an antimetabolite, an antimitotic, a topoisomeraseinhibitor, or an angiogenesis inhibitor.

Chemotherapeutic agents useful in the instant invention include, but arenot limited to, alkylating agents such as thiotepa and cyclosphosphamide(CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan andpiposulfan; aziridines such as benzodopa, carboquone, meturedopa, anduredopa; ethylenimines and methylamelamines including altretamine,triethylenemelamine, trietylenephosphoramide,triethylenethiophosphaoramide and trimethylolomelamime; nitrogenmustards such as chlorambucil, chlornaphazine, cyclophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine,bleomycins, cactinomycin, calicheamicin, carabicin, caminomycin,carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytosine arabinoside, dideoxyuridine, doxifluridine, enocitabine,floxuridine, 5-FU; androgens such as calusterone, dromostanolonepropionate, epitiostanol, mepitiostane, testolactone; anti-adrenals suchas aminoglutethimide, mitotane, trilostane; folic acid replenishers suchas folinic acid; aceglatone; aldophosphamide glycoside; aminolevulinicacid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone;mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK; razoxane;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (Ara-C); taxoids, e.g. paclitaxel (TAXOL®) and docetaxel(TAXOTERE®); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine;platinum analogs such as cisplatin and carboplatin; vinblastine;platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone;vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin;aminopterin; ibandronate; CPT11; topoisomerase inhibitor RFS 2000;difluoromethylornithine (DMFO); retinoic acid; esperamicins;capecitabine (XELODA®); and pharmaceutically acceptable salts, acids orderivatives of any of the above. Chemotherapeutic agents also includeanti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens including for example tamoxifen,raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and toremifene(FARESTON®); and anti-androgens such as flutamide, nilutamide,bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptablesalts, acids or derivatives of any of the above. In certain embodiments,the additional therapeutic agent is cisplatin. In certain embodiments,the additional therapeutic agent is carboplatin.

In certain embodiments, the chemotherapeutic agent is a topoisomeraseinhibitor. Topoisomerase inhibitors are chemotherapy agents thatinterfere with the action of a topoisomerase enzyme (e.g., topoisomeraseI or II). Topoisomerase inhibitors include, but are not limited to,doxorubicin HCl, daunorubicin citrate, mitoxantrone HCl, actinomycin D,etoposide, topotecan HCl, teniposide (VM-26), and irinotecan, as well aspharmaceutically acceptable salts, acids, or derivatives of any ofthese. In some embodiments, the additional therapeutic agent isirinotecan.

In certain embodiments, the chemotherapeutic agent is ananti-metabolite. An anti-metabolite is a chemical with a structure thatis similar to a metabolite required for normal biochemical reactions,yet different enough to interfere with one or more normal functions ofcells, such as cell division. Anti-metabolites include, but are notlimited to, gemcitabine, fluorouracil, capecitabine, methotrexatesodium, ralitrexed, pemetrexed, tegafur, cytosine arabinoside,thioguanine, 5-azacytidine, 6-mercaptopurine, azathioprine,6-thioguanine, pentostatin, fludarabine phosphate, and cladribine, aswell as pharmaceutically acceptable salts, acids, or derivatives of anyof these. In certain embodiments, the additional therapeutic agent isgemcitabine.

In certain embodiments, the chemotherapeutic agent is an antimitoticagent, including, but not limited to, agents that bind tubulin. In someembodiments, the agent is a taxane. In certain embodiments, the agent ispaclitaxel or docetaxel, or a pharmaceutically acceptable salt, acid, orderivative of paclitaxel or docetaxel. In certain embodiments, the agentis paclitaxel (TAXOL®), docetaxel (TAXOTERE®), albumin-bound paclitaxel(ABRAXANE®), DHA-paclitaxel, or PG-paclitaxel. In certain alternativeembodiments, the antimitotic agent comprises a vinca alkaloid, such asvincristine, vinblastine, vinorelbine, or vindesine, or pharmaceuticallyacceptable salts, acids, or derivatives thereof. In some embodiments,the antimitotic agent is an inhibitor of kinesin Eg5 or an inhibitor ofa mitotic kinase such as Aurora A or Plk1. In certain embodiments, theadditional therapeutic agent is paclitaxel. In certain embodiments, theadditional therapeutic agent is albumin-bound paclitaxel (ABRAXANE®).

In some embodiments, an additional therapeutic agent comprises an agentsuch as a small molecule. For example, treatment can involve thecombined administration of an agent of the present invention with asmall molecule that acts as an inhibitor against tumor-associatedantigens including, but not limited to, EGFR, HER2 (ErbB2), and/or VEGF.In some embodiments, an agent of the present invention is administeredin combination with a protein kinase inhibitor selected from the groupconsisting of: gefitinib (IRESSA®), erlotinib (TARCEVA®), sunitinib(SUTENT®), lapatanib, vandetanib (ZACTIMA®), AEE788, CI-1033, cediranib(RECENTIN®), sorafenib (NEXAVAR®), and pazopanib (GW786034B). In someembodiments, an additional therapeutic agent comprises an mTORinhibitor.

In certain embodiments, the additional therapeutic agent is an agentthat inhibits a cancer stem cell pathway. In some embodiments, theadditional therapeutic agent is an inhibitor of the Notch pathway. Insome embodiments, the additional therapeutic agent is an inhibitor ofthe Wnt pathway. In some embodiments, the additional therapeutic agentis an inhibitor of the BMP pathway. In some embodiments, the additionaltherapeutic agent is an inhibitor of the Hippo pathway. In someembodiments, the additional therapeutic agent is an inhibitor of theRSPO/LGR pathway. In some embodiments, the additional therapeutic agentis an inhibitor of the mTOR/AKR pathway.

In some embodiments of the methods described herein, an additionaltherapeutic agent comprises a biological molecule, such as an antibody.For example, treatment can involve the combined administration of aTIGIT-binding agent with an antibody against a tumor-associated antigenincluding, but not limited to, an antibody that binds EGFR, HER2/ErbB2,and/or VEGF. In certain embodiments, the additional therapeutic agent isan antibody specific for a cancer stem cell marker. In some embodiments,the additional therapeutic agent is an antibody that binds a componentof the Notch pathway. In some embodiments, the additional therapeuticagent is an antibody that binds a component of the Wnt pathway. Incertain embodiments, the additional therapeutic agent is an antibodythat inhibits a cancer stem cell pathway. In some embodiments, theadditional therapeutic agent is an inhibitor of the Notch pathway. Insome embodiments, the additional therapeutic agent is an inhibitor ofthe Wnt pathway. In some embodiments, the additional therapeutic agentis an inhibitor of the BMP pathway. In some embodiments, the additionaltherapeutic agent is an antibody that inhibits β-catenin signaling. Incertain embodiments, the additional therapeutic agent is an antibodythat is an angiogenesis inhibitor (e.g., an anti-VEGF or VEGF receptorantibody). In certain embodiments, the additional therapeutic agent isbevacizumab (AVASTIN®), ramucirumab, trastuzumab (HERCEPTIN®),pertuzumab (OMNITARG™), panitumumab (VECTIBIX®), nimotuzumab,zalutumumab, or cetuximab (ERBITUX®).

In certain embodiments of the methods described herein, in addition toadministering a TIGIT-binding agent, the method or treatment furthercomprises administering at least one additional immunotherapeutic agent.In some embodiments, the additional immunotherapeutic agent is an immuneresponse stimulating agent. In some embodiments, the immunotherapeuticagent (e g , immune response stimulating agent) includes, but is notlimited to, a colony stimulating factor (e.g., granulocyte-macrophagecolony stimulating factor (GM-CSF), macrophage colony stimulating factor(M-CSF), granulocyte colony stimulating factor (G-CSF), stem cell factor(SCF)), an interleukin (e.g., IL-1, IL2, IL-3, IL-7, IL-12, IL-15,IL-18), an antibody that blocks immunosuppressive functions (e.g., ananti-CTLA4 antibody, anti-CD28 antibody, anti-CD3 antibody, anti-PD-1antibody, anti-PD-L1 antibody), an antibody that enhances immune cellfunctions (e.g., an anti-GITR antibody or an anti-OX-40 antibody), atoll-like receptor (e.g., TLR4, TLR7, TLR9), a soluble ligand (e.g.,GITRL or OX-40L), or a member of the B7 family (e.g., CD80, CD86). Anadditional immunotherapeutic agent (e.g., an immune response stimulatingagent) can be administered prior to, concurrently with, and/orsubsequently to, administration of the TIGIT-binding agent.Pharmaceutical compositions comprising a TIGIT-binding agent and anadditional immunotherapeutic agent (e.g., an immune response stimulatingagent(s)) are also provided. In some embodiments, the immunotherapeuticagent comprises 1, 2, 3, or more immunotherapeutic agents. In someembodiments, the immune response stimulating agent comprises 1, 2, 3, ormore immune response stimulating agents.

In some embodiments of the methods described herein, the additionaltherapeutic agent is an antibody that is an immune checkpoint inhibitor.In some embodiments, the immune checkpoint inhibitor is an anti-PD-1antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, an anti-CD28antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, an anti-GITRantibody, or an anti-OX-40 antibody. In some embodiments, the immunecheckpoint inhibitor is an anti-4-1BB antibody. In some embodiments, theadditional therapeutic agent is an anti-PD-1 antibody selected from thegroups consisting of: nivolumab (OPDIVO®), pembrolizumab (KEYTRUDA®), orpidilzumab. In some embodiments, the additional therapeutic agent is ananti-PD-1 antibody selected from the groups consisting of: MEDI0680,REGN2810, BGB-A317, and PDR001. In some embodiments, the additionaltherapeutic agent is an anti-PD-L1 antibody selected from the groupconsisting of: BMS935559 (MDX-1105), atezolizumab (TECENTRIQ®),durvalumab (MEDI4736), or avelumab (MSB0010718C). In some embodiments,the additional therapeutic agent is an anti-CTLA-4 antibody selectedfrom the group consisting of: ipilimumab (YERVOY®) or tremelimumab. Insome embodiments, the additional therapeutic agent is an anti-LAG-3antibody selected from the group consisting of: BMS-986016 and LAG525.In some embodiments, the additional therapeutic agent is an anti-OX-40antibody selected from the group consisting of: MEDI6469, MEDI0562, andMOXR0916. In some embodiments, the additional therapeutic agent is ananti-4-1BB antibody selected from the group consisting of: PF-05082566.

Furthermore, treatment with a TIGIT-binding agent can includecombination treatment with other biologic molecules, such as one or morecytokines (e.g., lymphokines, interleukins, interferons, tumor necrosisfactors, and/or growth factors) or can be accompanied by surgicalremoval of tumors, removal of cancer cells, or any other therapy deemednecessary by a treating physician.

In some embodiments, the TIGIT-binding agent can be administered incombination with a biologic molecule selected from the group consistingof: adrenomedullin (AM), angiopoietin (Ang), BMPs, BDNF, EGF,erythropoietin (EPO), FGF, GDNF, G-CSF, GM-CSF, GDF9, HGF, HDGF, IGF,migration-stimulating factor, myostatin (GDF-8), NGF, neurotrophins,PDGF, thrombopoietin, TGF-α, TGF-β, TNF-α, VEGF, P1GF, gamma-IFN, IL-1,IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, and IL-18. In someembodiments, the TIGIT-binding agent can be administered in combinationwith a biologic molecule selected from the group consisting of:macrophage colony stimulating factor (M-CSF) and stem cell factor (SCF),

In some embodiments of the methods described herein, treatment with aTIGIT-binding agent can be accompanied by surgical removal of tumors,removal of cancer cells, or any other surgical therapy deemed necessaryby a treating physician.

In certain embodiments of the methods described herein, treatmentinvolves the administration of a TIGIT-binding agent in combination withradiation therapy. Treatment with a TIGIT-binding agent can occur priorto, concurrently with, or subsequent to administration of radiationtherapy. Dosing schedules for such radiation therapy can be determinedby the skilled medical practitioner.

Combined administration can include co-administration, either in asingle pharmaceutical formulation or using separate formulations, orconsecutive administration in either order but generally within a timeperiod such that all active agents can exert their biological activitiessimultaneously.

It will be appreciated that the combination of a TIGIT-binding agent andat least one additional therapeutic agent may be administered in anyorder or concurrently. In some embodiments, a TIGIT-binding agent willbe administered to patients that have previously undergone treatmentwith a second/different therapeutic agent. In certain other embodiments,the TIGIT-binding agent and a second additional therapeutic agent willbe administered substantially simultaneously or concurrently. Forexample, a subject may be given a TIGIT-binding agent while undergoing acourse of treatment with an additional therapeutic agent (e.g.,chemotherapy). In certain embodiments, a TIGIT-binding agent will beadministered within 1 year of the treatment with the second therapeuticagent. In certain alternative embodiments, a TIGIT-binding agent will beadministered within 10, 8, 6, 4, or 2 months of any treatment with asecond therapeutic agent. In certain other embodiments, a TIGIT-bindingagent will be administered within 4, 3, 2, or 1 weeks of any treatmentwith a second therapeutic agent. In some embodiments, an agent will beadministered within 5, 4, 3, 2, or 1 days of any treatment with a secondtherapeutic agent. It will further be appreciated that the two (or more)agents or treatments may be administered to the subject within a matterof hours or minutes (i.e., substantially simultaneously).

For the treatment of a disease, the appropriate dosage of aTIGIT-binding agent depends on the type of disease to be treated, theseverity and course of the disease, the responsiveness of the disease,whether the agent is administered for therapeutic or preventativepurposes, previous therapy, the patient's clinical history, and so on,all at the discretion of the treating physician. The TIGIT-binding agentcan be administered one time or over a series of treatments lasting fromseveral days to several months, or until a cure is effected or adiminution of the disease state is achieved (e.g., reduction in tumorsize). In some embodiments, the TIGIT-binding agent is administered overa series of treatments until there is disease progression. In someembodiments, optimal dosing schedules are calculated from measurementsof drug accumulation in the body of the patient and will vary dependingon the relative potency of an individual agent. The administeringphysician can determine optimum dosages, dosing methodologies, andrepetition rates.

In certain embodiments of the methods described herein, dosage of theTIGIT-binding agent is from 0.01 μg to 100 mg/kg of body weight, from0.1 μg to 100 mg/kg of body weight, from 1 μg to 100 mg/kg of bodyweight, from 1 mg to 100 mg/kg of body weight, 1 mg to 80 mg/kg of bodyweight from 10 mg to 100 mg/kg of body weight, from 10 mg to 75 mg/kg ofbody weight, or from 10 mg to 50 mg/kg of body weight. In certainembodiments, a TIGIT binding agent is administered to a subject at adose of about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 1.5mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 5 mg/kg,about 7.5 kg/kg, about 10 mg/kg, about 12 mg/kg, about 12.5 mg/kg about15 mg/kg, about 17.5 mg/kg, about 20 mg/kg or about 25 mg/kg. In certainembodiments, the dosage of the TIGIT-binding agent is from about 0.1 mgto about 20 mg/kg. In some embodiments, the dosage of the TIGIT-bindingagent is about 0.3 mg/kg. In some embodiments, the dosage of theTIGIT-binding agent is about 1 mg/kg. In some embodiments, the dosage ofthe TIGIT-binding agent is about 1.5 mg/kg. In some embodiments, thedosage of the TIGIT-binding agent is about 2 mg/kg. In some embodiments,the dosage of the TIGIT-binding agent is about 2.5 mg/kg. In someembodiments, the dosage of the TIGIT-binding agent is about 3 mg/kg. Insome embodiments, the dosage of the TIGIT-binding agent is about 5mg/kg. In some embodiments, the dosage of the TIGIT-binding agent isabout 7.5 mg/kg. In some embodiments, the dosage of the TIGIT-bindingagent is about 10 mg/kg. In some embodiments, the dosage of theTIGIT-binding agent is about 12.5 mg/kg. In some embodiments, the dosageof the TIGIT-binding agent is about 15 mg/kg. In some embodiments, thedosage of the TIGIT-binding agent is about 17.5 mg/kg. In someembodiments, the dosage of the TIGIT-binding agent is about 20 mg/kg. Incertain embodiments, the dosage can be given once or more daily, weekly,monthly, or yearly. In certain embodiments, the TIGIT-binding agent isgiven once every week, once every two weeks, once every three weeks, oronce every four weeks.

In some embodiments, a TIGIT-binding agent may be administered at aninitial higher “loading” dose, followed by one or more lower doses. Insome embodiments, the frequency of administration may also change. Insome embodiments, a dosing regimen may comprise administering an initialdose, followed by additional doses (or “maintenance” doses) once a week,once every two weeks, once every three weeks, or once every month. Forexample, a dosing regimen may comprise administering an initial loadingdose, followed by a weekly maintenance dose of, for example, one-half ofthe initial dose. Or a dosing regimen may comprise administering aninitial loading dose, followed by maintenance doses of, for exampleone-half of the initial dose every other week. Or a dosing regimen maycomprise administering three initial doses for 3 weeks, followed bymaintenance doses of, for example, the same amount every other week.

As is known to those of skill in the art, administration of anytherapeutic agent may lead to side effects and/or toxicities. In somecases, the side effects and/or toxicities are so severe as to precludeadministration of the particular agent at a therapeutically effectivedose. In some cases, drug therapy must be discontinued, and other agentsmay be tried. However, many agents in the same therapeutic class oftendisplay similar side effects and/or toxicities, meaning that the patienteither has to stop therapy, or if possible, suffer from the unpleasantside effects associated with the therapeutic agent.

In some embodiments, the dosing schedule may be limited to a specificnumber of administrations or “cycles”. In some embodiments, the agent isadministered for 3, 4, 5, 6, 7, 8, or more cycles. For example, theagent is administered every 2 weeks for 6 cycles, the agent isadministered every 3 weeks for 6 cycles, the agent is administered every2 weeks for 4 cycles, the agent is administered every 3 weeks for 4cycles, etc. Dosing schedules can be decided upon and subsequentlymodified by those skilled in the art.

In embodiments, the TIGIT binding agent is administered once about everyweek, once about every two weeks, once about every three weeks, onceabout every four weeks, once about every five weeks, once about everysix weeks, once about every eight weeks, once about every twelve weeks,once about every month, once about every two months, once about everythree months or longer. In certain embodiments, a TIGIT binding agent isadministered to a subject at a dose of about 0.1 mg/kg, about 0.3 mg/kg,about 1 mg/kg, about 1.5 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3mg/kg, about 5 mg/kg, about 7.5 kg/kg, about 10 mg/kg, about 12 mg/kg,about 12.5 mg/kg about 15 mg/kg, about 17.5 mg/kg, about 20 mg/kg orabout 25 mg/kg once about every two weeks.

In some embodiments, a TIGIT binding agent is administered to thesubject at a dose of about 0.3 mg/kg once every two weeks.

In some embodiments, a TIGIT binding agent is administered to thesubject at a dose of about 1 mg/kg once every two weeks.

In some embodiments, a TIGIT binding agent is administered to thesubject at a dose of about 3 mg/kg once every two weeks.

In some embodiments, a TIGIT binding agent is administered to thesubject at a dose of about 10 mg/kg once every two weeks.

In some embodiments, a TIGIT binding agent is administered to thesubject at a dose of about 15 mg/kg once every two weeks.

In certain embodiments, the subject has received prior treatment with aPD-1 antagonist or a and/or a PD-L1 antagonist. In certain embodiments,the subject has a histologically confirmed advanced relapsed orrefractory solid tumor.

In certain embodiments, the subject has head and neck cancer,esophageal/gastroesophageal cancer, gastric cancer, colorectal cancer,anal cancer, hepatocellular cancer/liver cancer, cervical cancer, lungcancer, melanoma, Merkel cell carcinoma, renal cell carcinoma/kidneycancer, bladder cancer, ovarian cancer, pancreatic cancer, endometrialcancer, anal cancer, triple negative breast cancer, a known MSI highsolid tumor (including MSI CRC) or a MSS colorectal cancer.

The present invention provides methods of administering to a subject aTIGIT-binding agent comprising using an intermittent dosing strategy foradministering one or more agents, which may reduce side effects and/ortoxicities associated with administration of an agent, chemotherapeuticagent, etc. In some embodiments, a method for inhibiting tumor growthand/or treating cancer in a human subject comprises administering to thesubject a therapeutically effective dose of a TIGIT-binding agent incombination with a therapeutically effective dose of a chemotherapeuticagent, wherein one or both of the agents are administered according toan intermittent dosing strategy. In some embodiments, the intermittentdosing strategy comprises administering an initial dose of aTIGIT-binding agent to the subject, and administering subsequent dosesof the TIGIT-binding agent about once every 2 weeks. In someembodiments, the intermittent dosing strategy comprises administering aninitial dose of a TIGIT-binding agent to the subject, and administeringsubsequent doses of the TIGIT-binding agent about once every 3 weeks. Insome embodiments, the intermittent dosing strategy comprisesadministering an initial dose of a TIGIT-binding agent to the subject,and administering subsequent doses of the TIGIT-binding agent about onceevery 4 weeks. In some embodiments, the TIGIT-binding agent isadministered using an intermittent dosing strategy and a second agent isadministered weekly.

The present invention provides methods using compositions comprisingTIGIT-binding agents. The present invention also provides methodsdescribed herein using pharmaceutical compositions comprisingTIGIT-binding agents and a pharmaceutically acceptable vehicle. In someembodiments, the pharmaceutical compositions find use in immunotherapy.In some embodiments, the compositions find use in inhibiting tumorgrowth. In some embodiments, the pharmaceutical compositions find use ininhibiting tumor growth in a subject (e.g., a human patient). In someembodiments, the compositions find use in treating cancer. In someembodiments, the pharmaceutical compositions find use in treating cancerin a subject (e.g., a human patient).

Formulations are prepared for storage and use by combining a purifiedTIGIT-binding agent with a pharmaceutically acceptable vehicle (e.g., acarrier or excipient). Those of skill in the art generally considerpharmaceutically acceptable carriers, excipients, and/or stabilizers tobe inactive ingredients of a formulation or pharmaceutical composition.

Suitable pharmaceutically acceptable vehicles include, but are notlimited to, nontoxic buffers such as phosphate, citrate, and otherorganic acids; salts such as sodium chloride; antioxidants includingascorbic acid and methionine; preservatives such asoctadecyldimethylbenzyl ammonium chloride, hexamethonium chloride,benzalkonium chloride, benzethonium chloride, phenol, butyl or benzylalcohol, alkyl parabens, such as methyl or propyl paraben, catechol,resorcinol, cyclohexanol, 3-pentanol, and m-cresol; low molecular weightpolypeptides (e.g., less than about 10 amino acid residues); proteinssuch as serum albumin, gelatin, or immunoglobulins; hydrophilic polymerssuch as polyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; carbohydrates such asmonosaccharides, disaccharides, glucose, mannose, or dextrins; chelatingagents such as EDTA; sugars such as sucrose, mannitol, trehalose orsorbitol; salt-forming counter-ions such as sodium; metal complexes suchas Zn-protein complexes; and non-ionic surfactants such as TWEEN orpolyethylene glycol (PEG). (Remington: The Science and Practice ofPharmacy, 22^(st) Edition, 2012, Pharmaceutical Press, London.).

The pharmaceutical compositions of the present invention can beadministered in any number of ways for either local or systemictreatment. In some embodiments, administration is (i) topical byepidermal or transdermal patches, ointments, lotions, creams, gels,drops, suppositories, sprays, liquids and powders; (ii) pulmonary byinhalation or insufflation of powders or aerosols, including bynebulizer, intratracheal, and intranasal; (iii) oral; or (iv) parenteralincluding intravenous, intraarterial, intratumoral, subcutaneous,intraperitoneal, intramuscular (e.g., injection or infusion), orintracranial (e.g., intrathecal or intraventricular).

The therapeutic formulation can be in unit dosage form. Suchformulations include tablets, pills, capsules, powders, granules,solutions or suspensions in water or non-aqueous media, orsuppositories. In solid compositions such as tablets the principalactive ingredient is mixed with a pharmaceutical carrier. Conventionaltableting ingredients include corn starch, lactose, sucrose, sorbitol,talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, anddiluents (e.g., water). These can be used to form a solid preformulationcomposition containing a homogeneous mixture of a compound of thepresent invention, or a non-toxic pharmaceutically acceptable saltthereof. The solid preformulation composition is then subdivided intounit dosage forms of a type described above. The tablets, pills, etc. ofthe formulation or composition can be coated or otherwise compounded toprovide a dosage form affording the advantage of prolonged action. Forexample, the tablet or pill can comprise an inner composition covered byan outer component. Furthermore, the two components can be separated byan enteric layer that serves to resist disintegration and permits theinner component to pass intact through the stomach or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials include a number of polymeric acids andmixtures of polymeric acids with such materials as shellac, cetylalcohol and cellulose acetate.

TIGIT-binding agents can also be entrapped in microcapsules. Suchmicrocapsules are prepared, for example, by coacervation techniques orby interfacial polymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nanoparticles andnanocapsules) or in macroemulsions as described in Remington: TheScience and Practice of Pharmacy, 22^(st) Edition, 2012, PharmaceuticalPress, London.

In certain embodiments, pharmaceutical formulations include aTIGIT-binding agent complexed with liposomes. Methods to produceliposomes are known to those of skill in the art. For example, someliposomes can be generated by reverse phase evaporation with a lipidcomposition comprising phosphatidylcholine, cholesterol, andPEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes can beextruded through filters of defined pore size to yield liposomes withthe desired diameter.

In certain embodiments, sustained-release preparations comprising aTIGIT-binding agent are produced. Suitable examples of sustained-releasepreparations include semi-permeable matrices of solid hydrophobicpolymers containing an agent, where the matrices are in the form ofshaped articles (e.g., films or microcapsules). Examples ofsustained-release matrices include polyesters, hydrogels such aspoly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol), polylactides,copolymers of L-glutamic acid and 7 ethyl-L-glutamate, non-degradableethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymerssuch as the LUPRON DEPOT™ (injectable microspheres composed of lacticacid-glycolic acid copolymer and leuprolide acetate), sucrose acetateisobutyrate, and poly-D-(−)-3-hydroxybutyric acid.

III. TIGIT Binding Agents

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a type Itransmembrane glycoprotein that contains an immunoglobulin variable(IgV) domain. TIGIT belongs to the poliovirus receptor (PVR) family andbinds to the poliovirus receptor (PVR; CD155) with high affinity and toPVRL-2 (CD112) and PVRL-3 (CD113) with a lower affinity. TIGIT isexpressed on T-cells, including regulatory T-cells (Tregs) and memoryT-cells, as well as on NK cells and is upregulated following activationof naive CD4+ T-cells. The full-length amino acid (aa) sequence forhuman TIGIT (UniProtKB No. Q495A1) is known in the art and are providedherein as SEQ ID NO:1. As used herein, reference to amino acid positionsrefer to the numbering of full-length amino acid sequences including thesignal sequence.

The present invention provides methods that use agents that specificallybind TIGIT. These agents are referred to herein as “TIGIT-bindingagents”. In some embodiments, the TIGIT-binding agent is an antibody. Insome embodiments, the TIGIT-binding agent is a polypeptide. In certainembodiments, the TIGIT-binding agent binds mouse TIGIT. In certainembodiments, the TIGIT-binding agent binds human TIGIT. In certainembodiments, the TIGIT-binding agent binds mouse TIGIT and human TIGIT.In some embodiments, the TIGIT-binding agent binds human TIGIT and doesnot bind mouse TIGIT. Non-limiting examples of TIGIT-binding agents havebeen described in, for example, International Patent Application No.PCT/US2016/034549; International Patent Pub. Nos. WO 2016/106302 and WO2016/028656; and U.S. Patent Application No. 2013/0251720.

In some embodiments, an agent binds TIGIT and interferes with theinteraction of TIGIT with a second protein. In some embodiments, anagent binds TIGIT and interferes with the interaction of TIGIT with PVR.In some embodiments, an agent binds TIGIT and interferes with theinteraction of TIGIT with PVRL2. In some embodiments, an agent bindsTIGIT and interferes with the interaction of TIGIT with PVRL3. In someembodiments, an agent specifically binds TIGIT and the agent disruptsbinding of TIGIT to PVR, and/or disrupts PVR activation of TIGITsignaling.

In certain embodiments, the TIGIT-binding agent is an antibody thatspecifically binds the extracellular domain of TIGIT, or a fragmentthereof. In certain embodiments, the TIGIT-binding agent is an antibodythat specifically binds the extracellular domain of mouse TIGIT, or afragment thereof. In certain embodiments, the TIGIT-binding agent is anantibody that specifically binds the extracellular domain of humanTIGIT, or a fragment thereof. In certain embodiments, the TIGIT-bindingagent is an antibody that specifically binds the extracellular domain ofmouse TIGIT and human TIGIT, or a fragment thereof. In some embodiments,the TIGIT-binding agent is an antibody that specifically binds theIg-like domain of TIGIT. In some embodiments, the TIGIT-binding agent isan antibody that specifically binds the IgV domain of TIGIT. In someembodiments, the TIGIT-binding agent is an antibody that binds withinamino acids 22-141 of human TIGIT. In some embodiments, theTIGIT-binding agent is an antibody that binds within amino acids 22-141of SEQ ID NO:1. In some embodiments, the agent binds within amino acids22-124 of human TIGIT. In some embodiments, the agent binds within aminoacids 22-124 of SEQ ID NO:1. In certain embodiments, the TIGIT-bindingagent binds within SEQ ID NO:3, or a fragment thereof. In someembodiments, the TIGIT-binding agent is an antibody that binds withinamino acids 50-124 of human TIGIT. In some embodiments, theTIGIT-binding agent is an antibody that binds within amino acids 50-124of SEQ ID NO:1. In certain embodiments, the TIGIT-binding agent bindswithin SEQ ID NO:3, or a fragment thereof.

In some embodiments, the TIGIT-binding agent is an antibody that bindsan epitope comprising amino acids within SEQ ID NO:27. In someembodiments, the TIGIT-binding agent is an antibody that binds anepitope comprising amino acids within SEQ ID NO:28. In some embodiments,the TIGIT-binding agent is an antibody that binds an epitope comprisingamino acids within SEQ ID NO:27 and SEQ ID NO:28. In some embodiments,the TIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62 and I109 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62 and T119 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q64 and I109 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q64 and T119 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62, Q64, and I109 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62, Q64, and T119 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62, 1109, and T119 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q64, 1109, and T119 of SEQ ID NO:1. In some embodiments, theTIGIT-binding agent is an antibody that binds an epitope comprisingamino acids Q62, Q64, 1109, and T119 of SEQ ID NO:1. In someembodiments, the TIGIT-binding agent is an antibody that binds anepitope comprising at least one amino acid selected from the groupconsisting of: N58, E60, Q62, Q64, L65, F107,1109, H111, T117, T119,G120, and R121 of SEQ ID NO:1. In some embodiments, the epitope is aconformational epitope. In some embodiments, the TIGIT-binding agent isan antibody that binds an epitope which does not comprise amino acidV100 of SEQ ID NO:1.

In certain embodiments, the TIGIT-binding agent (e.g., an antibody)binds TIGIT with a dissociation constant (K_(D)) of about 1 μM or less,about 100 nM or less, about 40 nM or less, about 20 nM or less, about 10nM or less, about 1 nM or less, about 0.1 nM or less, 50 pM or less, 10pM or less, or 1 pM or less. In some embodiments, a TIGIT-binding agentbinds TIGIT with a K_(D) of about 20 nM or less. In some embodiments, aTIGIT-binding agent binds TIGIT with a K_(D) of about 10 nM or less. Insome embodiments, a TIGIT-binding agent binds TIGIT with a K_(D) ofabout 1nM or less. In some embodiments, a TIGIT-binding agent bindsTIGIT with a K_(D) of about 0.5 nM or less. In some embodiments, aTIGIT-binding agent binds TIGIT with a K_(D) of about 0.1 nM or less. Insome embodiments, a TIGIT-binding agent binds TIGIT with a K_(D) ofabout 50 pM or less. In some embodiments, a TIGIT-binding agent bindsTIGIT with a K_(D) of about 25 pM or less. In some embodiments, aTIGIT-binding agent binds TIGIT with a K_(D) of about 10 pM or less. Insome embodiments, a TIGIT-binding agent binds TIGIT with a K_(D) ofabout 1 pM or less. In some embodiments, the TIGIT-binding agent bindsboth human TIGIT and mouse TIGIT with a K_(D) of about 10 nM or less. Insome embodiments, a TIGIT-binding agent binds both human TIGIT and mouseTIGIT with a K_(D) of about 1 nM or less. In some embodiments, aTIGIT-binding agent binds both human TIGIT and mouse TIGIT with a K_(D)of about 0.1 nM or less. In some embodiments, the dissociation constantof the binding agent (e.g., an antibody) to TIGIT is the dissociationconstant determined using a TIGIT fusion protein comprising at least aportion of the extracellular domain of TIGIT protein immobilized on aBiaCore™ chip. In some embodiments, the dissociation constant of thebinding agent (e.g., an antibody) to TIGIT is the dissociation constantdetermined using the binding agent captured by an anti-human IgGantibody on a BiaCore™ chip and a soluble TIGIT protein.

In some embodiments, a TIGIT-binding agent comprises a firstantigen-binding site that specifically binds TIGIT and a secondantigen-binding site that specifically binds a second target. In someembodiments, a TIGIT-binding agent is a bispecific agent that comprisesa first antigen-binding site that specifically binds TIGIT and a secondantigen-binding site that specifically binds a second target. In someembodiments, a TIGIT-binding agent binds both TIGIT and the secondtarget with a K_(D) of about 100 nM or less. In some embodiments, aTIGIT-binding agent binds both TIGIT and the second target with a K_(D)of about 50 nM or less. In some embodiments, a TIGIT-binding agent bindsboth TIGIT and the second target with a K_(D) of about 20 nM or less. Insome embodiments, a TIGIT-binding agent binds both TIGIT and the secondtarget with a K_(D) of about 10 nM or less. In some embodiments, aTIGIT-binding agent binds both TIGIT and the second target with a K_(D)of about 1 nM or less. In some embodiments, the affinity of one of theantigen-binding sites may be weaker than the affinity of the otherantigen-binding site. For example, the K_(D) of one antigen binding sitemay be about 1 nM and the K_(D) of the second antigen-binding site maybe about 10 nM. In some embodiments, the difference in affinity betweenthe two antigen-binding sites may be about 2-fold or more, about 3-foldor more, about 5-fold or more, about 8-fold or more, about 10-fold ormore, about 15-fold or more, about 20-fold or more, about 30-fold ormore, about 50-fold or more, or about 100-fold or more. Modulation ofthe affinities of the two antigen-binding sites may affect thebiological activity of the bispecific antibody. For example, decreasingthe affinity of the antigen-binding site for TIGIT or the second target,may have a desirable effect, for example decreased toxicity of thebinding agent and/or increased therapeutic index.

In certain embodiments, the TIGIT-binding agent (e.g., an antibody)binds TIGIT with a half maximal effective concentration (EC₅₀) of about1 μM or less, about 100 nM or less, about 40 nM or less, about 20 nM orless, about 10 nM or less, about 1 nM or less, or about 0.1 nM or less.In certain embodiments, a TIGIT-binding agent binds to human TIGIT witha half maximal effective concentration (EC₅₀) of about 1 μM or less,about 100 nM or less, about 40 nM or less, about 20 nM or less, about 10nM or less, about 1 nM or less, or about 0.1 nM or less. In certainembodiments, a TIGIT-binding agent binds mouse TIGIT and/or human TIGITwith an EC₅₀, of about 40 nM or less, about 20 nM or less, about 10 nMor less, about 1 nM or less or about 0.1 nM or less.

In certain embodiments, the TIGIT-binding agent is an antibody. In someembodiments, the antibody is a recombinant antibody. In someembodiments, the antibody is a monoclonal antibody. In some embodiments,the antibody is a chimeric antibody. In some embodiments, the antibodyis a humanized antibody. In some embodiments, the antibody is a humanantibody. In some embodiments, the antibody is an IgA, IgD, IgE, IgG, orIgM antibody. In certain embodiments, the antibody is an IgG1 antibody.In certain embodiments, the antibody is an IgG2 antibody. In someembodiments, the antibody is an IgG4 antibody. In certain embodiments,the antibody is an antibody fragment comprising an antigen-binding site.In some embodiments, the antibody is a bispecific antibody or amultispecific antibody. In some embodiments, the antibody is amonovalent antibody. In some embodiments, the antibody is a monospecificantibody. In some embodiments, the antibody is a bivalent antibody. Insome embodiments, the antibody is conjugated to a cytotoxic moiety. Insome embodiments, the antibody is isolated. In some embodiments, theantibody is substantially pure.

In some embodiments, the TIGIT-binding agents are polyclonal antibodies.Polyclonal antibodies can be prepared by any known method. In someembodiments, polyclonal antibodies are produced by immunizing an animal(e.g., a rabbit, rat, mouse, goat, donkey) with an antigen of interest(e.g., a purified peptide fragment, full-length recombinant protein, orfusion protein) using multiple subcutaneous or intraperitonealinjections. The antigen can be optionally conjugated to a carrier suchas keyhole limpet hemocyanin (KLH) or serum albumin. The antigen (withor without a carrier protein) is diluted in sterile saline and usuallycombined with an adjuvant (e.g., Complete or Incomplete Freund'sAdjuvant) to form a stable emulsion. After a sufficient period of time,polyclonal antibodies are recovered from the immunized animal, usuallyfrom blood or ascites. The polyclonal antibodies can be purified fromserum or ascites according to standard methods in the art including, butnot limited to, affinity chromatography, ion-exchange chromatography,gel electrophoresis, and dialysis.

In some embodiments, a TIGIT-binding agent is a monoclonal antibody.Monoclonal antibodies can be prepared using hybridoma methods known toone of skill in the art. In some embodiments, using the hybridomamethod, a mouse, rat, rabbit, hamster, or other appropriate host animal,is immunized as described above to elicit the production of antibodiesthat specifically bind the immunizing antigen. In some embodiments,lymphocytes can be immunized in vitro. In some embodiments, theimmunizing antigen can be a human protein or a fragment thereof. In someembodiments, the immunizing antigen can be a mouse protein or a fragmentthereof.

Following immunization, lymphocytes are isolated and fused with asuitable myeloma cell line using, for example, polyethylene glycol. Thehybridoma cells are selected using specialized media as known in the artand unfused lymphocytes and myeloma cells do not survive the selectionprocess. Hybridomas that produce monoclonal antibodies directedspecifically against a chosen antigen may be identified by a variety ofmethods including, but not limited to, immunoprecipitation,immunoblotting, and in vitro binding assays (e.g., flow cytometry, FACS,ELISA, and radioimmunoassay). The hybridomas can be propagated either inin vitro culture using standard methods or in vivo as ascites tumors inan animal. The monoclonal antibodies can be purified from the culturemedium or ascites fluid according to standard methods in the artincluding, but not limited to, affinity chromatography, ion-exchangechromatography, gel electrophoresis, and dialysis.

In certain embodiments, monoclonal antibodies can be made usingrecombinant DNA techniques as known to one skilled in the art. Thepolynucleotides encoding a monoclonal antibody are isolated from matureB-cells or hybridoma cells, such as by RT-PCR using oligonucleotideprimers that specifically amplify the genes encoding the heavy and lightchains of the antibody, and their sequence is determined using standardtechniques. The isolated polynucleotides encoding the heavy and lightchains are then cloned into suitable expression vectors which producethe monoclonal antibodies when transfected into host cells such as E.coli, simian COS cells, Chinese hamster ovary (CHO) cells, or myelomacells that do not otherwise produce immunoglobulin proteins.

In certain other embodiments, recombinant monoclonal antibodies, orfragments thereof, can be isolated from phage display librariesexpressing variable domains or CDRs of a desired species.

The polynucleotide(s) encoding a monoclonal antibody can be modified,for example, by using recombinant DNA technology to generate alternativeantibodies. In some embodiments, the constant domains of the light chainand heavy chain of, for example, a mouse monoclonal antibody can besubstituted for constant regions of, for example, a human antibody togenerate a chimeric antibody, or for a non-immunoglobulin polypeptide togenerate a fusion antibody. In some embodiments, the constant regionsare truncated or removed to generate a desired antibody fragment of amonoclonal antibody. Site-directed or high-density mutagenesis of thevariable region(s) can be used to optimize specificity, affinity, etc.of a monoclonal antibody.

In some embodiments, a TIGIT-binding agent is a humanized antibody.Typically, humanized antibodies are human immunoglobulins in which theamino acid residues of the CDRs are replaced by amino acid residues fromCDRs of a non-human species (e.g., mouse, rat, rabbit, hamster, etc.)that have the desired specificity, affinity, and/or binding capabilityusing methods known to one skilled in the art. In some embodiments, someof the framework variable region amino acid residues of a humanimmunoglobulin are replaced with corresponding amino acid residues in anantibody from a non-human species. In some embodiments, a humanizedantibody can be further modified by the substitution of additionalresidues either in the framework variable region and/or within thereplaced non-human residues to further refine and optimize antibodyspecificity, affinity, and/or capability. In general, a humanizedantibody will comprise variable domain regions containing all, orsubstantially all, of the CDRs that correspond to the non-humanimmunoglobulin whereas all, or substantially all, of the frameworkregions are those of a human immunoglobulin sequence. In someembodiments, the framework regions are those of a human consensusimmunoglobulin sequence. In some embodiments, a humanized antibody canalso comprise at least a portion of an immunoglobulin constant region ordomain (Fc), typically that of a human immunoglobulin. In certainembodiments, such humanized antibodies are used therapeutically becausethey may reduce antigenicity and HAMA (human anti-mouse antibody)responses when administered to a human subject.

In certain embodiments, a TIGIT-binding agent is a human antibody. Humanantibodies can be directly prepared using various techniques known inthe art. In some embodiments, human antibodies may be generated fromimmortalized human B lymphocytes immunized in vitro or from lymphocytesisolated from an immunized individual. In either case, cells thatproduce an antibody directed against a target antigen can be generatedand isolated. In some embodiments, the human antibody can be selectedfrom a phage library, where that phage library expresses humanantibodies. Alternatively, phage display technology can be used toproduce human antibodies and antibody fragments in vitro, fromimmunoglobulin variable domain gene repertoires from unimmunized donors.Techniques for the generation and use of antibody phage libraries arewell known in the art. Once antibodies are identified, affinitymaturation strategies known in the art, including but not limited to,chain shuffling and site-directed mutagenesis, may be employed togenerate higher affinity human antibodies.

In some embodiments, human antibodies can be made in transgenic micethat contain human immunoglobulin loci. Upon immunization these mice arecapable of producing the full repertoire of human antibodies in theabsence of endogenous immunoglobulin production.

In some embodiments, the TIGIT-binding agent is a bispecific antibody.Thus, this invention encompasses bispecific antibodies that specificallyrecognize TIGIT and at least one additional target. Bispecificantibodies are capable of specifically recognizing and binding at leasttwo different antigens or epitopes. The different epitopes can either bewithin the same molecule (e.g., two epitopes on TIGIT) or on differentmolecules (e.g., one epitope on TIGIT and one epitope on a differentprotein). In some embodiments, a bispecific antibody has enhancedpotency as compared to an individual antibody or to a combination ofmore than one antibody. In some embodiments, a bispecific antibody hasreduced toxicity as compared to an individual antibody or to acombination of more than one antibody. It is known to those of skill inthe art that any therapeutic agent may have unique pharmacokinetics (PK)(e.g., circulating half-life). In some embodiments, a bispecificantibody has the ability to synchronize the PK of two active bindingagents wherein the two individual binding agents have different PKprofiles. In some embodiments, a bispecific antibody has the ability toconcentrate the actions of two agents in a common area (e.g., a tumorand/or tumor microenvironment). In some embodiments, a bispecificantibody has the ability to concentrate the actions of two agents to acommon target (e.g., a tumor or a tumor cell). In some embodiments, abispecific antibody has the ability to target the actions of two agentsto more than one biological pathway or function. In some embodiments, abispecific antibody has the ability to target two different cells andbring them closer together (e.g., an immune cell and a tumor cell).

In some embodiments, the bispecific antibody is a monoclonal antibody.In some embodiments, the bispecific antibody is a humanized antibody. Insome embodiments, the bispecific antibody is a human antibody. In someembodiments, the bispecific antibody is an IgG1 antibody. In someembodiments, the bispecific antibody is an IgG2 antibody. In someembodiments, the bispecific antibody is an IgG4 antibody. In someembodiments, the bispecific antibody has decreased toxicity and/or sideeffects. In some embodiments, the bispecific antibody has decreasedtoxicity and/or side effects as compared to a mixture of the twoindividual antibodies or the antibodies as single agents. In someembodiments, the bispecific antibody has an increased therapeutic index.In some embodiments, the bispecific antibody has an increasedtherapeutic index as compared to a mixture of the two individualantibodies or the antibodies as single agents.

In some embodiments, the antibodies can specifically recognize and bindTIGIT as well as a second antigen target, such as an effector moleculeon an immune cell (e.g., CD2, CD3, CD28, CTLA4, PD-1, PD-L1, CD80, orCD86) or a Fc receptor (e.g., CD64, CD32, or CD16). In some embodiments,the antibodies can be used to direct cytotoxic agents to cells whichexpress a particular target antigen. These antibodies possess anantigen-binding arm and an arm which binds a cytotoxic agent or aradionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.

Techniques for making bispecific antibodies are known by those skilledin the art. In some embodiments, the bispecific antibodies compriseheavy chain constant regions with modifications in the amino acids whichare part of the interface between the two heavy chains. In someembodiments, the bispecific antibodies can be generated using a“knobs-into-holes” strategy. In some cases, the “knobs” and “holes”terminology is replaced with the terms “protuberances” and “cavities”.In some embodiments, the bispecific antibodies may comprise varianthinge regions incapable of forming disulfide linkages between the heavychains. In some embodiments, the modifications may comprise changes inamino acids that result in altered electrostatic interactions. In someembodiments, the modifications may comprise changes in amino acids thatresult in altered hydrophobic/hydrophilic interactions.

Bispecific antibodies can be intact antibodies or antibody fragmentscomprising antigen-binding sites. Antibodies with more than twovalencies are also contemplated. For example, trispecific antibodies canbe prepared. Thus, in certain embodiments the antibodies to TIGIT aremultispecific.

In certain embodiments, the antibodies (or other polypeptides) describedherein may be monospecific. In certain embodiments, each of the one ormore antigen-binding sites that an antibody contains is capable ofbinding (or binds) a homologous epitope on TIGIT.

In certain embodiments, a TIGIT-binding agent is an antibody fragment.Antibody fragments may have different functions or capabilities thanintact antibodies; for example, antibody fragments can have increasedtumor penetration. Various techniques are known for the production ofantibody fragments including, but not limited to, proteolytic digestionof intact antibodies. In some embodiments, antibody fragments include aF(ab′)2 fragment produced by pepsin digestion of an antibody molecule.In some embodiments, antibody fragments include a Fab fragment generatedby reducing the disulfide bridges of an F(ab′)2 fragment. In otherembodiments, antibody fragments include a Fab fragment generated by thetreatment of the antibody molecule with papain and a reducing agent. Incertain embodiments, antibody fragments are produced by recombinantmethods. In some embodiments, antibody fragments include Fv or singlechain Fv (scFv) fragments. Fab, Fv, and scFv antibody fragments can beexpressed in and secreted from E. coli or other host cells, allowing forthe production of large amounts of these fragments. In some embodiments,antibody fragments are isolated from antibody phage libraries asdiscussed herein. For example, methods can be used for the constructionof Fab expression libraries to allow rapid and effective identificationof monoclonal Fab fragments with the desired specificity for TIGIT orderivatives, fragments, analogs or homologs thereof. In someembodiments, antibody fragments are linear antibody fragments. Incertain embodiments, antibody fragments are monospecific or bispecific.In certain embodiments, the TIGIT-binding agent is a scFv. Varioustechniques can be used for the production of single-chain antibodiesspecific to TIGIT.

In some embodiments, especially in the case of antibody fragments, anantibody is modified in order to alter (e.g., increase or decrease) itsserum half-life. This can be achieved, for example, by incorporation ofa salvage receptor binding epitope into the antibody fragment bymutation of the appropriate region in the antibody fragment or byincorporating the epitope into a peptide tag that is then fused to theantibody fragment at either end or in the middle (e.g., by DNA orpeptide synthesis).

Heteroconjugate antibodies are also within the scope of the presentinvention. Heteroconjugate antibodies are composed of two covalentlyjoined antibodies. Such antibodies have, for example, been proposed totarget immune cells to unwanted cells. It is also contemplated that theheteroconjugate antibodies can be prepared in vitro using known methodsin synthetic protein chemistry, including those involving crosslinkingagents. For example, immunotoxins can be constructed using a disulfideexchange reaction or by forming a thioether bond. Examples of suitablereagents for this purpose include iminothiolate andmethyl-4-mercaptobutyrimidate.

For the purposes of the present invention, it should be appreciated thatmodified antibodies can comprise any type of variable region thatprovides for the association of the antibody with the target (i.e.,TIGIT). In this regard, the variable region may comprise or be derivedfrom any type of mammal that can be induced to mount a humoral responseand generate immunoglobulins against the desired antigen. As such, thevariable region of the modified antibodies can be, for example, ofhuman, murine, rat, rabbit, non-human primate (e.g. cynomolgus monkeys,macaques, etc.), or rabbit origin. In some embodiments, both thevariable and constant regions of the modified immunoglobulins are humanIn other embodiments, the variable regions of compatible antibodies(usually derived from a non-human source) can be engineered orspecifically tailored to improve the binding properties or reduce theimmunogenicity of the molecule. In this respect, variable regions usefulin the present invention can be humanized or otherwise altered throughthe inclusion of imported amino acid sequences.

In certain embodiments, the variable domains in both the heavy and lightchains are altered by at least partial replacement of one or more CDRsand, if necessary, by partial framework region replacement and sequencemodification and/or alteration. Although the CDRs may be derived from anantibody of the same class or even subclass as the antibody from whichthe framework regions are derived, it is envisaged that the CDRs may bederived from an antibody of different class and often from an antibodyfrom a different species. It may not be necessary to replace all of theCDRs with all of the CDRs from the donor variable region to transfer theantigen binding capacity of one variable domain to another. Rather, itmay only be necessary to transfer those residues that are required tomaintain the activity of the antigen-binding site.

Alterations to the variable region notwithstanding, those skilled in theart will appreciate that the modified antibodies of this invention willcomprise antibodies (e.g., full-length antibodies or immunoreactivefragments thereof) in which at least a fraction of one or more of theconstant region domains has been deleted or otherwise altered so as toprovide desired biochemical characteristics such as increased tumorlocalization or increased serum half-life when compared with an antibodyof approximately the same immunogenicity comprising a native orunaltered constant region. In some embodiments, the constant region ofthe modified antibodies will comprise a human constant region.Modifications to the constant region compatible with this inventioncomprise additions, deletions or substitutions of one or more aminoacids in one or more domains. The modified antibodies disclosed hereinmay comprise alterations or modifications to one or more of the threeheavy chain constant domains (CH1, CH2 or CH3) and/or to the light chainconstant domain (CL). In some embodiments, one or more domains arepartially or entirely deleted from the constant regions of the modifiedantibodies. In some embodiments, the modified antibodies will comprisedomain deleted constructs or variants wherein the entire CH2 domain hasbeen removed (ACH2 constructs). In some embodiments, the omittedconstant region domain is replaced by a short amino acid spacer (e.g.,10 amino acid residues) that provides some of the molecular flexibilitytypically imparted by the absent constant region.

In some embodiments, the modified antibodies are engineered to fuse theCH3 domain directly to the hinge region of the antibody. In otherembodiments, a peptide spacer is inserted between the hinge region andthe modified CH2 and/or CH3 domains. For example, constructs may beexpressed wherein the CH2 domain has been deleted and the remaining CH3domain (modified or unmodified) is joined to the hinge region with a5-20 amino acid spacer. Such a spacer may be added to ensure that theregulatory elements of the constant domain remain free and accessible orthat the hinge region remains flexible. However, it should be noted thatamino acid spacers may, in some cases, prove to be immunogenic andelicit an unwanted immune response against the construct. Accordingly,in certain embodiments, any spacer added to the construct will berelatively non-immunogenic so as to maintain the desired biologicalqualities of the modified antibodies.

In some embodiments, the modified antibodies may have only a partialdeletion of a constant domain or substitution of a few or even a singleamino acid. For example, the mutation of a single amino acid in selectedareas of the CH2 domain may be enough to substantially reduce Fcbinding. In some embodiments, the mutation of a single amino acid inselected areas of the CH2 domain may be enough to substantially reduceFc binding and increase cancer cell localization and/or tumorpenetration. Similarly, it may be desirable to simply delete the part ofone or more constant region domains that control a specific effectorfunction (e.g. complement C lq binding) to be modulated. Such partialdeletions of the constant regions may improve selected characteristicsof the antibody (serum half-life) while leaving other desirablefunctions associated with the subject constant region domain intact.Moreover, as alluded to above, the constant regions of the disclosedantibodies may be modified through the mutation or substitution of oneor more amino acids that enhances the profile of the resultingconstruct. In this respect it may be possible to disrupt the activityprovided by a conserved binding site (e.g., Fc binding) whilesubstantially maintaining the configuration and immunogenic profile ofthe modified antibody. In certain embodiments, the modified antibodiescomprise the addition of one or more amino acids to the constant regionto enhance desirable characteristics such as decreasing or increasingeffector function or provide for more cytotoxin or carbohydrateattachment sites.

It is known in the art that the constant region mediates severaleffector functions. For example, binding of the Cl component ofcomplement to the Fc region of IgG or IgM antibodies (bound to antigen)activates the complement system. Activation of complement is importantin the opsonization and lysis of cell pathogens. The activation ofcomplement also stimulates the inflammatory response and can also beinvolved in autoimmune hypersensitivity. In addition, the Fc region ofan antibody can bind a cell expressing a Fc receptor (FcR). There are anumber of Fc receptors which are specific for different classes ofantibody, including IgG (gamma receptors), IgE (epsilon receptors), IgA(alpha receptors) and IgM (mu receptors). Binding of antibody to Fcreceptors on cell surfaces triggers a number of important and diversebiological responses including engulfment and destruction ofantibody-coated particles, clearance of immune complexes, lysis ofantibody-coated target cells by killer cells (called antibody-dependentcell cytotoxicity or ADCC), release of inflammatory mediators, placentaltransfer, and control of immunoglobulin production.

In certain embodiments, the modified antibodies provide for alteredeffector functions that, in turn, affect the biological profile of theadministered antibody. For example, in some embodiments, the deletion orinactivation (through point mutations or other means) of a constantregion domain may reduce Fc receptor binding of the circulating modifiedantibody. In some embodiments, the deletion or inactivation (throughpoint mutations or other means) of a constant region domain may reduceFc receptor binding of the circulating modified antibody therebyincreasing cancer cell localization and/or tumor penetration. In otherembodiments, the constant region modifications increase the serumhalf-life of the antibody. In other embodiments, the constant regionmodifications reduce the serum half-life of the antibody. In someembodiments, the constant region is modified to eliminate disulfidelinkages or oligosaccharide moieties. Modifications to the constantregion in accordance with this invention may easily be made using wellknown biochemical or molecular engineering techniques.

In certain embodiments, a TIGIT-binding agent that is an antibody doesnot have one or more effector functions. For instance, in someembodiments, the antibody has no ADCC activity, and/or nocomplement-dependent cytotoxicity (CDC) activity. In certainembodiments, the antibody does not bind an Fc receptor and/or complementfactors. In certain embodiments, the antibody has no effectorfunction(s).

The present invention further embraces variants and equivalents whichare substantially homologous to the recombinant, monoclonal, chimeric,humanized, and human antibodies, or antibody fragments thereof,described herein. These variants can contain, for example, conservativesubstitution mutations, i.e. the substitution of one or more amino acidsby similar amino acids.

In certain embodiments, the antibodies described herein are isolated. Incertain embodiments, the antibodies described herein are substantiallypure.

The TIGIT-binding agents (e.g., antibodies) of the present invention canbe assayed for specific binding by any method known in the art. Theimmunoassays which can be used include, but are not limited to,competitive and non-competitive assay systems using techniques such asBiaCore™ analysis, FACS analysis, immunofluorescence,immunocytochemistry, Western blot analysis, radioimmunoassay, ELISA,“sandwich” immunoassay, immunoprecipitation assay, precipitationreaction, gel diffusion precipitin reaction, immunodiffusion assay,agglutination assay, complement-fixation assay, immunoradiometric assay,fluorescent immunoassay, and protein A immunoassay. Such assays areroutine and well-known in the art (see, e.g., Ausubel et al., Editors,1994-present, Current Protocols in Molecular Biology, John Wiley & Sons,Inc., New York, N.Y.).

In a non-limiting example, screening for specific binding of an antibodyto human TIGIT may be determined using ELISA. An ELISA comprisespreparing antigen (e.g., TIGIT or a fragment thereof), coating wells ofa 96-well microtiter plate with antigen, adding the test antibodiesconjugated to a detectable compound such as an enzymatic substrate (e.g.horseradish peroxidase or alkaline phosphatase) to the well, incubatingfor a period of time, and detecting the presence of an antibody bound tothe antigen. In some embodiments, the test antibodies are not conjugatedto a detectable compound, but instead a secondary antibody thatrecognizes the antibody (e.g., an anti-Fc antibody) and is conjugated toa detectable compound is added to the wells. In some embodiments,instead of coating the well with the antigen, the test antibodies can becoated to the wells, the antigen (e.g., TIGIT) is added to the wells,followed by a secondary antibody conjugated to a detectable compound.One of skill in the art would be knowledgeable as to the parameters thatcan be modified to increase the signal detected as well as othervariations of ELISAs known in the art.

In another non-limiting example, the specific binding of an antibody toTIGIT may be determined using FACS. A FACS screening assay may comprisegenerating a cDNA construct that expresses an antigen as a full-lengthprotein (TIGIT) or a fusion protein (e.g., TIGIT-CD4TM), transfectingthe construct into cells, expressing the antigen on the surface of thecells, mixing the test antibodies with the transfected cells, andincubating for a period of time. The cells bound by the test antibodiesmay be identified using a secondary antibody conjugated to a detectablecompound (e.g., PE-conjugated anti-Fc antibody) and a flow cytometer.One of skill in the art would be knowledgeable as to the parameters thatcan be modified to optimize the signal detected as well as othervariations of FACS that may enhance screening (e.g., screening forblocking antibodies).

The binding affinity of an antibody or other binding agent to an antigen(e.g., TIGIT) and the off-rate of an antibody-antigen interaction can bedetermined by competitive binding assays. One example of a competitivebinding assay is a radioimmunoassay comprising the incubation of labeledantigen (e.g., ³H or ¹²⁵I-TIGIT), or fragment or variant thereof, withthe antibody of interest in the presence of increasing amounts ofunlabeled antigen followed by the detection of the antibody bound to thelabeled antigen. The affinity of the antibody for the antigen and thebinding off-rates can be determined from the data by Scatchard plotanalysis. In some embodiments, BiaCore™ kinetic analysis is used todetermine the binding on and off rates of antibodies or agents that bindan antigen (e.g., TIGIT). In some embodiments, BiaCore™ kinetic analysiscomprises analyzing the binding and dissociation of antibodies fromchips with immobilized antigen (e.g., TIGIT) on their surface. In someembodiments, BiaCore™ kinetic analysis comprises analyzing the bindingand dissociation of antigen (e.g., TIGIT) from chips with immobilizedantibody (e.g., anti-TIGIT antibody) on their surface.

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises one, two,three, four, five, and/or six of the CDRs of antibody OMP-313M32 (seeTable 1). Anti-TIGIT antibody OMP-313M32 In some embodiments, theTIGIT-binding agent comprises one or more of the CDRs of OMP-313M32; twoor more of the CDRs of OMP-313M32; three or more of the CDRs ofOMP-313M32; four or more of the CDRs of OMP-313M32; five or more of theCDRs of OMP-313M32; or all six of the CDRs of OMP-313M32.

TABLE 1 OMP-313M32 HC CDR1 TSDYAWN (SEQ ID NO: 4) HC CDR2YISYSGSTSYNPSLRS (SEQ ID NO: 5) HC CDR3 ARRQVGLGFAY (SEQ ID NO: 6)LC CDR1 KASQDVSTAVA (SEQ ID NO: 7) LC CDR2 SASYRYT (SEQ ID NO: 8)LC CDR3 QQHYSTP (SEQ ID NO: 9)

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises a heavychain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), and a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6). In some embodiments, theTIGIT-binding agent further comprises a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the TIGIT-binding agent comprises a light chain CDR1comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9). In some embodiments, the TIGIT-binding agent comprises: (a) aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), and a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6); and (b) a light chain CDR1comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprisingSASYRYT (SEQ ID NO:8), and a light chain CDR3 comprising QQHYSTP (SEQ IDNO:9).

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises: (a) aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4) or a variant thereofcomprising 1, 2, 3, or 4 amino acid substitutions; (b) a heavy chainCDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5) or a variant thereofcomprising 1, 2, 3, or 4 amino acid substitutions; (c) a heavy chainCDR3 comprising ARRQVGLGFAY (SEQ ID NO:6) or a variant thereofcomprising 1, 2, 3, or 4 amino acid substitutions; (d) a light chainCDR1 comprising KASQDVSTAVA (SEQ ID NO:7) or a variant thereofcomprising 1, 2, 3, or 4 amino acid substitutions; (e) a light chainCDR2 comprising SASYRYT (SEQ ID NO:8) or a variant thereof comprising 1,2, 3, or 4 amino acid substitutions; and (f) a light chain CDR3comprising QQHYSTP (SEQ ID NO:9) or a variant thereof comprising 1, 2,3, or 4 amino acid substitutions. In certain embodiments, the amino acidsubstitutions are conservative substitutions. In some embodiments, thesubstitutions are made as part of a humanization process. In someembodiments, the substitutions are made as part of a germlinehumanization process. In some embodiments, the substitutions are made aspart of a binding optimization process.

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises a heavychain variable region having at least about 80% sequence identity to SEQID NO:10 and/or a light chain variable region having at least 80%sequence identity to SEQ ID NO:11. In certain embodiments, theTIGIT-binding agent comprises a heavy chain variable region having atleast about 85%, at least about 90%, at least about 95%, at least about97%, or at least about 99% sequence identity to SEQ ID NO:10. In certainembodiments, the TIGIT-binding agent comprises a light chain variableregion having at least about 85%, at least about 90%, at least about95%, at least about 97%, or at least about 99% sequence identity to SEQID NO:11. In certain embodiments, the TIGIT-binding agent comprises aheavy chain variable region having at least about 95% sequence identityto SEQ ID NO:10 and/or a light chain variable region having at leastabout 95% sequence identity to SEQ ID NO:11. In certain embodiments, theTIGIT-binding agent comprises a heavy chain variable region comprisingSEQ ID NO:10 and/or a light chain variable region comprising SEQ IDNO:11. In certain embodiments, the TIGIT-binding agent comprises a heavychain variable region comprising SEQ ID NO:10 and a light chain variableregion comprising SEQ ID NO:11. In certain embodiments, theTIGIT-binding agent comprises a heavy chain variable region consistingessentially of SEQ ID NO:10 and a light chain variable region consistingessentially of SEQ ID NO:11. In certain embodiments, the TIGIT-bindingagent comprises a heavy chain variable region consisting of SEQ ID NO:10and a light chain variable region consisting of SEQ ID NO:11.

In certain embodiments of the methods described herein, theTIGIT-binding agent comprises a heavy chain variable region comprisingSEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:11.In certain embodiments, the TIGIT-binding agent comprises a heavy chainvariable region consisting essentially of SEQ ID NO:10 and a light chainvariable region consisting essentially of SEQ ID NO:11. In certainembodiments, the TIGIT-binding agent comprises a heavy chain variableregion consisting of SEQ ID NO:10 and a light chain variable regionconsisting of SEQ ID NO:11.

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises: a heavychain having at least 90% sequence identity to SEQ ID NO:13 and/or alight chain having at least 90% sequence identity to SEQ ID NO:15. Insome embodiments, the TIGIT-binding agent comprises: a heavy chainhaving at least 95% sequence identity to SEQ ID NO:13 and/or a lightchain having at least 95% sequence identity to SEQ ID NO:15. In someembodiments, the TIGIT-binding agent comprises a heavy chain comprisingSEQ ID NO:13 and/or a light chain comprising SEQ ID NO:15. In someembodiments, the TIGIT-binding agent comprises a heavy chain consistingessentially of SEQ ID NO:13 and a light chain consisting essentially ofSEQ ID NO:15. In some embodiments, the TIGIT-binding agent comprises aheavy chain consisting of SEQ ID NO:13 and a light chain consisting ofSEQ ID NO:15.

In certain embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent (e.g., an antibody) that specificallybinds human TIGIT, wherein the TIGIT-binding agent comprises: a heavychain having at least 90% sequence identity to SEQ ID NO:17 and/or alight chain having at least 90% sequence identity to SEQ ID NO:15. Insome embodiments, the TIGIT-binding agent comprises: a heavy chainhaving at least 95% sequence identity to SEQ ID NO:17 and/or a lightchain having at least 95% sequence identity to SEQ ID NO:15. In someembodiments, the TIGIT-binding agent comprises a heavy chain comprisingSEQ ID NO:17 and/or a light chain comprising SEQ ID NO:15. In someembodiments, the TIGIT-binding agent comprises a heavy chain consistingessentially of SEQ ID NO:17 and a light chain consisting essentially ofSEQ ID NO:15. In some embodiments, the TIGIT-binding agent comprises aheavy chain consisting of SEQ ID NO:17 and a light chain consisting ofSEQ ID NO:15.

In certain embodiments of the methods described herein, a TIGIT-bindingagent comprises the heavy chain variable region and light chain variableregion of the OMP-313M32 antibody. In some embodiments, theTIGIT-binding agent comprises the variable regions of the OMP-313M32antibody wherein the heavy chain variable region and/or the light chainvariable region from the OMP-313M32 antibody have been affinity-matured.In certain embodiments, a TIGIT-binding agent comprises the heavy chainand light chain of the OMP-313M32 antibody (with or without the leadersequence). In certain embodiments, a TIGIT-binding agent is theOMP-313M32 antibody. In certain embodiments, a TIGIT-binding agentcomprises the heavy chain variable region of the OMP-313M32 antibody aspart of an IgG1, IgG2, or IgG4 heavy chain. In certain embodiments, aTIGIT-binding agent comprises the heavy chain variable region of theOMP-313M32 antibody as part of a human IgG1 heavy chain. In certainembodiments, a TIGIT-binding agent comprises the heavy chain variableregion of the OMP-313M32 antibody as part of a human IgG2 heavy chain.In certain embodiments, a TIGIT-binding agent comprises the heavy chainvariable region of the OMP-313M32 antibody as part of a human IgG4 heavychain. In certain embodiments, a TIGIT-binding agent which comprises theheavy chain variable region of the OMP-313M32 antibody as part of ahuman IgG4 heavy chain is referred to as the OMP-313M33 antibody.

In certain embodiments of the methods described herein, a TIGIT-bindingagent comprises, consists essentially of, or consists of, the antibodyOMP-313M32. In certain embodiments, a TIGIT-binding agent comprises,consists essentially of, or consists of, a variant of the antibodyOMP-313M32. In certain embodiments, a TIGIT-binding agent comprises,consists essentially of, or consists of, the antibody OMP-313M33.

In some embodiments of the methods described herein, the TIGIT-bindingagent comprises a heavy chain variable region encoded by the plasmiddeposited with American Type Culture Collection (ATCC), 10801 UniversityBoulevard, Manassas, Va., USA, under the conditions of the BudapestTreaty on Aug. 11, 2015, and designated PTA-122346. In some embodiments,the TIGIT-binding agent comprises a light chain variable region encodedby the plasmid deposited with ATCC, 10801 University Boulevard,Manassas, Va., USA, under the conditions of the Budapest Treaty on Aug.11, 2015, and designated PTA-122347. In some embodiments, theTIGIT-binding agent comprises a heavy chain variable region encoded bythe plasmid deposited with ATCC and designated PTA-122346 and a lightchain variable region encoded by the plasmid deposited with ATCC anddesignated PTA-122347. In some embodiments, the TIGIT-binding agentcomprises a heavy chain comprising a variable region encoded by theplasmid deposited with ATCC and designated PTA-122346. In someembodiments, the TIGIT-binding agent comprises a light chain encoded bythe plasmid deposited with ATCC and designated PTA-122347. In someembodiments, the TIGIT-binding agent comprises a heavy chain comprisinga variable region encoded by the plasmid deposited with ATCC anddesignated PTA-122346 and a light chain encoded by the plasmid depositedwith ATCC and designated PTA-122347.

In some embodiments of the methods described herein, the TIGIT-bindingagents are homodimeric agents/molecules and heterodimericagents/molecules. In some embodiments, the homodimeric agents arepolypeptides. In some embodiments, the heterodimeric molecules arepolypeptides. Generally the homodimeric molecule comprises two identicalpolypeptides. Generally the heterodimeric molecule comprises at leasttwo different polypeptides. In some embodiments, the heterodimericmolecule is capable of binding at least two targets, e.g., a bispecificagent. The targets may be, for example, two different proteins on asingle cell or two different proteins on two separate cells. The term“arm” may be used herein to describe the structure of a homodimericagent, a heterodimeric agent, and/or a bispecific agent. In someembodiments, each arm comprises at least one polypeptide. Generally,each arm of a heterodimeric molecule has a different function, forexample, binding two different targets. In some embodiments, one arm maycomprise an antigen-binding site from an antibody. In some embodiments,one arm may comprise a binding portion of a receptor. In someembodiments, one arm may comprise a ligand. In some embodiments, one armmay comprise a binding region of a ligand. In some embodiments, ahomodimeric agent comprises two identical arms. In some embodiments, aheterodimeric agent comprises two different arms. In some embodiments, abispecific agent comprises two different arms.

In some embodiments of the methods described herein, the inventionprovides a TIGIT-binding agent that is a homodimeric molecule. In someembodiments, the homodimeric molecule comprises two identicalpolypeptides. In some embodiments, the invention provides aTIGIT-binding agent that is a heterodimeric molecule. In someembodiments, the heterodimeric molecule comprises at least two differentpolypeptides. In some embodiments, the invention provides aTIGIT-binding agent that is a heterodimeric agent. In some embodiments,the invention provides a TIGIT-binding agent that is a bispecific agent.In certain embodiments, the TIGIT-binding agent is a bispecificantibody.

In some of the embodiments of the methods described herein the inventionprovides polypeptides, including, but not limited to, antibodies thatspecifically bind TIGIT. In some embodiments, a polypeptide binds humanTIGIT. In some embodiments, a polypeptide binds mouse TIGIT. In someembodiments, a polypeptide binds mouse TIGIT and human TIGIT. In someembodiments, a polypeptide binds human TIGIT and does not bind mouseTIGIT. In some embodiments, a polypeptide binds human TIGIT and does notbind rat TIGIT. In some embodiments, a polypeptide binds human TIGIT anddoes not bind rabbit TIGIT. In some embodiments, a polypeptide bindshuman TIGIT and does not bind marmoset TIGIT. In some embodiments, apolypeptide binds human TIGIT and does not bind dog TIGIT. In someembodiments, a polypeptide binds human TIGIT and does not bind pigTIGIT. In some embodiments, a polypeptide binds human TIGIT and does notbind cynomolgus monkey TIGIT. In some embodiments, a polypeptide bindshuman TIGIT and does not bind rhesus monkey TIGIT.

In certain embodiments of the methods described herein, a polypeptidecomprises one, two, three, four, five, and/or six of the CDRs ofantibody OMP-313M32 (see Table 1 herein). In some embodiments, apolypeptide comprises CDRs with up to four (i.e., 0, 1, 2, 3, or 4)amino acid substitutions per CDR. In certain embodiments, the heavychain CDR(s) are contained within a heavy chain variable region. Incertain embodiments, the light chain CDR(s) are contained within a lightchain variable region.

In some embodiments of the methods described herein, the inventionprovides a polypeptide that specifically binds human TIGIT, wherein thepolypeptide comprises an amino acid sequence having at least about 80%sequence identity to SEQ ID NO:10, and/or an amino acid sequence havingat least about 80% sequence identity to SEQ ID NO:11. In certainembodiments, the polypeptide comprises an amino acid sequence having atleast about 85%, at least about 90%, at least about 95%, at least about97%, or at least about 99% sequence identity to SEQ ID NO:10. In certainembodiments, the polypeptide comprises an amino acid sequence having atleast about 85%, at least about 90%, at least about 95%, at least about97%, or at least about 99% sequence identity to SEQ ID NO:64 or SEQ IDNO:11. In certain embodiments, the polypeptide comprises an amino acidsequence having at least about 95% sequence identity to SEQ ID NO:10and/or an amino acid sequence having at least about 95% sequenceidentity to SEQ ID NO:11. In certain embodiments, the polypeptidecomprises an amino acid sequence comprising SEQ ID NO:10 and/or an aminoacid sequence comprising SEQ ID NO:11.

In some embodiments of the methods described herein, a polypeptidecomprises one or more amino acid sequences selected from the groupconsisting of: SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13,SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17. As definedherein, a polypeptide can occur as a single chain or as two or moreassociated chains. In certain embodiments, a polypeptide comprises anamino acid sequence comprising SEQ ID NO:10 and an amino acid sequencecomprising SEQ ID NO:11. In certain embodiments, a polypeptide comprisesan amino acid sequence comprising SEQ ID NO:12 and an amino acidsequence comprising SEQ ID NO:14. In certain embodiments, thepolypeptide comprises an amino acid sequence comprising SEQ ID NO:13 andan amino acid sequence comprising SEQ ID NO:15. In certain embodiments,the polypeptide comprises an amino acid sequence comprising SEQ ID NO:16and an amino acid sequence comprising SEQ ID NO:14. In certainembodiments, the polypeptide comprises an amino acid sequence comprisingSEQ ID NO:17 and an amino acid sequence comprising SEQ ID NO:15.

In certain embodiments of the methods described herein, a polypeptidecomprises an amino acid sequence consisting of SEQ ID NO:10 and an aminoacid sequence consisting of SEQ ID NO:11. In certain embodiments, apolypeptide comprises an amino acid sequence consisting of SEQ ID NO:12and an amino acid sequence consisting of SEQ ID NO:14. In certainembodiments, a polypeptide comprises an amino acid sequence consistingof SEQ ID NO:13 and an amino acid sequence consisting of SEQ ID NO:15.In certain embodiments, a polypeptide comprises an amino acid sequenceconsisting of SEQ ID NO:16 and an amino acid sequence consisting of SEQID NO:14. In certain embodiments, a polypeptide comprises an amino acidsequence consisting of SEQ ID NO:17 and an amino acid sequenceconsisting of SEQ ID NO:15.

Many proteins, including antibodies, contain a signal sequence thatdirects the transport of the proteins to various locations. Generally,signal sequences (also referred to as signal peptides or leadersequences) are located at the N-terminus of nascent polypeptides. Theytarget the polypeptide to the endoplasmic reticulum and the proteins aresorted to their destinations, for example, to the inner space of anorganelle, to an interior membrane, to the cell's outer membrane, or tothe cell exterior via secretion. Most signal sequences are cleaved fromthe protein by a signal peptidase after the proteins are transported tothe endoplasmic reticulum. The cleavage of the signal sequence from thepolypeptide usually occurs at a specific site in the amino acid sequenceand is dependent upon amino acid residues within the signal sequence.Although there is usually one specific cleavage site, more than onecleavage site may be recognized and/or may be used by a signal peptidaseresulting in a non-homogenous N-terminus of the polypeptide. Forexample, the use of different cleavage sites within a signal sequencecan result in a polypeptide expressed with different N-terminal aminoacids. Accordingly, in some embodiments, the polypeptides as describedherein may comprise a mixture of polypeptides with different N-terminiIn some embodiments, the N-termini differ in length by 1, 2, 3, 4, or 5amino acids. In some embodiments, the polypeptide is substantiallyhomogeneous, i.e., the polypeptides have the same N-terminus. In someembodiments, the signal sequence of the polypeptide comprises one ormore (e.g., one, two, three, four, five, six, seven, eight, nine, ten,etc) amino acid substitutions and/or deletions as compared to a “native”or “parental” signal sequence. In some embodiments, the signal sequenceof the polypeptide comprises amino acid substitutions and/or deletionsthat allow one cleavage site to be dominant, thereby resulting in asubstantially homogeneous polypeptide with one N-terminus. In someembodiments, a signal sequence of the polypeptide affects the expressionlevel of the polypeptide, e.g., increased expression or decreasedexpression.

In certain embodiments of the methods described herein, an antibody orother binding agent competes for specific binding to human TIGIT with aTIGIT-binding agent described herein. In some embodiments, an antibodyor other binding agent competes for specific binding to TIGIT with aTIGIT-binding agent comprising: (a) a heavy chain CDR1 comprisingTSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS(SEQ ID NO:5), and a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ IDNO:6) and (b) a light chain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), alight chain CDR2 comprising SASYRYT (SEQ ID NO:8), and a light chainCDR3 comprising QQHYSTP (SEQ ID NO:9).

In certain embodiments of the methods described herein, an antibody orother binding agent competes for specific binding to human TIGIT with aTIGIT-binding agent comprising a heavy chain variable region comprisingSEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:11.In certain embodiments, an antibody or other binding agent competes forspecific binding to human TIGIT with a TIGIT-binding agent comprising aheavy chain comprising SEQ ID NO:13 and a light chain comprising SEQ IDNO:15. In certain embodiments, an antibody or other binding agentcompetes for specific binding to human TIGIT with a TIGIT-binding agentcomprising a heavy chain comprising SEQ ID NO:17 and a light chaincomprising SEQ ID NO:15.

In certain embodiments of the methods described herein, an antibody orother binding agent competes with antibody OMP-313M32 for specificbinding to human TIGIT. In some embodiments, an antibody or otherbinding agent competes with a reference antibody for specific binding tohuman TIGIT, wherein the reference antibody is antibody OMP-313M32. Insome embodiments, an antibody or other binding agent competes with areference antibody for specific binding to human TIGIT, wherein thereference antibody is antibody 313M33.

In certain embodiments of the methods described herein, an antibody orother binding agent binds the same epitope, or essentially the sameepitope, on TIGIT as a TIGIT-binding agent described herein. In certainembodiments, an antibody or other binding agent binds the same epitope,or essentially the same epitope, on human TIGIT as antibody OMP-313M32.In certain embodiments, an antibody or other binding agent binds thesame epitope, or essentially the same epitope, on human TIGIT asantibody 313M33.

In another embodiment of the methods described herein, an antibody orother binding agent binds an epitope on TIGIT that overlaps with theepitope on TIGIT bound by a TIGIT-binding agent described herein. Inanother embodiment, the antibody or other binding agent binds an epitopeon TIGIT that overlaps with the epitope on human TIGIT bound by antibodyOMP-313M32. In another embodiment, the antibody or other binding agentbinds an epitope on TIGIT that overlaps with the epitope on human TIGITbound by antibody 313M33.

In some embodiments of the methods described herein, an antibody orother binding agent competes for binding to an epitope comprising aminoacids within SEQ ID NO:27 with a TIGIT-binding agent described herein.In some embodiments, an antibody or other binding agent competes forbinding to an epitope comprising amino acids within SEQ ID NO:28 with aTIGIT-binding agent described herein. In some embodiments, an antibodyor other binding agent competes for binding to an epitope comprisingamino acids within SEQ ID NO:27 and SEQ ID NO:28 with a TIGIT-bindingagent described herein. In some embodiments, an antibody or otherbinding agent competes for binding to an epitope comprising amino acidsQ62 and I109 of SEQ ID NO:1 with a TIGIT-binding agent described herein.In some embodiments, an antibody or other binding agent competes forbinding to an epitope comprising amino acids Q62 and T119 of SEQ ID NO:1with a TIGIT-binding agent described herein. In some embodiments, anantibody or other binding agent competes for binding with an epitopecomprising amino acids Q64 and I109 of SEQ ID NO:1 with a TIGIT-bindingagent described herein. In some embodiments, an antibody or otherbinding agent competes for binding to an epitope comprising amino acidsQ64 and T119 of SEQ ID NO:1 with a TIGIT-binding agent described herein.In some embodiments, an antibody or other binding agent competes forbinding to an epitope comprising amino acids Q62, Q64, and I109 of SEQID NO:1 with a TIGIT-binding agent described herein. In someembodiments, an antibody or other binding agent competes for binding toan epitope comprising amino acids Q62, Q64, and T119 of SEQ ID NO:1 witha TIGIT-binding agent described herein. In some embodiments, an antibodyor other binding agent competes for binding to an epitope comprisingamino acids Q62, 1109, and T119 of SEQ ID NO:1 with a TIGIT-bindingagent described herein. In some embodiments, an antibody or otherbinding agent competes for binding to an epitope comprising amino acidsQ64, 1109, and T119 of SEQ ID NO:1 with a TIGIT-binding agent describedherein. In some embodiments, an antibody or other binding agent competesfor binding to an epitope comprising amino acids Q62, Q64, 1109, andT119 of SEQ ID NO:1 with a TIGIT-binding agent described herein. In someembodiments, an antibody or other binding agent competes for binding toan epitope comprising at least one amino acid selected from the groupconsisting of: N58, E60, Q62, Q64, L65, F107, I109, H111, T117, T119,G120, and R121 of SEQ ID NO:1 with a TIGIT-binding agent describedherein.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., an antibody) binds TIGIT and modulates TIGITactivity. In some embodiments, the TIGIT-binding agent is a TIGITantagonist and decreases TIGIT activity. In certain embodiments, theTIGIT-binding agent inhibits TIGIT activity by at least about 10%, atleast about 20%, at least about 30%, at least about 50%, at least about75%, at least about 90%, or about 100%. In certain embodiments, aTIGIT-binding agent that inhibits TIGIT activity is antibody OMP-313M32.In certain embodiments, a TIGIT-binding agent that inhibits TIGITactivity is antibody OMP-313M32. In certain embodiments, a TIGIT-bindingagent that inhibits TIGIT activity is antibody OMP-313M33.

In some embodiments of the methods described herein, the TIGIT-bindingagent binds TIGIT and inhibits or reduces TIGIT signaling. In certainembodiments, the TIGIT-binding agent (e.g., an antibody) inhibits TIGITsignaling by at least about 10%, at least about 20%, at least about 30%,at least about 50%, at least about 75%, at least about 90%, or about100%. In some embodiments, the TIGIT-binding agent inhibits mouse TIGITsignaling. In some embodiments, the TIGIT-binding agent inhibits humanTIGIT signaling. In certain embodiments, a TIGIT-binding agent thatinhibits TIGIT signaling is antibody OMP-313M32. In certain embodiments,a TIGIT-binding agent that inhibits TIGIT signaling is antibodyOMP-313M33.

TIGIT is phosphorylated at its cytoplasmic tail after interaction withits counter-receptor PVR. The phosphorylation of TIGIT is the beginningof a cascade that includes downstream events affecting other knownsignaling pathways. Therefore, evaluating TIGIT phosphorylation can giveinformation about TIGIT activity and TIGIT signaling.

Phosphorylation assays are known to those of skill in the art and arecommonly used to monitor protein activation and/or pathway activation.The assays may be used to monitor the effect of various treatments onactivation of a target protein and/or a target pathway. For example, anin vitro phosphorylation assay can be used to evaluate the effect of aTIGIT antagonist on the PVR-induced activation of TIGIT.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) inhibits binding of TIGIT to areceptor. In certain embodiments, the TIGIT-binding agent inhibitsbinding of TIGIT to PVR. In some embodiments, the TIGIT-binding agentinhibits binding of TIGIT to PVR-L2, PVR-L3, and/or PVR-L4. In certainembodiments, the inhibition of binding of a TIGIT-binding agent to PVRis at least about 10%, at least about 25%, at least about 50%, at leastabout 75%, at least about 90%, or at least about 95%. In certainembodiments, the inhibition of binding of a TIGIT-binding agent toPVR-L2, PVR-L3, and/or PVR-L4 is at least about 10%, at least about 25%,at least about 50%, at least about 75%, at least about 90%, or at leastabout 95%. In certain embodiments, a TIGIT-binding agent that inhibitsbinding of TIGIT to PVR is antibody OMP-313M32. In certain embodiments,a TIGIT-binding agent that inhibits binding of TIGIT to PVR is antibodyOMP-313M33. In certain embodiments, a TIGIT-binding agent that inhibitsbinding of TIGIT to PVR-L2, PVR-L3, and/or PVR-L4 is antibodyOMP-313M32. In certain embodiments, a TIGIT-binding agent that inhibitsbinding of TIGIT to PVR-L2, PVR-L3, and/or PVR-L4 is antibodyOMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) blocks binding of TIGIT to areceptor. In certain embodiments, the TIGIT-binding agent blocks bindingof TIGIT to PVR. In certain embodiments, the blocking of binding of aTIGIT-binding agent to PVR is at least about 10%, at least about 25%, atleast about 50%, at least about 75%, at least about 90%, or at leastabout 95%. In some embodiments, the TIGIT-binding agent blocks bindingof TIGIT to PVRL2, PVRL3, and/or PVRL4. In certain embodiments, theblocking of binding of a TIGIT-binding agent to PVRL2, PVRL3, and/orPVRL4 is at least about 10%, at least about 25%, at least about 50%, atleast about 75%, at least about 90%, or at least about 95%. In certainembodiments, a TIGIT-binding agent that blocks binding of TIGIT to PVRis antibody OMP-313M32. In certain embodiments, a TIGIT-binding agentthat blocks binding of TIGIT to PVR is antibody OMP-313M33. In certainembodiments, a TIGIT-binding agent that blocks binding of TIGIT toPVRL2, PVRL3, and/or PVRL4 is antibody OMP-313M32. In certainembodiments, a TIGIT-binding agent that blocks binding of TIGIT toPVRL2, PVRL3, and/or PVRL4 is antibody OMP-313M33.

Binding assays are known to those of skill in the art and are describedherein. Binding assays may be used to monitor the effect of a test agenton the interaction between a target protein and the protein's bindingpartner (e.g., receptor or ligand). For example, an in vitro bindingassay can be used to evaluate if a TIGIT antagonist blocks theinteraction of TIGIT to PVR.

In certain embodiments, the TIGIT-binding agents described herein haveone or more of the following effects: inhibit proliferation of tumorcells, inhibit tumor growth, reduce the tumorigenicity of a tumor,reduce the tumorigenicity of a tumor by reducing the frequency of cancerstem cells in the tumor, trigger cell death of tumor cells, enhance orboost the immune response, enhance or boost the anti-tumor response,increase cytolytic activity of immune cells, increase killing of tumorcells, increase killing of tumor cells by immune cells, induce cells ina tumor to differentiate, differentiate tumorigenic cells to anon-tumorigenic state, induce expression of differentiation markers inthe tumor cells, prevent metastasis of tumor cells, decrease survival oftumor cells, increase cell contact-dependent growth inhibition, increasetumor cell apoptosis, reduce epithelial mesenchymal transition (EMT), ordecrease survival of tumor cells. In some embodiments, the agents haveone or more of the following effects: inhibit viral infection, inhibitchronic viral infection, reduce viral load, trigger cell death ofvirus-infected cells, or reduce the number or percentage ofvirus-infected cells.

In certain embodiments of the methods described herein, theTIGIT-binding agents inhibit tumor growth. In certain embodiments, theTIGIT-binding agents inhibit tumor growth in vivo (e.g., in a mousemodel, and/or in a human having cancer). In certain embodiments, tumorgrowth is inhibited at least about two-fold, about three-fold, aboutfive-fold, about ten-fold, about 50-fold, about 100-fold, or about1000-fold as compared to a untreated tumor.

In certain embodiments of the methods described herein, the agents(e.g., polypeptides and/or antibodies) bind TIGIT and modulate an immuneresponse. In some embodiments, a TIGIT-binding agent activates and/orincreases an immune response. In some embodiments, a TIGIT-binding agentincreases, promotes, or enhances cell-mediated immunity. In someembodiments, a TIGIT-binding agent increases, promotes, or enhancesinnate cell-mediated immunity. In some embodiments, a TIGIT-bindingagent increases, promotes, or enhances adaptive cell-mediated immunity.In some embodiments, a TIGIT-binding agent increases, promotes, orenhances T-cell activity. In some embodiments, a TIGIT-binding agentincreases, promotes, or enhances cytolytic T-cell (CTL) activity. Insome embodiments, a TIGIT-binding agent increases, promotes, or enhancesNK cell activity. In some embodiments, a TIGIT-binding agent increases,promotes, or enhances lymphokine-activated killer cell (LAK) activity.In some embodiments, a TIGIT-binding agent increases, promotes, orenhances tumor-infiltrating lymphocyte (TIL) activity. In someembodiments, a TIGIT-binding agent inhibits or decreases Treg cellactivity. In some embodiments, a TIGIT-binding agent inhibits ordecreases MDSC activity. In some embodiments, a TIGIT-binding agentincreases, promotes, or enhances tumor cell killing In some embodiments,a TIGIT-binding agent increases, promotes, or enhances the inhibition oftumor growth.

In certain embodiments of the methods described herein, a TIGIT-bindingagent is an antagonist of human TIGIT. In some embodiments, the agent isan antagonist of TIGIT and activates and/or increases an immuneresponse. In some embodiments, the agent is an antagonist of TIGIT andactivates and/or increases activity of NK cells. In certain embodiments,the agent increases the activity by at least about 10%, at least about20%, at least about 30%, at least about 50%, at least about 75%, atleast about 90%, or about 100%. In some embodiments, the agent is anantagonist of TIGIT and activates and/or increases activity of T-cells(e.g., T-cell cytolytic activity). In certain embodiments, the agentincreases the activity by at least about 10%, at least about 20%, atleast about 30%, at least about 50%, at least about 75%, at least about90%, or about 100%. In some embodiments, the agent is an antagonist ofTIGIT and induces and/or enhances a Th1-type immune response. Ingeneral, a Th1-type immune response includes production ofinterferon-gamma (IFN-γ), IL-2, and tumor necrosis factor-beta (TNF-β).In comparison, a Th2-type immune response generally includes productionof IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. In some embodiments, theagent is an antagonist of TIGIT and induces and/or increases cytokine orlymphokine production. In some embodiments, the induction and/orincrease in cytokine or lymphokines production may be an indirecteffect.

In certain embodiments of the methods described herein, a TIGIT-bindingagent increases activation of NK cells. In certain embodiments, aTIGIT-binding agent increases activation of T-cells. In certainembodiments, the activation of NK cells and/or T-cells by aTIGIT-binding agent results in an increase in the level of activation ofNK cells and/or T-cells of at least about 10%, at least about 25%, atleast about 50%, at least about 75%, at least about 90%, or at leastabout 95%. In certain embodiments, a TIGIT-binding agent that increasesactivation of NK cells is antibody OMP-313M32. In certain embodiments, aTIGIT-binding agent that increases activation of NK cells is antibodyOMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) is an antagonist of regulatoryT-cell (Treg) activity. In certain embodiments, a TIGIT-binding agentinhibits or decreases the activity of Tregs. In certain embodiments, theinhibition of activity of Tregs by a TIGIT-binding agent results in aninhibition of suppressive activity of a Treg cell of at least about 10%,at least about 25%, at least about 50%, at least about 75%, at leastabout 90%, at least about 95%, or about 100%. In certain embodiments, aTIGIT-binding agent that inhibits Treg activity is antibody OMP-313M32.In certain embodiments, a TIGIT-binding agent that inhibits Tregactivity is antibody OMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) is an antagonist of myeloid-derivedsuppressor cells (MDSCs). In certain embodiments, the TIGIT-bindingagent inhibits MDSC activity. In certain embodiments, the TIGIT-bindingagent inhibits MDSC activity by at least about 10%, at least about 20%,at least about 30%, at least about 50%, at least about 75%, at leastabout 90%, or about 100%. In certain embodiments, a TIGIT-binding agentthat inhibits MDSC activity is antibody OMP-313M32. In certainembodiments, a TIGIT-binding agent that inhibits MDSC activity isantibody OMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) increases natural killer (NK) cellactivity. In certain embodiments, the TIGIT-binding agent increases NKcell activity by at least about 10%, at least about 20%, at least about30%, at least about 50%, at least about 75%, at least about 90%, orabout 100%. In certain embodiments, a TIGIT-binding agent that increasesNK cell activity is antibody OMP-313M32. In certain embodiments, aTIGIT-binding agent that increases NK cell activity is antibodyOMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) increases tumor-infiltratinglymphocyte (TIL) activity. In certain embodiments, the TIGIT-bindingagent increases TIL activity by at least about 10%, at least about 20%,at least about 30%, at least about 50%, at least about 75%, at leastabout 90%, or about 100%. In certain embodiments, a TIGIT-binding agentthat increases TIL cell activity is antibody OMP-313M32. In certainembodiments, a TIGIT-binding agent that increases TIL cell activity isantibody OMP-313M33.

In certain embodiments of the methods described herein, theTIGIT-binding agent (e.g., antibody) increases or enhanceslymphokines-activated killer cell (LAK) activity. In certainembodiments, the TIGIT-binding agent increases LAK activity by at leastabout 10%, at least about 20%, at least about 30%, at least about 50%,at least about 75%, at least about 90%, or about 100%. In certainembodiments, a TIGIT-binding agent that increases LAK cell activity isantibody OMP-313M32. In certain embodiments, a TIGIT-binding agent thatincreases LAK cell activity is antibody OMP-313M33.

In vivo and in vitro assays for determining whether a TIGIT-bindingagent (or candidate binding agent) modulates an immune response areknown in the art or are being developed. In some embodiments, afunctional assay that detects T-cell activation may be used. In someembodiments, a functional assay that detects T-cell proliferation may beused. In some embodiments, a functional assay that detects NK activitymay be used. In some embodiments, a functional assay that detects CTLactivity may be used. In some embodiments, a functional assay thatdetects Treg activity may be used. In some embodiments, a functionalassay that detects MDSC activity may be used. In some embodiments, afunctional assay that detects production of cytokines or lymphokines orcells producing cytokines or lymphokines may be used. In someembodiments, an ELISpot™ assay is used to measure antigen-specificT-cell frequency. In some embodiments, an ELISpot™ assay is used tomeasure cytokine release/production and/or used to measure the number ofcytokine producing cells. In some embodiments, cytokine assays are usedto identify a Th1-type response. In some embodiments, cytokine assaysare used to identify a Th2-type response. In some embodiments, cytokineassays are used to identify a Th17-type response. In some embodiments,FACS analysis is used to measure activation markers on immune cells,including but not limited to, T-cells, B-cells, NK cells, macrophages,and/or myeloid cells.

In certain embodiments of the methods described herein, theTIGIT-binding agents have a circulating half-life in mice, rats,cynomolgus monkeys, or humans of at least about 2 hours, at least about5 hours, at least about 10 hours, at least about 24 hours, at leastabout 3 days, at least about 1 week, or at least about 2 weeks. Incertain embodiments, the TIGIT-binding agent is an IgG (e.g., IgG1,IgG2, or IgG4) antibody that has a circulating half-life in mice,cynomolgus monkeys, or humans of at least about 2 hours, at least about5 hours, at least about 10 hours, at least about 24 hours, at leastabout 3 days, at least about 1 week, or at least about 2 weeks. Methodsof increasing (or decreasing) the half-life of agents such aspolypeptides and antibodies are known in the art. For example, knownmethods of increasing the circulating half-life of IgG antibodiesinclude the introduction of mutations in the Fc region which increasethe pH-dependent binding of the antibody to the neonatal Fc receptor(FcRn) at pH 6.0. Known methods of increasing the circulating half-lifeof antibody fragments lacking the Fc region include such techniques asPEGylation.

In some embodiments of the methods described herein, the TIGIT-bindingagents are polypeptides. In some embodiments, the polypeptides arerecombinant polypeptides, natural polypeptides, or syntheticpolypeptides comprising an antibody, or fragment thereof, that bindTIGIT. It will be recognized in the art that some amino acid sequencesof the invention can be varied without significant effect of thestructure or function of the protein. Thus, the invention furtherincludes variations of the polypeptides which show substantial activityor which include regions of an antibody, or fragment thereof, that bindsTIGIT. In some embodiments, amino acid sequence variations ofTIGIT-binding polypeptides include deletions, insertions, inversions,repeats, and/or other types of substitutions.

The polypeptides, analogs and variants thereof, can be further modifiedto contain additional chemical moieties not normally part of thepolypeptide. The derivatized moieties can improve or otherwise modulatethe solubility, the biological half-life, and/or absorption of thepolypeptide. The moieties can also reduce or eliminate undesirable sideeffects of the polypeptides and variants. An overview for chemicalmoieties can be found in Remington: The Science and Practice ofPharmacy, 22^(nd) Edition, 2012, Pharmaceutical Press, London.

In certain embodiments of the methods described herein, theTIGIT-binding agents are used in any one of a number of conjugated (i.e.an immunoconjugate or radioconjugate) or non-conjugated forms. Incertain embodiments, the agents can be used in a non-conjugated form toharness the subject's natural defense mechanisms includingcomplement-dependent cytotoxicity (CDC) and antibody dependent cellularcytotoxicity (ADCC) to eliminate malignant or cancer cells.

In some embodiments of the methods described herein, the TIGIT-bindingagent is conjugated to a cytotoxic agent. In some embodiments, theTIGIT-binding agent is an antibody is conjugated to a cytotoxic agent asan ADC (antibody-drug conjugate). In some embodiments, the cytotoxicagent is a chemotherapeutic agent including, but not limited to,methotrexate, adriamycin/doxorubicin, melphalan, mitomycin C,chlorambucil, daunorubicin, pyrrolobenzodiazepines (PBDs), or otherintercalating agents. In some embodiments, the cytotoxic agent is anenzymatically active toxin of bacterial, fungal, plant, or animalorigin, or fragments thereof, including, but not limited to, diphtheriaA chain, non-binding active fragments of diphtheria toxin, exotoxin Achain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin,Aleurites fordii proteins, dianthin proteins, Phytolaca americanaproteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor,curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin,restrictocin, phenomycin, enomycin, and the tricothecenes. In someembodiments, the cytotoxic agent is a radioisotope to produce aradioconjugate or a radioconjugated antibody. A variety of radionuclidesare available for the production of radioconjugated antibodiesincluding, but not limited to, ⁹⁰Y, ¹²⁵I, ¹³¹I, ¹²³I, ¹¹¹In, ¹³¹In,¹⁰⁵Rh, ¹⁵³Sm, ⁶⁷Cu, ⁶⁷Ga, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re and ²¹²Bi.Conjugates of an antibody and one or more small molecule toxins, such ascalicheamicins, maytansinoids, trichothenes, and CC 1065, and thederivatives of these toxins that have toxin activity, can also be used.Conjugates of an antibody and cytotoxic agent may be made using avariety of bifunctional protein-coupling agents such asN-succinimidyl-3-(2-pyridyidithiol) propionate (SPDP), iminothiolane(IT), bifunctional derivatives of imidoesters (such as dimethyladipimidate HCl), active esters (such as disuccinimidyl suberate),aldehydes (such as glutaraldehyde), bis-azido compounds (such asbis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astoluene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene).

IV. Polynucleotides

The present invention provides polynucleotides comprisingpolynucleotides that encode a TIGIT-binding agent. The term“polynucleotides that encode a polypeptide” encompasses a polynucleotidewhich includes only coding sequences for the polypeptide as well as apolynucleotide which includes additional coding and/or non-codingsequences. The polynucleotides of the invention can be in the form ofRNA or in the form of DNA. DNA includes cDNA, genomic DNA, and syntheticDNA; and can be double-stranded or single-stranded, and if singlestranded can be the coding strand or non-coding (anti-sense) strand.

In certain embodiments, the polynucleotide comprises a polynucleotide(e.g., a nucleotide sequence) encoding a polypeptide comprising an aminoacid sequence selected from the group consisting of: SEQ ID NO:10, SEQID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ IDNO:16, and SEQ ID NO:17.

In certain embodiments, a polynucleotide comprises a polynucleotidehaving a nucleotide sequence at least about 80% identical, at leastabout 85% identical, at least about 90% identical, at least about 95%identical, and in some embodiments, at least about 96%, 97%, 98% or 99%identical to a polynucleotide encoding an amino acid sequence selectedfrom the group consisting of: SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12,SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ IDNO:17. Also provided is a polynucleotide that comprises a polynucleotidethat hybridizes to a polynucleotide encoding an amino acid sequenceselected from the group consisting of: SEQ ID NO:10, SEQ ID NO:11, SEQID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, andSEQ ID NO:17. In certain embodiments, the hybridization is underconditions of high stringency. Conditions of high stringency are knownto those of skill in the art and may include but are not limited to, (1)employ low ionic strength and high temperature for washing, for example15 mM sodium chloride/1.5 mM sodium citrate (1×SSC) with 0.1% sodiumdodecyl sulfate at 50° C.; (2) employ during hybridization a denaturingagent, such as formamide, for example, 50% (v/v) formamide with 0.1%bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodiumphosphate buffer at pH 6.5 in 5×SSC (0.75M NaCl, 75mM sodium citrate) at42° C.; or (3) employ 50% formamide, 5×SSC, 50 mM sodium phosphate (pH6.8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicatedsalmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C., with washes in 0.2×SSC containing 50% formamide at 55° C., followedby a high-stringency wash consisting of 0.1×SSC containing EDTA at 55°C.

In some embodiments, the polynucleotide comprises a polynucleotidesequence selected from the group consisting of: SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22. In certainembodiments, a polynucleotide comprises a polynucleotide having anucleotide sequence at least about 80% identical, at least about 85%identical, at least about 90% identical, at least about 95% identical,and in some embodiments, at least about 96%, 97%, 98% or 99% identicalto a nucleotide sequence selected from the group consisting of: SEQ IDNO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22. Alsoprovided is a polynucleotide that comprises a polynucleotide thathybridizes to a polynucleotide sequence selected from the groupconsisting of: SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21,and SEQ ID NO:22. In certain embodiments, the hybridization techniquesare conducted under conditions of high stringency as described above.

In certain embodiments, a polynucleotide comprises the coding sequencefor the mature polypeptide fused in the same reading frame to apolynucleotide which aids, for example, in expression and secretion of apolypeptide from a host cell (e.g., a leader sequence which functions asa secretory sequence for controlling transport of a polypeptide from thecell). The polypeptide having a leader sequence is a pre-protein and canhave the leader sequence cleaved by the host cell to form the matureform of the polypeptide. The polynucleotides can also encode for apro-protein which is the mature protein plus additional 5′ amino acidresidues. A mature protein having a pro-sequence is a pro-protein and isan inactive form of the protein. Once the pro-sequence is cleaved anactive mature protein remains.

In certain embodiments, a polynucleotide comprises the coding sequencefor the mature polypeptide fused in the same reading frame to a markersequence that allows, for example, for purification of the encodedpolypeptide. For example, the marker sequence can be a hexa-histidinetag supplied by a pQE-9 vector to provide for purification of the maturepolypeptide fused to the marker in the case of a bacterial host, or themarker sequence can be a hemagglutinin (HA) tag derived from theinfluenza hemagglutinin protein when a mammalian host (e.g., COS-7cells) is used. In some embodiments, the marker sequence is a FLAG-tag,a peptide of sequence DYKDDDDK (SEQ ID NO:29) which can be used inconjunction with other affinity tags.

The present invention further relates to variants of the polynucleotidesdescribed herein, wherein the variant encodes, for example, fragments,analogs, and/or derivatives.

In certain embodiments, the present invention provides a polynucleotidecomprising a polynucleotide having a nucleotide sequence at least about80% identical, at least about 85% identical, at least about 90%identical, at least about 95% identical, and in some embodiments, atleast about 96%, 97%, 98% or 99% identical to a polynucleotide encodinga polypeptide comprising a TIGIT-binding agent.

As used herein, the phrase a polynucleotide having a nucleotide sequenceat least, for example, 95% “identical” to a reference nucleotidesequence is intended to mean that the nucleotide sequence of thepolynucleotide is identical to the reference sequence except that thepolynucleotide sequence can include up to five point mutations per each100 nucleotides of the reference nucleotide sequence. In other words, toobtain a polynucleotide having a nucleotide sequence at least 95%identical to a reference nucleotide sequence, up to 5% of thenucleotides in the reference sequence can be deleted or substituted withanother nucleotide, or a number of nucleotides up to 5% of the totalnucleotides in the reference sequence can be inserted into the referencesequence. These mutations of the reference sequence can occur at the 5′or 3′ terminal positions of the reference nucleotide sequence oranywhere between those terminal positions, interspersed eitherindividually among nucleotides in the reference sequence or in one ormore contiguous groups within the reference sequence.

The polynucleotide variants can contain alterations in the codingregions, non-coding regions, or both. In some embodiments, apolynucleotide variant contains alterations which produce silentsubstitutions, additions, or deletions, but does not alter theproperties or activities of the encoded polypeptide. In someembodiments, a polynucleotide variant comprises silent substitutionsthat results in no change to the amino acid sequence of the polypeptide(due to the degeneracy of the genetic code). Polynucleotide variants canbe produced for a variety of reasons, for example, to optimize codonexpression for a particular host (i.e., change codons in the human mRNAto those preferred by a bacterial host such as E. coli). In someembodiments, a polynucleotide variant comprises at least one silentmutation in a non-coding or a coding region of the sequence.

In some embodiments, a polynucleotide variant is produced to modulate oralter expression (or expression levels) of the encoded polypeptide. Insome embodiments, a polynucleotide variant is produced to increaseexpression of the encoded polypeptide. In some embodiments, apolynucleotide variant is produced to decrease expression of the encodedpolypeptide. In some embodiments, a polynucleotide variant has increasedexpression of the encoded polypeptide as compared to a parentalpolynucleotide sequence. In some embodiments, a polynucleotide varianthas decreased expression of the encoded polypeptide as compared to aparental polynucleotide sequence.

In some embodiments, at least one polynucleotide variant is produced(without changing the amino acid sequence of the encoded polypeptide) toincrease production of a heterodimeric molecule. In some embodiments, atleast one polynucleotide variant is produced (without changing the aminoacid sequence of the encoded polypeptide) to increase production of abispecific antibody.

In certain embodiments, the polynucleotides are isolated. In certainembodiments, the polynucleotides are substantially pure.

Vectors and cells comprising the polynucleotides described herein arealso provided. In some embodiments, an expression vector comprises apolynucleotide molecule. In some embodiments, a host cell comprises anexpression vector comprising the polynucleotide molecule. In someembodiments, a host cell comprises a polynucleotide molecule.

V. Kits Comprising Agents Described Herein

The present invention provides kits that comprise the TIGIT-bindingagents described herein and that can be used to perform the methodsdescribed herein. In certain embodiments, a kit comprises at least onepurified TIGIT-binding agent in one or more containers. In someembodiments, the kits contain all of the components necessary and/orsufficient to perform a detection assay, including all controls,directions for performing assays, and any necessary software foranalysis and presentation of results. One skilled in the art willreadily recognize that the disclosed TIGIT-binding agents of the presentinvention can be readily incorporated into one of the established kitformats which are well known in the art.

Further provided are kits that comprise a TIGIT-binding agent as well asat least one additional therapeutic agent. In certain embodiments, thesecond (or more) therapeutic agent is a chemotherapeutic agent. Incertain embodiments, the second (or more) therapeutic agent is anantibody.

VI. Additional Exemplary Embodiments

In some embodiments, the methods of inhibiting tumor growth in a subjectprovided throughout this application comprise administering to a subjecta therapeutically effective amount of an antibody that specificallybinds the extracellular domain of TIGIT, wherein the tumor is a solidtumor with high MSI, and wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments the tumor with high MSI is selected from the groupconsisting of CRC, gastric cancer, endometrium cancer, hepatobiliarytract cancer, urinary tract cancer, brain cancer and skin cancer. Insome embodiments, the antibody that specifically binds the extracellulardomain of TIGIT is administered every two weeks at a dose of about 0.3mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a solid tumor with high MSI selected fromthe group consisting of a MSI CRC, a MSI gastric cancer, a MSIendometrium cancer, a MSI hepatobiliary tract cancer, a MSI urinarytract cancer, a MSI brain cancer and a MSI skin cancer, wherein theantibody is administered every two weeks at a dose of about 3mg/kg, andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a solid tumor with high MSI selected fromthe group consisting of a MSI CRC, a MSI gastric cancer, a MSIendometrium cancer, a MSI hepatobiliary tract cancer, a MSI urinarytract cancer, a MSI brain cancer and a MSI skin cancer, wherein theantibody is administered every two weeks at a dose of about 10mg/kg, andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a solid tumor with high MSI selected fromthe group consisting of a MSI CRC, a MSI gastric cancer, a MSIendometrium cancer, a MSI hepatobiliary tract cancer, a MSI urinarytract cancer, a MSI brain cancer and a MSI skin cancer, wherein theantibody is administered every two weeks at a dose of about 15mg/kg, andwherein the antibody that binds human TIGIT comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a tumor refractory to treatment with ananti-PD1 antibody selected from the group consisting of a melanoma, aNSCLC, a renal cell carcinoma, a squamous cell carcinoma of the head andneck, a urothelial carcinoma, a colorectal cancer (e.g. MS1 or dMMRmetastatic CRC) and hepatocellular carcinoma, and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the antibody thatspecifically binds the extracellular domain of TIGIT is administeredevery two weeks at a dose of about 0.3 mg/kg, about 1 mg/kg, about 3mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a tumor refractory to treatment with ananti-PD-L1 antibody selected from the group consisting of a melanoma, aNSCLC, a renal cell carcinoma, a squamous cell carcinoma of the head andneck, a urothelial carcinoma, a colorectal cancer (e.g. MSI or dMMRmetastatic CRC) and hepatocellular carcinoma, and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the antibody thatspecifically binds the extracellular domain of TIGIT is administeredevery two weeks at a dose of about 0.3 mg/kg, about 1 mg/kg, about 3mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a tumor resistant to treatment with ananti-PD1 antibody selected from the group consisting of a melanoma, aNSCLC, a renal cell carcinoma, a squamous cell carcinoma of the head andneck, a urothelial carcinoma, a. colorectal cancer (e.g. MS1 or dMMRmetastatic CRC) and hepatocellular carcinoma, and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the subject has previouslybeen treated with an anti-PD1 antibody. In some embodiments, theantibody that specifically binds the extracellular domain of TIGIT isadministered every two weeks at a dose of about 0.3 mg/kg, about 1mg/kg, about 3 mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise administering to a subject a therapeutically effective amountof an antibody that specifically binds the extracellular domain ofTIGIT, wherein the tumor is a tumor resistant to treatment with ananti-PD-L1 antibody selected from the group consisting of a melanoma, aNSCLC, a renal cell carcinoma, a squamous cell carcinoma of the head andneck, a urothelial carcinoma, a colorectal cancer (e.g. MSI or dMMRmetastatic CRC) and hepatocellular carcinoma, and wherein the antibodythat binds human TIGIT comprises a heavy chain CDR1 comprising TSDYAWN(SEQ ID NO:4), a heavy chain CDR2 comprising YISYSGSTSYNPSLRS (SEQ IDNO:5), a heavy chain CDR3 comprising ARRQVGLGFAY (SEQ ID NO:6), a lightchain CDR1 comprising KASQDVSTAVA (SEQ ID NO:7), a light chain CDR2comprising SASYRYT (SEQ ID NO:8), and a light chain CDR3 comprisingQQHYSTP (SEQ ID NO:9). In some embodiments, the subject has previouslybeen treated with an anti-PD-L1 antibody. In some embodiments, theantibody that specifically binds the extracellular domain of TIGIT isadministered every two weeks at a dose of about 0.3 mg/kg, about 1mg/kg, about 3 mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise selectively administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of TIGIT, on the basis that the tumor/cancerexpresses PVR and/or PVRL2, wherein the antibody that binds human TIGITcomprises a heavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavychain CDR2 comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3comprising ARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprisingKASQDVSTAVA (SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ IDNO:8), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:9). In someembodiments, the tumor is selected from the group consisting of head andneck cancer, esophageal cancer, gastric cancer, cervical cancer, TNBR,anal cancer, hepatocellular cancer, a solid tumor with high MSI (e.g.MSI CRC), NSCLC and colorectal cancer. In some embodiments, the antibodythat specifically binds the extracellular domain of TIGI is administeredevery two weeks at a dose of about 0.3 mg/kg, about 1 mg/kg, about 3mg/kg, about 10 mg/kg, or about 15 mg/kg.

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise selectively administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of TIGIT, on the basis that the tumor/cancerexpresses PVR and/or PVRL2, wherein the tumor/cancer is selected fromthe group consisting of head and neck cancer, esophageal cancer, gastriccancer, cervical cancer, TNBR, anal cancer, hepatocellular cancer, asolid tumor with high MSI (e.g. MSI CRC), NSCLC and colorectal cancer,wherein the antibody is administered every two weeks at a dose of about3 mg/kg, and wherein the antibody that binds human TIGIT comprises aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise selectively administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of TIGIT, on the basis that the tumor/cancerexpresses PVR and/or PVRL2, wherein the tumor/cancer is selected fromthe group consisting of head and neck cancer, esophageal cancer, gastriccancer, cervical cancer, TNBR, anal cancer, hepatocellular cancer, asolid tumor with high MSI (e.g. MSI CRC), NSCLC and colorectal cancer,wherein the antibody is administered every two weeks at a dose of about10 mg/kg, and wherein the antibody that binds human TIGIT comprises aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

In some embodiments, the methods of inhibiting tumor growth in a subjectcomprise selectively administering to the subject a therapeuticallyeffective amount of an antibody that specifically binds theextracellular domain of TIGIT, on the basis that the tumor/cancerexpresses PVR and/or PVRL2, wherein the tumor/cancer is selected fromthe group consisting of head and neck cancer, esophageal cancer, gastriccancer, cervical cancer, TNBR, anal cancer, hepatocellular cancer, asolid tumor with high MSI (e.g. MSI CRC), NSCLC and colorectal cancer,wherein the antibody is administered every two weeks at a dose of about15mg/kg, and wherein the antibody that binds human TIGIT comprises aheavy chain CDR1 comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2comprising YISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9).

Embodiments of the present disclosure can be further defined byreference to the following non-limiting examples, which describe indetail preparation of certain antibodies of the present disclosure andmethods for using antibodies of the present disclosure. It will beapparent to those skilled in the art that many modifications, both tomaterials and methods, may be practiced without departing from the scopeof the present disclosure.

EXAMPLES Example 1 In Vivo Tumor Growth Inhibition in Humanized Mice Byan Anti-Tigit Antibody

A humanized mouse model was used to study the efficacy of treatment withan anti-hTIGIT antibody on a human tumor. The humanized mice wereobtained from Jackson Laboratories. These mice were created by injectinghuman hematopoietic stem cells (CD34+ cells) into irradiated NSG mice.After 15 weeks, the presence of mature human lymphocytes was confirmedby flow cytometry. Each mouse was injected subcutaneously withpatient-derived melanoma tumor cells (OMP-M9; 75,000 cells/mouse).Tumors were allowed to grow 19 days until they had reached an averagevolume of approximately 50 mm³. Tumor-bearing mice were randomized intogroups (n=8 mice per group). Tumor-bearing mice were treated with eithera control antibody or anti-hTIGIT antibody OMP-313M32. Mice were dosedevery 5 days at 1 mg/kg or 5 mg/kg. Tumor growth was monitored and tumorvolumes were measured with electronic calipers at the indicated timepoints.

As shown in FIG. 1, tumor growth was inhibited in the mice treated withantibody OMP-313M32 as compared to control. These results show thattargeting TIGIT was effective at augmenting an anti-tumor immuneresponse of human lymphocytes and contributing to inhibiting human tumorgrowth in vivo. In addition, these results demonstrated that humanizedmouse models bearing patient-derived xenografts can be used to study theanti-hTIGIT antibody OMP-313M32 (which only binds human TIGIT) inparallel with pre-clinical studies carried out with the anti-TIGITantibodies 313R12 and 313R19 and murine tumor models.

Example 2 Phase 1 Study

An open-label Phase 1 dose escalation and expansion study of OMP-313M32in patients with certain locally advanced or metastatic tumors wasdesigned. Patients have tumors that have progressed after standardtherapy or have tumors where therapy has proven to be intolerable or isconsidered inappropriate. Prior to enrollment, patients will undergoscreening to determine study eligibility. The study objectives are toevaluate the safety and tolerability of OMP-313M32 in patients; toestimate the maximum tolerated dose (MTD) of OMP-313M32; to characterizethe dose-limiting toxicities (DLTs) of OMP-313M32; to identify arecommended Phase 2 dose of OMP-313M32; to characterize thepharmacokinetics of OMP-313M32; to characterize the immunogenicpotential of OMP-313M32; to make preliminary assessment of theanti-tumor activity of OMP-313M32; and to make a preliminary assessmentof pharmacodynamics (PD) markers.

As shown in FIG. 2, dose escalation is performed to determine themaximum tolerated dose (MTD) or the maximum administered dose (MAD) inthe initial phase of the study. Dose levels of 0.3, 1.0, 3, 10, and 15mg/kg of OMP-313M32 are administered by IV infusion once every 2 weeks.No dose escalation or reduction is allowed within a dose cohort. Threepatients are treated at each dose level if no DLTs are observed. If 1 of3 patients experiences a DLT, the dose level is expanded to 6 patients.If 2 or more patients experience a DLT, no further patients are dosed atthat level and 3 additional patients are added to the preceding dosecohort unless 6 patients are being treated at that dose level. Patientsare assessed for DLTs for 28 days (Day 1 to Day 29).

In the dose expansion phase of the study, patients will be enrolled at adose level equal to the MTD or MAD of OMP-313M32. The expansion phase isdesigned to better characterize the safety and tolerability and topreliminarily evaluate the anti-tumor activity of OMP-313M32 in patientswith specific tumor types or subtypes. The tumor types to be consideredfor evaluation in the dose expansion phase(s) include, but are notlimited to, head and neck cancer, esophageal/gastroesophageal cancer,gastric cancer, colorectal cancer, hepatocellular cancer/liver cancer,cervical cancer, lung cancer, melanoma, Merkel cell carcinoma, renalcell carcinoma/kidney cancer, bladder cancer, ovarian cancer, pancreaticcancer, endometrial cancer, and triple negative breast cancer. As usedherein, “lung cancer” includes non-small cell lung cancer (NSCLC) andsmall cell lung cancer. NSCLC may include NSCLC squamous cell and NSCLCadenocarcinoma. The colorectal cancers (CRCs) may include microsatelliteinstability-high CRC and microsatellite stable CRC. Patients in the doseexpansion phase may have tumors that are resistant or refractory totreatment with a PD-1 antagonist (e.g., an anti-PD-1 antibody) or aPD-L1 antagonist (e.g., an anti-PD-L1 antibody). Patients in the doseexpansion phase may be subjects that have been previously treated with aPD-1 antagonist (e.g., an anti-PD-1 antibody) or a PD-L1 antagonist(e.g., an anti-PD-L1 antibody) where tumor growth has progressed duringor after treatment (may be referred to as anti-PD-1/PD-L1 progressors).

All patients enrolled in the dose escalation and expansion cohorts willundergo a biopsy prior to treatment and at least one tumor biopsy aftertreatment has started unless there is a medical contraindication. Abiopsy will be performed at baseline and approximately 2-3 weeks afterthe first administration of OMP-313M32. Additional biopsies may becollected at the investigator's discretion. Biopsy methods may includecore needle, punch, forceps, or excisional/incisional biopsies. Theexpression of TIGIT, PVR, PVRL2, FOXP3 and other immune markers will beassessed in FFPE tumor specimens. The expression levels of additionalproteins and genes (e g , immune gene signatures) may be evaluated andcorrelated with clinical benefit.

Example 3 TIGIT Protein Expression Assessed by IHC

To investigate TIGIT protein expression, a TIGIT immunohistochemistry(IHC) assay was developed and optimized using a proprietary mouseanti-hTIGIT monoclonal antibody. Four-micron FFPE sections were cut andmounted onto positively-charged capillary gap slides. Tissues weredewaxed through four, 5-minute changes of xylene followed by a gradedalcohol series to distilled water. Steam heat-induced epitope recovery(SHIER) was performed with SHIER 2 solution (citrate-based buffer pH6.0-6.2) for 20 minutes in the upper chamber of a Black & Decker®Steamer. Slides were pre-treated with proteinase K enzyme (1:40dilution) for 10 minutes and were incubated in a blocking solution for15 minutes to reduce non-specific background staining. Slides wereincubated with the anti-hTIGIT antibody overnight at 1 μg/ml. To blockendogenous peroxidase activity slides were incubated in hydrogenperoxide 3 times for 2.5 minutes and washed in PBS. Specific binding wasdetected using a Polink-2 Plus Detection Kit designed for mouseantibodies and using DAB and hematoxylin. Positive staining is indicatedby the presence of a brown chromogen reaction product of the horseradishperoxidase and DAB substrate. Hematoxylin counterstain provides a bluenuclear stain to assess cell and tissue morphology.

A panel of samples covering 17 different cancer types was assessed inthe IHC assay (Table 2) for staining of TIGIT in tumor cells, intumor-associated immune cells, and in non-tumor/stromal immune cells.

TABLE 2 Cancer Type No. of Samples NSCLC Adenocarcinoma 25 NSCLCSquamous cell carcinoma 20 Ovarian Cancer 24 Prostate Cancer 22Pancreatic Cancer 25 Colorectal Cancer 24 Head & Neck Cancer 20 CervicalCancer 15 Bladder Cancer 23 Esophageal Cancer 15 T-cell Lymphoma 18Leukemia 13 Melanoma 22 Endometrial Cancer 13 Triple Negative BreastCancer 21 (TNBC) Renal Cell Carcinoma 27 Gastric Cancer 22

For tumor cells, reactivity was evaluated on the plasma membrane, usingpercentages observed at differential intensities. Intensity scoringincluded: 0=null, 1+=low or weak, 2+=moderate, and 3+=high or strong.The percentage recorded at each intensity level was reported as 0 to100% in increments of 10 above 10% and increments of 1 below 10%. Thescoring data for TIGIT expression in tumor cells was evaluated using astandard H-score approach and a Percent Score approach. The H-score iscalculated using the percentage of cells with intensity of expression ona three-point semi-quantitative scale (0, 1+, 2+, or 3+). Thus, scoresrange from 0 to 300. H-score=[(% at 1+)×1]+[(% at 2+)×2]+[(% at 3+)×3].The Percent Score is calculated by summing the percentage of intensities≥1+, ≥2+, and ≥3+. Thus scores range from 0 to 100. Percent score≥1+=(%at 1+)+(% at 2+)+(% at 3+); percent score≥2+=(% at 2+)+(% at 3+);percent score≥3+=(% at 3+).

Each sample was also analyzed for TIGIT reactivity in immune cells in(1) areas of stroma/non-tumor and (2) areas within tumor orclosely-associated with tumor Immune cell reactivity was scored using anAbundance Scale from 0-3 where, 0=no immune cell staining; 1=few immunecell staining; 2=moderate amount of immune cell staining; and 3=highamount of immune cell staining.

The results of the IHC assay for TIGIT expression on tumor-associatedimmune cells summarized in Table 3.

TABLE 3 TIGIT staining on tumor-associated immune cells % of Cases withCancer Indication Abundance ≥ 2+ High TNBC 67 Range = 30-100% T-celllymphoma 50 of cases ≥ 2+ Head and Neck cancer 35 Cervical cancer 33Moderate Gastric cancer 18 Range = 10-29% Melanoma 18 of cases ≥ 2+NSCLC squamous cell 15 Bladder cancer 13 Ovarian cancer 8 LowEndometrial cancer 8 Range = 0-9% Renal cell cancer 7 of cases ≥ 2+Colon cancer 4 NSCLC adenocarcinoma 4 Pancreatic cancer 4 Esophagealcancer 0 Leukemia 0 Prostate cancer 0

Overall, triple negative breast cancer, T-cell lymphoma, head and neckcancer, and cervical cancer had the highest staining in both stroma andtumor-associated immune cells. Consistent with this IHC data, analysesof 33 tumor types in The Cancer Genome Atlas (TGCA) by RNA-Seq showed agood correlation of the expression levels of TIGIT and T-cell markers.The overall incidence of TIGIT staining on the plasma membrane of tumorcells was infrequent and low intensity. These results strongly suggestthat TIGIT is expressed predominantly on immune cells in tumors and thetumor microenvironment.

Example 4 Pharmacodynamics (PD) Biomarkers

A multi-platform approach was taken to investigate anti-TIGIT treatmentpharmacodynamic (PD) biomarkers in tumors and in matched whole bloodsamples from tumor-bearing mice treated with the surrogate anti-TIGITantibody 313R12. Tumor tissues and matched whole blood samples wereanalyzed by microarray, immunochemistry (IHC), and flow cytometry forimmune cell prevalence and function.

Antibody 313R12 was administered to immunocompetent mice bearing CT26.WTcolon, 4T1 breast, or B 16F10 melanoma tumors. These tumors areconsidered to have varying levels of immunogenicity—CT26.WT tumors arehighly immunogenic and cytotoxic T-cell rich; 4T1 tumors are highlyimmunogenic and immunosuppressive; and B16F10 tumors are poorlyimmunogenic and immunologically silent. Mice were treated once a week ineach of the models.

To identify potential gene expression PD biomarkers that correlate withefficacy, RNA was isolated from tumor tissue and peripheral bloodsamples collected at study termination for each of the 3 models.Microarray analyses were performed using samples from 3 animals from thefollowing groups: (1) 4T1 tumor bearing mice treated with 0.1mg/kg and12.5mg/kg 313R12, (2) B16F10 tumor-bearing mice treated with 0.1mg/kgand 12.5mg/kg 313R12, (3) CT26.WT tumor-bearing mice treated with 0.1,0.5, 2.5, and 12.5mg/kg 313R12, and (4) control mice. Global geneexpression levels were profiled by microarray on treated and controltissues Immune cell-related gene changes, with emphasis on T-cell, NKcell, and B-cell markers were examined Changes of immune cellpopulations and cytokine secretions were monitored by flow cytometry,Luminex, and IHC.

In tumor samples, anti-TIGIT treatment promoted increased expression ofgenes associated with T-cells, CD8 T-cells, cytotoxic cells, Thl cells,NK cells, Teff cells, and T-cell activation markers. These geneexpression changes were validated by quantitative real-time PCR, (i.e.,CD3e, CD8a, Ncr1, Ifn-gamma, Gzma, and CD266). Similar results were seenin gene expression changes in the blood samples. These results suggestthat PD biomarkers can be used in the clinic to study on-target activityof anti-TIGIT antibody OMP-313M32.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to person skilled in the art and areto be included within the spirit and purview of this application.

All publications, patents, patent applications, internet sites, andaccession numbers/database sequences including both polynucleotide andpolypeptide sequences cited herein are hereby incorporated by referenceherein in their entirety for all purposes to the same extent as if eachindividual publication, patent, patent application, internet site, oraccession number/database sequence were specifically and individuallyindicated to be so incorporated by reference.

Following are the sequences disclosed in the application:

Human TIGIT amino acid sequence (SEQ ID NO: 1)MRWCLLLIWAQGLRQAPLASGMMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFF TETGHuman TIGIT amino acid sequence without predicted signal sequence(SEQ ID NO: 2)MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSAPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETGHuman TIGIT extracellular domain amino acid sequence (SEQ ID NO: 3)MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPOMP-313M32/313M33 Heavy chain CDR1 (SEQ ID NO: 4) TSDYAWNOMP-313M32/313M33 Heavy chain CDR2 (SEQ ID NO: 5) YISYSGSTSYNPSLRSOMP-313M32/313M33 Heavy chain CDR3 (SEQ ID NO: 6) ARRQVGLGFAYOMP-313M32/313M33 Light chain CDR1 (SEQ ID NO: 7) KASQDVSTAVAOMP-313M32/313M33 Light chain CDR2 (SEQ ID NO: 8) SASYRYTOMP-313M32/313M33 Light chain CDR3 (SEQ ID NO: 9) QQHYSTPOMP-313M32/313M33 Heavy chain variable region amino acid sequence(SEQ ID NO: 10)QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSSOMP-313M32/313M33 Light chain variable region amino acid sequence(SEQ ID NO: 11)DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGOMP-313M32 Heavy chain (IgG1) amino acid sequence with predicted signalsequence underlined (SEQ ID NO: 12)MDWTWRILFLVAAATGAHSQVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKOMP-313M32 Heavy chain (IgG1) amino acid sequence without signal sequence(SEQ ID NO: 13)QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKOMP-313M32/313M33 Light chain amino acid sequence with predicted signal sequenceunderlined (SEQ ID NO: 14)MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSNTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECOMP-313M32/313M33 Light chain amino acid sequence without signal sequence(SEQ ID NO: 15)DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSNTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC313M33 Heavy chain (IgG4) amino acid sequence with predicted signal sequenceunderlined (SEQ ID NO: 16)MDWTWRILFLVAAATGAHSQVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK313M33 Heavy chain (IgG4) amino acid sequence without signal sequence(SEQ ID NO: 17)QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKOMP-313M32/313M33 Heavy chain variable region nucleotide sequence(SEQ ID NO: 18)CAGGTCCAGCTGCAGGAGTCTGGCCCAGGACTGGTGAAGCCTTCTGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTTACTCCATCACCTCCGATTATGCCTGGAACTGGATTCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGTACATAAGCTACTCTGGTAGCACTAGCTACAACCCATCTCTCCGGTCACGGGTCACAATATCACGGGACACATCCAAGAACCAGTTCTTCCTGAAGCTGTCCTCTGTGACCGCCGCTGACACCGCCGTGTATTACTGTGCAAGGAGACAGGTCGGGCTGGGGTTTGCTTACTGGGGCCAAGGAACCCTGGTCACCGTCAGCTCAOMP-313M32/313M33 Light chain variable region nucleotide sequence(SEQ ID NO: 19)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGAGACAGAGTCACCATCACTTGCAAGGCTTCTCAGGATGTGTCTACTGCTGTTGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACTCTGCATCCTATCGGTACACTGGGGTCCCATCAAGGTTCTCCGGATCTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAGCAACATTATTCTACTCCTTGGACATTCGGCOMP-313M32 Heavy chain (IgG1) nucleotide sequence (SEQ ID NO: 20)ATGGACTGGACCTGGAGGATACTCTTTCTCGTGGCTGCAGCCACAGGAGCCCACTCCCAGGTCCAGCTGCAGGAGTCTGGCCCAGGACTGGTGAAGCCTTCTGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTTACTCCATCACCTCCGATTATGCCTGGAACTGGATTCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGTACATAAGCTACTCTGGTAGCACTAGCTACAACCCATCTCTCCGGTCACGGGTCACAATATCACGGGACACATCCAAGAACCAGTTCTTCCTGAAGCTGTCCTCTGTGACCGCCGCTGACACCGCCGTGTATTACTGTGCAAGGAGACAGGTCGGGCTGGGGTTTGCTTACTGGGGCCAAGGAACCCTGGTCACCGTCAGCTCAGCCAGCACAAAGGGCCCCTCCGTGTTCCCTCTGGCCCCTTCCTCCAAGTCCACCTCCGGCGGCACCGCCGCTCTGGGCTGCCTGGTGAAGGACTACTTCCCTGAGCCTGTGACCGTGTCCTGGAACTCTGGCGCCCTGACCTCTGGCGTGCACACCTTCCCAGCCGTGCTGCAGTCCTCCGGCCTGTACTCCCTGTCCTCCGTGGTGACCGTGCCTTCCTCCTCCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGCCTTCCAACACCAAGGTGGACAAGCGGGTGGAGCCTAAGTCCTGCGACAAGACCCACACCTGCCCTCCCTGCCCTGCCCCTGAGCTGCTGGGCGGACCTTCCGTGTTCCTGTTCCCTCCTAAGCCTAAGGACACCCTGATGATCTCCCGGACCCCTGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGATCCTGAGGTGAAGTTCAATTGGTACGTGGACGGCGTGGAGGTGCACAACGCTAAGACCAAGCCAAGGGAGGAGCAGTACAACTCCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCCGCTCCCATCGAGAAAACCATCTCCAAGGCCAAGGGCCAGCCTCGCGAGCCTCAGGTGTACACCCTGCCACCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCTTCCGATATCGCCGTGGAGTGGGAGTCTAACGGCCAGCCCGAGAACAACTACAAGACCACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGTCTCTGTCTCCTGGCAAGTGAOMP-313M32/313M33 Light chain nucleotide sequence (SEQ ID NO: 21)ATGGTGCTCCAGACCCAGGTCTTCATTTCCCTGCTGCTCTGGATCAGCGGAGCCTACGGGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGAGACAGAGTCACCATCACTTGCAAGGCTTCTCAGGATGTGTCTACTGCTGTTGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACTCTGCATCCTATCGGTACACTGGGGTCCCATCAAGGTTCTCCGGATCTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAGCAACATTATTCTACTCCTTGGACATTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCTCCATCTGATGAGCAGCTCAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTCCAGTGGAAGGTGGATAACGCCCTCCAATCCGGCAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAACACCCTGACACTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGTCTTCCCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGCTAA313M33 Heavy chain (IgG4) nucleotide sequence (SEQ ID NO: 22)ATGGACTGGACCTGGAGGATACTCTTTCTCGTGGCTGCAGCCACAGGAGCCCACTCCCAGGTCCAGCTGCAGGAGTCTGGCCCAGGACTGGTGAAGCCTTCTGAGACCCTGTCCCTCACCTGCGCTGTCTCTGGTTACTCCATCACCTCCGATTATGCCTGGAACTGGATTCGGCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGTACATAAGCTACTCTGGTAGCACTAGCTACAACCCATCTCTCCGGTCACGGGTCACAATATCACGGGACACATCCAAGAACCAGTTCTTCCTGAAGCTGTCCTCTGTGACCGCCGCTGACACCGCCGTGTATTACTGTGCAAGGAGACAGGTCGGGCTGGGGTTTGCTTACTGGGGCCAAGGAACCCTGGTCACCGTCAGCTCAGCCAGCACAAAGGGCCCATCCGTCTTCCCCCTGGCACCCTGCTCCCGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCCGTTACCGTGTCTTGGAACTCCGGCGCACTGACCAGCGGCGTGCACACCTTCCCTGCTGTCCTCCAATCCTCTGGACTCTACTCCCTCTCCTCCGTGGTGACAGTGCCCTCCAGCAGCCTGGGCACTAAGACCTACACCTGCAACGTCGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGACCCCCATGCCCACCTTGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACTTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTATGTGGATGGCGTGGAGGTTCATAATGCCAAGACAAAGCCTCGGGAGGAGCAGTTCAACAGCACCTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAAGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGGCTCCCATCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGGGAGCCACAGGTGTACACCCTGCCCCCATCCCAAGAGGAGATGACCAAGAACCAAGTGTCCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCTGAGAACAACTACAAGACCACTCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACTCCCGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGCAATGTCTTCTCCTGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGCAAATGA Human IgG1 Heavy chain constant region (SEQ ID NO: 23)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Human IgG2 Heavy chain constant region(SEQ ID NO: 24)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Human IgG3 Heavy chain constant region(SEQ ID NO: 25)ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK Human IgG4 Heavy chain constant region (SEQ ID NO: 26)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK Human TIGIT amino acids 55-70(SEQ ID NO: 27) TQVNWEQQDQLLAICN Human TIGIT amino acids 105-122(SEQ ID NO: 28) EYFCIYHTYPDGTYTGRI FLAG Tag (SEQ ID NO: 29) DYKDDDDK

1-51. (canceled)
 52. A method of treating cancer in a human patienthaving cancer, comprising administering to said human patient atherapeutically effective amount of a full-length antibody thatspecifically binds the extracellular domain of human TIGIT, wherein saidhuman patient is characterized by one or more of the following parts a)through d): a) was previously treated with a human PD-1 antagonist or ahuman PD-L1 antagonist and there is tumor growth, progression, orrecurrence during or after treatment with said human PD-1 antagonist orsaid human PD-L1 antagonist; b) has a cancer selected from the groupconsisting of head and neck cancer, cervical carcinoma, gastric cancer,ovarian cancer, melanoma, sarcoma, lung cancer, gastroesophageal,leukemia, lymphoma, anal cancer, pancreatic cancer, hepatocellularcancer, liver cancer, renal cell carcinoma, kidney cancer, bladdercancer, a microsatellite instability-high colorectal cancer, amicrosatellite stable colorectal cancer, a triple negative breastcancer, a Merkel cell carcinoma, an endometrial cancer, and anesophageal cancer; c) has a cancer that expresses poliovirus receptor(PVR) or poliovirus receptor-related 2 (PVRL2); and d) has a cancer thatcomprises tumor-infiltrating lymphocytes (TILS) or regulatory T-cells;and wherein said full-length antibody that binds human TIGIT is capableof mediating antibody-dependent cell cytotoxicity (ADCC) and/orcomplement-dependent cytotoxicity (CDC) and comprises a heavy chain CDR1comprising TSDYAWN (SEQ ID NO:4), a heavy chain CDR2 comprisingYISYSGSTSYNPSLRS (SEQ ID NO:5), a heavy chain CDR3 comprisingARRQVGLGFAY (SEQ ID NO:6), a light chain CDR1 comprising KASQDVSTAVA(SEQ ID NO:7), a light chain CDR2 comprising SASYRYT (SEQ ID NO:8), anda light chain CDR3 comprising QQHYSTP (SEQ ID NO:9), and wherein saidfull-length antibody that binds human TIGIT is administered at a dose of1 mg/kg to 80 mg/kg of body weight.
 53. The method of claim 52, whereinsaid full-length antibody that binds human TIGIT comprises: (i) a heavychain variable region comprising SEQ ID NO:10 and a light chain variableregion comprising SEQ ID NO:11; (ii) a heavy chain amino acid sequenceof SEQ ID NO:13 and a light chain amino acid sequence of SEQ ID NO:15;or (iii) a heavy chain amino acid sequence of SEQ ID NO:17 and a lightchain amino acid sequence of SEQ ID NO:15.
 54. The method of claim 53,wherein said full-length antibody that binds human TIGIT comprises: (i)a heavy chain variable region comprising SEQ ID NO:10 and a light chainvariable region comprising SEQ ID NO:11; or (ii) a heavy chain aminoacid sequence of SEQ ID NO:13 and a light chain amino acid sequence ofSEQ ID NO:15.
 55. The method of claim 54, wherein said full-lengthantibody that binds human TIGIT comprises a heavy chain amino acidsequence of SEQ ID NO:13 and a light chain amino acid sequence of SEQ IDNO:15.
 56. The method of claim 52, wherein the method further comprisesadministering to said patient an additional human therapeutic agent,wherein said additional human therapeutic agent is administered priorto, concurrently with, or subsequently to the administration of saidfull-length antibody that binds to human TIGIT.
 57. The method of claim56, wherein said additional human therapeutic agent is selected from thegroup consisting of a human anti-PD-1 antibody and a human anti-PD-L1antibody.
 58. The method of claim 57, wherein said additional humantherapeutic is a human anti-PD-1 antibody and is selected from the groupconsisting of nivolumab, pembrolizumab, and pidilzumab.
 59. The methodof claim 57, wherein said additional human therapeutic is a humananti-PD-L1 antibody and is selected from the group consisting ofatezolizumab, durvalumab, and avelumab.
 60. The method of claim 52,wherein said full-length antibody that binds human TIGIT isintravenously administered to said human patient.
 61. The method ofclaim 52, wherein said full-length antibody that binds human TIGIT isadministered once every week, once every two weeks, once every threeweeks, or once every four weeks.
 62. The method of claim 52, whereinsaid human patient was previously treated with a human PD-1 antagonistor a human PD-L1 antagonist and there is tumor growth, progression, orrecurrence during or after treatment with said human PD-1 antagonist orsaid human PD-L1 antagonist.
 63. The method of claim 52, wherein saidpatient has a cancer selected from the group consisting of head and neckcancer, cervical carcinoma, gastric cancer, ovarian cancer, melanoma,sarcoma, lung cancer, gastroesophageal, leukemia, lymphoma, anal cancer,pancreatic cancer, hepatocellular cancer, liver cancer, renal cellcarcinoma, kidney cancer, bladder cancer, a microsatelliteinstability-high colorectal cancer, a microsatellite stable colorectalcancer, a triple negative breast cancer, a Merkel cell carcinoma, anendometrial cancer, and an esophageal cancer.
 64. The method of claim52, wherein said patient has a cancer that expresses poliovirus receptor(PVR) or poliovirus receptor-related 2 (PVRL2).
 65. The method of claim52, wherein said patient has a cancer that comprises tumor-infiltratinglymphocytes (TILS) or regulatory T-cells.
 66. The method of claim 57,wherein said full-length antibody that binds human TIGIT comprises aheavy chain amino acid sequence of SEQ ID NO:13 and a light chain aminoacid sequence of SEQ ID NO:15; and wherein said full-length antibodythat binds human TIGIT is intravenously administered to said humanpatient once every two weeks.
 67. The method of claim 66, wherein ahuman anti-PD-1 antibody is administered prior to, concurrently with, orsubsequently to the administration of said antibody that binds to humanTIGIT and wherein said human anti-PD-1 antibody is selected from thegroup consisting of nivolumab, pembrolizumab, and pidilzumab.
 68. Themethod of claim 66, wherein a human anti-PD-L1 antibody is administeredprior to, concurrently with, or subsequently to the administration ofsaid antibody that binds to human TIGIT and wherein said humananti-PD-L1 antibody is selected from the group consisting ofatezolizumab, durvalumab, and avelumab.
 69. The method of claim 63,wherein said full-length antibody that binds human TIGIT comprises aheavy chain amino acid sequence of SEQ ID NO:13 and a light chain aminoacid sequence of SEQ ID NO:15; and wherein said full-length antibodythat binds human TIGIT is intravenously administered to said humanpatient once every two weeks.
 70. The method of claim 69, wherein ahuman anti-PD-1 antibody is administered prior to, concurrently with, orsubsequently to the administration of said antibody that binds to humanTIGIT and wherein said human anti-PD-1 antibody is selected from thegroup consisting of nivolumab, pembrolizumab, and pidilzumab.
 71. Themethod of claim 69, wherein a human anti-PD-L1 antibody is administeredprior to, concurrently with, or subsequently to the administration ofsaid antibody that binds to human TIGIT and wherein said humananti-PD-L1 antibody is selected from the group consisting ofatezolizumab, durvalumab, and avelumab.